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Everything will be okay in the end.  
If it’s not okay, it’s not the end. 
John Lennon 
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ABSTRACT 
Obstructive sleep apnea (OSA) is a common disorder associated with various 
adverse health effects, including an increased risk of cardiovascular disease (CVD) 
events, metabolic dysregulation, and motor vehicle accidents (MVA). This study 
evaluated the long-term effects of continuous positive airway pressure (CPAP), the 
primary treatment for OSA, in a large retrospective cohort of 1030 CPAP-adherent 
patients and 1030 controls matched for age, gender and apnea-hypopnea index 
(AHI). Controls had discontinued CPAP treatment despite their doctor’s advice. 
Approximately one half of the patients commencing CPAP had continued the 
treatment for ≥5 years, generally with good short- and long-term adherence. Only a 
weak positive correlation was found between AHI and long-term CPAP usage, while 
no association could be verified between AHI and the risk of CVDs or MVAs. 
CPAP-treated patients at the cohort level had a slight weight gain at a comparable 
rate to that observed in the general middle-aged Finnish population, while 10 % of 
the patients at the individual level had a significant weight gain. Those individuals, 
at baseline, were already more severely obese despite being younger than the rest of 
the cohort. An association between CPAP and a reduced risk of CVDs and all-cause 
mortality, in comparison to controls, was observed over a median follow-up of 9 
years but only among those with CPAP use of >4–6 h/day. The incidence of MVAs 
did not change when compared 9 years before and after treatment or in CPAP-treated 
patients and controls regardless of the level of adherence.  
The results of the present study emphasize that OSA is a heterogeneous disease, 
and the use of AHI alone is insufficient to assess OSA severity or to identify high-
risk patients for adverse outcomes. The results further imply that CPAP use of >4–6 
h/day is needed to achieve potential improvements in CVD risk. Patients are more 
likely to gain than lose weight during CPAP treatment, underlying the urge for 
lifestyle interventions. The incidence of MVAs did not change after CPAP use, 
suggesting that the MVA risk is likely to be multifactorial, and even longer 
observation periods may be needed to detect a significant difference. 
 
KEYWORDS: adherence, cardiovascular disease, continuous positive airway 
pressure treatment, mortality, motor vehicle accident, obstructive sleep apnea 
syndrome, personalized medicine, real-world study, weight control  
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TIIVISTELMÄ 
Obstruktiivinen uniapnea on yleinen sairaus, johon liittyy vakavia terveysriskejä, 
kuten sydän- ja verisuonisairaudet, aineenvaihdunnan toimintahäiriöt ja suurentunut 
liikenneonnettomuusalttius. Tämä tutkimus kartoitti takautuvasti obstruktiivisen 
uniapnean ensisijaisen hoitomuodon, ylipaine- eli CPAP-hoidon vaikuttavuutta. 
Tutkimuksessa oli mukana 1030 pitkäaikaisesti hoitoon sitoutunutta potilasta ja 
1030 iän, sukupuolen ja apnea-hypopneaindeksin (AHI) suhteen kaltaistettua 
verrokkia, jotka olivat lopettaneet CPAP-hoidon lääkärin suosituksesta huolimatta.  
Keskimäärin puolet hoidon aloittaneista oli jatkanut hoitoa ≥5 vuotta. Hoitoon 
sitoutuminen oli hyvällä tasolla sekä lyhyt- että pitkäaikaisesti. Heikko tilastollinen 
vastaavuus havaittiin AHI:n ja pitkäaikaisten käyttötuntien välillä, mutta yhteyttä 
AHI:n ja sydän- ja verisuonitautisairastavuuden tai liikenneonnettomuusriskin 
välillä ei todettu. Ryhmätasolla havaittiin vähäinen painonnousu, joka oli vastaava 
kuin suomalaisessa keski-ikäisessä väestössä yleensä. Yksilötasolla 10 % potilaista 
lihoi merkittävästi. Nuoremmasta iästään huolimatta he olivat jo lähtötilanteessa 
vaikeammin lihavia kuin muut tutkimuspotilaat. Verrokkiryhmään verrattuna 
CPAP-hoidon käyttö >4–6 tuntia päivässä liittyi pienempään sydän- ja 
verisuonitautisairastavuuteen ja kokonaiskuolleisuuteen 9 vuoden seuranta-aikana. 
Liikenneonnettomuuksien esiintyvyys ei muuttunut, kun potilaita verrattiin 9 vuotta 
ennen ja jälkeen hoidon, käyttötuntien perusteella tai suhteessa verrokkipotilaisiin.   
Tulosten perusteella obstruktiivinen uniapnea on monimuotoinen sairaus, jonka 
vaikeusastetta ei voida luotettavasti arvioida eikä suurimmassa terveysriskissä olevia 
tunnistaa pelkän AHI:n perusteella. Mahdollinen suotuisa vaikutus sydän- ja 
verisuonitautisairastavuuteen edellyttänee CPAP-hoidon käyttöä >4–6 tuntia 
päivässä. Lihominen hoidon aikana on todennäköisempää kuin laihtuminen 
painottaen elintapahoitojen tärkeyttä. Liikenneonnettomuuksien esiintyvyys ei 
muuttunut CPAP-hoidon myötä. Liikenneonnettomuuteen joutuminen on toden-
näköisesti monitekijäinen tapahtuma ja pidempi seuranta-aika saattaa olla tarpeen, 
jotta merkittävä ero voitaisiin havaita.  
 
AVAINSANAT: CPAP-hoito, hoitoon sitoutuminen, kuolleisuus, liikenneonnet-
tomuus, obstruktiivinen uniapnea, painonhallinta, reaalimaailman tutkimus, sydän- 
ja verisuonisairaus, yksilöllinen lääketiede   
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1 INTRODUCTION 
Obstructive sleep apnea (OSA) is a major public disorder with a range of adverse 
consequences to patients’ health and is a heavy burden on health care systems (Kapur 
et al. 2017, Patil et al. 2019). It has been associated with various daytime and 
nocturnal symptoms, and it may increase the risk for weight gain, hypertension, other 
cardiovascular diseases (CVDs), metabolic dysregulation and motor vehicle 
accidents (MVAs) (Javaheri et al. 2017, Joosten et al. 2017, Pamidi & Tasali 2012, 
Patil et al. 2019, Tregear et al. 2009). A growing rate of obesity, in addition to an 
aging population, are expected to contribute to the increasing OSA prevalence 
(Qaseem et al. 2014). 
The pathogenic significance of upper airway collapse during sleep and its 
potential connection with obesity was initially described in the 1960’s (Gastaut et al. 
1965). At first, tracheostomy was the only known effective treatment for OSA (Patil 
et al. 2019). The development of nasal continuous positive airway pressure (CPAP) 
treatment by Professor Sullivan and colleagues in 1981 completely changed the 
treatment of OSA (Sullivan et al. 1981). The CPAP device provides positive pressure 
throughout the respiratory cycle, thereby acting as a pneumatic splint that maintains 
the patency of the upper airway during sleep (Leech et al. 1992, Sullivan et al. 1981). 
It is still the primary treatment for OSA 40 years later (Chowdhuri et al. 2016, Gay 
et al. 2006, Sullivan 2018). However, adherence to CPAP has been challenging, even 
though technological advancements have enabled the development of auto-adjusting 
computer algorithms, modified pressure profiles, and the use of telemonitoring 
(Anttalainen et al. 2016a, Bakker et al. 2019, Patil et al. 2019). Inadequate adherence 
has hampered the evaluation of treatment effectiveness on different outcomes, 
particularly in randomized controlled trials (RCTs) assessing the risk of CVDs 
(McEvoy et al. 2016, Peker et al. 2016, Sánchez-de-la-Torre et al. 2020). 
Our understanding of OSA heterogeneity has developed further during the past 
two decades, and recent studies have focused on identifying different symptom-, 
pathophysiological- and polysomnographic-based OSA phenotypes (Zinchuk & 
Yaggi 2020). Mounting evidence has shown that OSA development is dependent on 
several anatomic and non-anatomic factors and their varying combinations (Eckert 
et al. 2013). Advances in the knowledge of OSA and its pathogenesis provide an 
INTRODUCTION 
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opportunity towards more personalized medicine, since new targeted therapies could 
be developed (Eckert et al. 2013). Studies on OSA phenotypes have also suggested 
that the use of the apnea-hypopnea index (AHI) alone is insufficient for assessing 
OSA severity, since patients with a similar AHI may significantly differ in terms of 
symptoms and OSA-related outcomes (Keenan et al. 2018). New tools are needed to 
identify patients who are at the highest risk of encountering adverse outcomes and 
most likely to benefit from CPAP. 
The aim of this thesis was to evaluate the impact of long-term CPAP treatment 
with adequate adherence on the incidence of CVD events, all-cause mortality and 
MVAs in comparison to untreated control patients matched for, age, gender and AHI. 
Another aim was to evaluate the effect of long-term CPAP treatment on weight 
maintenance, since the majority of previous studies have investigated these changes 
only in the short term (Drager et al. 2015). Finally, patient characteristics associated 
with an increased risk of adverse outcomes were determined, and the significance of 
the level of CPAP adherence on the incidence of CVDs and MVAs was evaluated. 
This work seeks to provide further data on OSA heterogeneity and to identify those 
patients who are either most likely to benefit from CPAP or who require additional 
support during treatment.  
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2 REVIEW OF THE LITERATURE 
2.1 Obstructive sleep apnea (OSA) 
2.1.1 Definition of OSA 
OSA is characterized by recurrent episodes of complete (apnea) and partial 
(hypopnea) upper airway obstruction during sleep that results in repetitive 
interruption of ventilation (The Report of an American Academy of Sleep Medicine 
Task Force 1999). An obstructive apnea is defined as ≥90 % drop in airflow for ≥10 
seconds in the presence of ongoing inspiratory efforts against the occluded airway 
(Berry et al. 2012). The 1999 guidelines of the American Academy of Sleep 
Medicine (AASM), known as the “Chicago Criteria”, defined hypopnea as ≥50 % 
drop in airflow for ≥10 seconds with no requirement for oxygen desaturation, or 
alternatively, <50 % drop in airflow for ≥10 seconds associated with ≥4 % oxygen 
desaturation or an arousal (The Report of an American Academy of Sleep Medicine 
Task Force 1999). The 2007 AASM scoring manual provided two hypopnea 
definitions: the recommended hypopnea definition required ≥30 % drop in airflow 
for ≥10 seconds associated with ≥4 % oxygen desaturation, while the alternative 
hypopnea definition required ≥50 % drop in airflow for ≥10 seconds associated with 
≥3 % oxygen desaturation or an arousal (Iber et al. 2007). Based on the current 2012 
AASM criteria, a hypopnea is defined as ≥30 % drop in airflow for ≥10 seconds 
associated with ≥3 % oxygen desaturation or an arousal (Berry et al. 2012).  
The number of apneas and hypopneas per hour of sleep is defined by AHI. An 
AHI of <5 /h is considered normal, whereas obstructive sleep apnea syndrome 
(OSAS) is characterized by an AHI of ≥5 /h in addition to OSA-related symptoms 
(The Report of an American Academy of Sleep Medicine Task Force 1999).  Based 
on the third edition of the International Classification of Sleep Disorders (ICSD-3), 
OSA is defined as either 1) having an obstructive respiratory disturbance index 
(RDI) of ≥5 /h in polysomnography (PSG) in addition to typical OSA symptoms, or 
2) having an obstructive RDI of ≥15 /h with or without OSA-related symptoms 
(American Academy of Sleep Medicine 2014). RDI, with a difference from AHI, 
also includes the number of respiratory effort-related arousals (RERAs), which can 
only be determined by PSG. RERA is defined as increasing respiratory effort or 
REVIEW OF THE LITERATURE 
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flattening of the nasal airflow during inspiration, which lasts ≥10 seconds and results 
in arousal from sleep but does not fulfill the definition criteria of an apnea or a 
hypopnea (Berry et al. 2012).  
2.1.2 Prevalence 
A recent population-based study from Europe revealed that 50 % of middle-aged 
men and 23 % of women had moderate to severe OSA based on the current AASM 
definition for hypopnea (Heinzer et al. 2015). OSA may be overlooked, especially 
among women, since men are reported to be more likely to be referred for a sleep 
study and to receive treatment for OSA than are women, despite women having 
similar symptoms suggestive of sleep-disordered breathing (SDB) (Lindberg et al. 
2017). The gender difference in OSA prevalence decreases after menopause 
(Heinzer et al. 2015). Mild or more severe OSA was found in 90 % of men and 78 
% of women in the elderly population aged 60–85 years (Senaratna et al. 2017). The 
prevalence of OSA has been shown to be 2- to 3-fold higher among patients with 
than without CVD (Somers et al. 2008). A higher prevalence has also been reported 
among commercial vehicle (CMV) drivers, since mild OSA was found in 28 % and 
severe OSA in 5 % of the subjects in a study of 406 CMV drivers (Pack et al. 2006).  
2.1.3 Pathophysiology 
Obstruction of the upper airway during sleep with OSA may be induced by several 
anatomic and non-anatomic factors and their varying combinations (White 2005). 
The critical closing pressure (Pcrit) that will cause it to collapse is used to define the 
required pressure level inside the airway (Eckert et al. 2013, White 2017). Pcrit may 
be evaluated by reducing the CPAP pressure to a level at which the airway collapses 
(White 2017). Studies evaluating Pcrit during sleep have shown an overlap between 
healthy controls, snorers and patients with apneas and hypopneas. One study 
reported that OSA was found in all subjects with a Pcrit of -1 centimeter of water 
(cmH2O) or more positive, while only healthy subjects had a Pcrit of -6 cmH2O or 
more negative; a Pcrit between -5 and -2 cmH2O was found in both groups. With the 
same Pcrit value, patients may have OSA of different severities or they may not have 
OSA at all (Eckert et al. 2013, White 2017). Thus, abnormal anatomy does not 
entirely explain OSA’s pathophysiology (White 2017).  
2.1.3.1 Anatomic factors 
The majority of the patients with OSA have an anatomically small pharyngeal airway 
due to alterations in craniofacial structures (e.g. small maxilla and mandible, 
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enlarged tonsils) or extra soft tissue around the airway (e.g. increase in fat tissue due 
to obesity). Peripheral edema may also accumulate to the neck area in supine position 
and construct the airway. Extra soft tissue or edema surrounding the airway increases 
extraluminal pressure, which, in turn, may exceed the elastance of the airway walls 
and partially or completely collapse the airway. Lung inflation generates longitudinal 
traction on the trachea and larynx, which stiffens the airway and decreases 
collapsibility. A reduction in lung volume during sleep or due to obesity results in a 
loss of longitudinal traction on the upper airway, predisposing it to collapse (Javaheri 
et al. 2017, White 2005). Figure 1 summarizes the main forces that increase or 
decrease the collapsibility of the pharyngeal airway. 
 
Figure 1.  A sagittal section through the pharyngeal airway, and the main forces that increase or 
decrease the collapsibility of the airway. Reprinted from The Lancet (Malhotra & White 
2002) with permission from Elsevier.  
2.1.3.2 Non-anatomic factors 
Non-anatomic factors include upper airway dilator muscle dysfunction (decreased 
muscle responsiveness during sleep), low arousal threshold and a high loop gain 
(Eckert et al. 2013, White 2005). The function of the pharyngeal dilator muscles, 
particularly genioglossus, primarily prevents the airway from collapsing. 
Genioglossus activation is mainly controlled by three neural inputs that respond to 
1) negative pressure in the airway, 2) respiratory drive and 3) arousal state. Thus, 
pharyngeal muscle activity is elevated by increased negative airway pressure, 
hypoxia or hypercapnia, inspiration and wakefulness. The airway becomes more 
vulnerable to collapse during sleep due to diminished muscle responsiveness to 
negative airway pressure and carbon dioxide (CO2), in addition to changes in arousal 
state (White 2005).  
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The arousal threshold as a response to respiratory stimulation has been shown to 
vary between individuals, since subjects with a low arousal threshold are likely to 
wake up in response to small increases in respiratory drive, while those with a higher 
arousal threshold demand clearly increased respiratory drive to wake up. A higher 
arousal threshold enables the activation of pharyngeal dilator muscles, revising the 
patency of the airway before arousal from sleep occurs. However, it may also lead 
to prolongation of apneas and hypopneas in subjects with decreased upper airway 
responsiveness (White 2017). Apneic or hypopneic events result in hypoxia and 
hypercapnia in OSA, which stimulates the respiratory drive and usually leads to 
arousal from sleep in order to stop the apneic event (Somers et al. 2008). 
The respiratory system is regulated by feedback loops that enables it to become 
unstable. Loop gain, defined as the ratio of ventilatory response per ventilatory 
disturbance (apnea or hypopnea), may be used to represent the stability or 
instability of such system. A high loop gain (>1) stands for ventilatory instability, 
in which case a disturbance in the respiratory system will result in a large 
ventilatory response and unstable ventilatory control. Loop gain is influenced by 
controller gain (chemoreceptors reacting to the partial pressure of CO2 (pCO2): 
responsiveness to hypercapnia) and plant gain (lungs, respiratory muscles: change 
in ventilation). A high controller gain is generally caused by brisk responsiveness 
to hypercapnia, whereas a small change in ventilation induces a large change in 
pCO2 in high plant gain (e.g. reduced cardiac output, low metabolic rate, 
hypercapnia). It has been suggested that high loop gain may contribute to OSA’s 
pathogenesis, particularly in patients with a moderately collapsible airway, while 
it does not seem to increase the risk in those without other factors predisposing to 
OSA (White 2005, White 2017). 
2.1.4 Risk factors 
Obesity is the best-documented risk factor for OSA (Qaseem et al. 2014), although 
20–40 % of OSA patients are not obese (Javaheri et al. 2017). OSA has been 
associated with a higher body-mass index (BMI), increased waist-to-hip ratio and 
neck girth (Heinzer et al. 2015, Qaseem et al. 2014). Fat deposited in lateral fat pads 
and tongue base decrease the patency of the upper airway, and abdominal fat tissue 
mechanically compresses the chest and abdominal wall, resulting in reduced lung 
volumes and longitudinal traction. Additionally, obesity-related leptin resistance 
may also lead to alterations in respiratory control (Joosten et al. 2017). In the 
population-based Wisconsin Sleep Cohort Study, a 10 % weight gain was associated 
with a 32 % increase in AHI in addition to a 6-fold greater risk of developing 
moderate to severe OSA over a 4-year follow-up (Peppard et al. 2000a). 
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Large population-based studies have also shown that the risk of having moderate 
to severe SDB was 1.7-fold greater among those aged ≥60 years compared to 
younger subjects (Young et al. 2002), and that every 10-year elevation in age 
increased the risk by 50 to 70 % (Heinzer et al. 2015). In addition to older age, a 2- 
to 3-fold greater risk for OSA has been reported among men compared to women 
(Heinzer et al. 2015, Young et al. 2002). This could be at least partly explained by 
the differences in upper airway anatomy, including longer pharyngeal airway length 
and increased pharyngeal soft tissue mass in the soft palate and tongue among men 
(Dempsey et al. 2010). The response to arousal, hormones, the distribution of fat 
tissue, and neurochemical mechanisms may also contribute to the gender difference. 
Menopause is a significant risk factor for OSA in women, and hormone replacement 
therapy has been associated with a lower prevalence of OSA, but a causal 
relationship has not been confirmed (Lin et al. 2008).  
Patients with OSA were associated in a meta-analysis of 26 studies with 
craniofacial disharmony, such as decreased pharyngeal airway space, inferiorly 
located hyoid bone and increased anterior facial heights compared to controls. In the 
majority of the included studies, patients were mainly men and the average BMI was 
<30 kg/m2 (Neelapu et al. 2017). Additionally, smoking, a positive family history 
for OSA, endocrine abnormalities, such as hypothyroidism and acromegaly, and the 
use of alcohol or benzodiazepines have been shown to increase the risk for apneas 
and OSA (Somers et al. 2008, The Report of an American Academy of Sleep 
Medicine Task Force 1999). 
2.1.5 Diagnostic methods 
Symptoms and clinical examination (signs and OSA risk factors) can suggest OSA, 
but the diagnostic standard is based on sleep studies (American Academy of Sleep 
Medicine 2014). 
2.1.5.1 Clinical features 
OSA patients may present with a number of different daytime and/ or nocturnal 
symptoms, which may have an adverse effect on quality of life (Patil et al. 2019). 
Excessive daytime sleepiness (EDS), defined as inability to stay awake during 
daytime resulting in increased need for sleep or unintentional dozing, is one of the 
most significant daytime symptoms (Berry et al. 2012, Kapur et al. 2017). 
However, <50 % of OSA patients have been shown to report on EDS (Saaresranta 
et al. 2016, Ye et al. 2014). Other symptoms suggestive for OSA include 
unrefreshing sleep, daytime fatigue, insomnia, witnessed apnea or gasping during 
sleep, frequent awakenings from sleep, loud snoring, sleep-related cardiac 
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dysrhythmias, morning headache, impaired concentration, nocturia and sexual 
dysfunction. None of these symptoms are specific to OSA, and symptoms may also 
differ between genders, since women are more likely to report on fatigue, 
insomnia, morning headaches and depression than men (American Academy of 
Sleep Medicine 2014, Lin et al. 2008, Qaseem et al. 2014, The Report of an 
American Academy of Sleep Medicine Task Force 1999). Patients with OSA may 
also be asymptomatic (Somers et al. 2008). 
Different questionnaires may be used to identify patients for further evaluation 
(Kapur et al. 2017). The most common questionnaire is the self-reported Epworth 
Sleepiness Scale (ESS) (Appendix 1), which includes eight questions that assess 
the level of daytime sleepiness and tendency to fall asleep during daytime. A score 
of ≤10 is considered normal, while mild to moderate EDS is defined as a score of 
11–15 and severe EDS as a score of 16–24 (Johns 1991, Kapur et al. 2017). The 
risk for OSA is classified in the Berlin Questionnaire as high or low according to 
eleven questions that are divided into three categories (Netzer et al. 1999). The 
STOP-Bang questionnaire, a validated screening questionnaire for OSA, includes 
questions of symptoms (snoring, tiredness, observed apneas), age, gender, BMI, 
neck circumference and the history of high blood pressure (BP) (Chung et al. 
2008).  
Clinical signs suggestive for OSA include obesity, enlarged neck size, crowded-
appearing pharyngeal airway, craniofacial disharmony, elevated BP in addition to 
other OSA-related comorbidities (Monderer et al. 2017, Neelapu et al. 2017). The 
physical examination should include the evaluation of throat, nose, neck, 
cervicofacial angle, lungs and heart. The measurement of weight, height, BMI, BP 
and the circumference of neck and waistline should also be included (Monderer et 
al. 2017). The accuracy of symptoms, clinical signs and questionnaires for the OSA 
diagnosis has been low compared to sleep studies, which underlines the need for 
differential diagnosis and further evaluation in patients suspected of having OSA 
(American Academy of Sleep Medicine 2014, Kapur et al. 2017). 
2.1.5.2 Sleep studies 
Sleep studies have been traditionally categorized into four groups: Type I (full 
attended PSG with ≥7 channels in a laboratory setting), Type II (full unattended 
portable PSG with ≥7 channels), Type III (limited number of sensors of 4–7), and 
Type IV (usually 1–2 sensors). Unattended studies that can be performed at a 
patient’s home (home sleep apnea testing) belong to the categories of II–IV 
according to the number of monitoring sensors that are utilized. Type II studies have 
the same sensors as a full attended PSG, including electroencephalography (EEG), 
electro-oculography (EOG), chin electromyography (EMG), electrocardiogram 
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(ECG) or heart rate, airflow, respiratory effort (movement of the thorax and 
abdomen) and blood oxygen saturation level (SpO2), but they can be performed 
outside the sleep laboratory. Type III studies measure at least two respiratory 
variables (at least two channels of respiratory movement, or respiratory movement 
and airflow), the level of SpO2 and a cardiac variable (ECG or heart rate). Type IV 
studies usually measure only SpO2 and heart rate (Kapur et al. 2017). 
In-hospital, technician-attended PSG is considered the reference standard for 
OSA diagnosis (Kapur et al. 2017). However, it requires the patient to spend the 
night in a sleep laboratory, which increases the costs and limits the study’s 
accessibility. The EEG, EOG and chin EMG that are measured in PSG are not 
utilized in cardiorespiratory polygraphy, a type III sleep study (Dingli et al. 2003); 
thus, the exact sleep time, stages of sleep or cortical arousals cannot be determined, 
and the AHI has been shown to be approximately 20 to 30 % higher in patients 
investigated with PSG than those studied by cardiorespiratory polygraphy 
(Escourrou et al. 2015, Hedner et al. 2011). According to the international standards, 
the term respiratory event index (REI) should actually be used instead of AHI when 
the OSA diagnosis is based on cardiorespiratory polygraphy (Kapur et al. 2017).   
Cardiorespiratory polygraphy has been shown to be more accurate in the 
diagnosis of severe OSA and less accurate in mild OSA. Risk of technical failures 
is also increased if the study is performed unattended (Kapur et al. 2017). The use 
of cardiorespiratory polygraphy is particularly common in Europe, since it was 
used for OSA diagnosis in 67 % of 5103 subjects included in the European Sleep 
Apnea Database study (Hedner et al. 2011). Based on the clinical practice guideline 
from the AASM, either PSG or home sleep apnea testing may be used for OSA 
diagnosis in uncomplicated patients with suspected risk of moderate to severe 
OSA. The use of PSG is primarily recommended for patients with a significant 
cardiorespiratory disease, hypoventilation during wakefulness, long-term use of 
opioid medication, a history of stroke or severe insomnia, or suspected respiratory 
muscle weakness due to a neuromuscular condition or sleep-related 
hypoventilation (Kapur et al. 2017). 
2.1.5.3 Other diagnostic methods 
The Multiple Sleep Latency Test (MSLT) (Carskadon & Dement 1977) and the 
Maintenance of Wakefulness Test (MWT) (Mitler et al. 1982) have been used to 
objectively assess sleepiness and alertness. In the MSLT, patients are requested to 
fall asleep in a quiet, dark room, and sleepiness is measured by sleep latency during 
four registrations that occur at 2-hour intervals. The test is based on the assumption 
that the degree of sleepiness is associated with sleep latency (Carskadon & Dement 
1977). The MWT measures ability to remain awake in a sleepy environment. The 
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test includes four 20- or 40-minutes registrations that occur at 2-hour intervals 
(Mitler et al. 1982). A significant, but a rather weak, correlation has been observed 
between the results of MSLT and MWT (Arand et al. 2005). Wide range in normal 
values and requirement for a laboratory environment, which differs significantly 
from workplace conditions, have been identified as limitations of MSLT, whereas 
motivation to stay awake may influence the MWT performance (Arand et al. 2005). 
Overall, the MSLT and MWT both have limitations in identifying OSA patients from 
the general population and should not be the main factors in assessing daytime 
sleepiness, verifying the OSA diagnosis, or in evaluating responsiveness to treatment 
(Arand et al. 2005). 
The Oxford Sleep Resistance Test (OSLER) is a behavioral test that measures 
the ability to maintain wakefulness and daytime vigilance. Patients are requested not 
only to remain awake for four 40-minutes registrations but also to respond to a flash 
of light appearing every 3 seconds by hitting a button on a portable device. Seven 
subsequent misses are interpreted as falling asleep (Bennett et al. 1997). It has been 
shown to be a reliable tool for assessing daytime sleepiness compared to MWT. The 
main limitation of the OSLER test is its requirement for patient co-operation (Patil 
et al. 2019). 
Driving simulation and real-life driving performance have been used to evaluate 
daytime sleepiness, especially in CMV drivers (Philip et al. 2008). However, the use 
of driving simulators has not accurately predicted real-life MVAs or near-miss 
accidents and it has actually been shown to artificially increase driving impairment 
compared to real-life driving performance (Dwarakanath & Elliott 2019, Philip et al. 
2008). Subjects usually drive on a straight highway for 90 minutes in a real-life 
driving performance evaluation. They are instructed to maintain a constant speed 
while driving in the center of the lane without crossing the lanes. A professional 
driving instructor monitors the driving speed, inappropriate line crossings and 
subject’s vigilance (Philip et al. 2008). 
2.1.6 Severity 
OSA severity can be determined by the level of daytime sleepiness, AHI and SpO2 
and it should be based on the most severe component (Current Care Guidelines for 
Adult Obstructive Sleep Apnea 2017, Institute for Clinical Systems Improvement 
(ICSI) 2005, The Report of an American Academy of Sleep Medicine Task Force 
1999). Table 1 summarizes the evaluation of OSA severity. 
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Table 1.  The severity of obstructive sleep apnea determined by the level of daytime sleepiness, 
apnea-hypopnea index (AHI) and blood oxygen saturation level (SpO2). Modified with 
permission from Current Care Guidelines for Adult Obstructive Sleep Apnea 2017. 
Based on the references: Institute for Clinical Systems Improvement (ICSI) 2005 and 
The Report of an American Academy of Sleep Medicine Task Force 1999.  
Severity Daytime sleepiness SpO2 (%) AHI (/h) 
Mild Occurs only during activities that require little 
attention (e.g. reading or watching television) 
Only a minor effect on social or occupational 
function 
Mean ≥90 
AND 
Minimum ≥85  
≥5 and <15  
Moderate Occurs during activities that require some 
attention (e.g. during meetings or concerts) 
A moderate effect on social or occupational 
function 
Mean <90  
AND 
Minimum ≥70 
≥15 and <30 
Severe Occurs during activities that require more 
active attention (e.g. during conversation or 
driving) 
A significant effect on social or occupational 
function 
Mean <90  
AND 
Minimum <70 
≥30 
 
2.1.7 Differential diagnosis 
Sleepiness may also be explained by numerous other factors than OSA: other sleep 
disorders, chronic hypoventilation syndromes, periodic limb movements of sleep 
(PLMS), narcolepsy, insomnia, idiopathic hypersomnia, insufficient sleep, personal 
stressors, shift working, circadian rhythm disorders, hypersomnia due to a 
medication or a psychiatric disorder, chronic fatigue syndrome, fibromyalgia, 
endocrine abnormalities (e.g. hypothyroidism, diabetes mellitus, excessive growth 
hormone), brain tumors or other malignancies, stroke, head trauma, epilepsy, the use 
of alcohol or illicit drugs, other basic diseases (e.g. chronic renal insufficiency, 
congestive heart failure (HF)) (Monderer et al. 2017), obesity (Vgontzas et al. 2006) 
or menopause in women (Lin et al. 2008). 
Questionnaires may also be used in differential diagnosis for OSA, e.g. ESS 
(Johns 1991) and the STOP-Bang screening questionnaire (Chung et al. 2008). The 
12-item General Health Questionnaire (GHQ-12) (Appendix 2) can also be used to 
assess psychological distress (a score of ≥3 of 12 indicates psychological distress) 
(Goldberg et al. 1997) and the Depression Scale (DEPS) to screen for depression (a 
score of ≥9 of 30 is associated with an increased likelihood of depression) 
(Salokangas et al. 1995). The laboratory tests are unspecific for OSA but are 
necessary in differential diagnosis and due to OSA-related comorbidities (The 
Report of an American Academy of Sleep Medicine Task Force 1999). Based on the 
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Finnish Current Care Guideline for obstructive sleep apnea in adults, the evaluation 
of at least basic blood count, glycated hemoglobin, serum lipid concentrations, 
thyroid-stimulating hormone and ECG are recommended for all patients. The need 
for chest or sinus X-ray, spirometry and the measurement of arterial or 
transcutaneous CO2 is evaluated individually (Current Care Guidelines for Adult 
Obstructive Sleep Apnea 2017). 
2.1.8 Other types of sleep apnea 
Central sleep apnea (CSA) is defined by cessation of airflow without respiratory 
effort (American Academy of Sleep Medicine 2014). CSA generally results from the 
instability of the respiratory control system caused by a high loop gain (particularly 
a high controller gain). High loop gain predisposes to hyperventilation due to an 
elevated hypercapnic ventilatory response, which leads to a reduction in pCO2. An 
apnea will occur when pCO2 decreases below the apneic threshold and does not end 
until pCO2 elevates above the threshold (Berry et al. 2012, Randerath et al. 2017, 
White 2005). Patients may have both obstructive and central apneas, since unstable 
respiratory control may also induce obstructive respiratory events (Randerath et al. 
2017). Inclusion criteria have often required >50–80 % of the respiratory events to 
be central in studies involving patients with CSA (Somers et al. 2008).  
CSA may be idiopathic (high controller gain) or induced by ambient hypoxia at 
high altitude, different comorbidities, including particularly HF but also acute stroke, 
other neurological diseases and end-stage renal disease, or the use of opioids. CSA 
has been estimated to affect 18 to 37 % of HF patients, being slightly more common 
among those with a reduced left ventricular ejection fraction (LVEF) (Randerath et 
al. 2017). Furthermore, Cheyne-Stokes respiration is commonly seen in HF patients 
due to a high controller gain, deceleration of circulation and hypocapnia resulting 
from increased filling pressures and lung edema. It is characterized by fluctuations 
in ventilation, which results in a crescendo-decrescendo pattern of breathing 
followed by central apneas (Randerath et al. 2017, White 2005).  
Mixed sleep apnea is a combination of both central and obstructive apneas in 
which the interruption in ventilation begins with a central apnea and continues as an 
obstructive one (Berry et al. 2012). Dilating forces of the upper airway are sufficient 
enough to prevent the development of apneas and hypopneas but not to maintain the 
complete patency of the airway in prolonged partial upper airway obstruction. 
During these episodes, the upper airway is usually partially obstructed for several 
minutes, resulting in reduced inspiratory airflow and increased respiratory effort 
against the partially obstructed airway. The specific definition criteria include 
prolonged flow limitation for >20–30 % of total recording or sleep time, sustained 
flow limitation in nasal prongs, crescendo snoring, pCO2 >6 kPa and absence of 
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repetitive arousals from sleep. It occurs particularly among women and is associated 
with daytime symptoms and increased risk of hypertension. It has been suggested as 
a clinically significant form of SDB. However, these patients may have a low AHI 
and are, thus, commonly interpreted incorrectly as having mild sleep apnea 
(Anttalainen et al. 2016b). 
2.2 Comorbidities in OSA 
2.2.1 Cardiovascular comorbidities and type 2 diabetes 
The most compelling evidence supports an independent causal link between OSA 
and hypertension, since RCTs have demonstrated a reduction in BP after CPAP 
(Javaheri et al. 2017, Lurie 2011, Peker & Balcan 2018). OSA has been suggested 
to be a potential risk factor for atherosclerosis, since it has been associated with 
carotid intima-media thickness and an increased burden of noncalcified and calcified 
coronary plaques (Drager et al. 2011a, Hoyos et al. 2017, Yoshihisa et al. 2019, Zhou 
et al. 2017). Small studies have demonstrated an improvement in carotid intima-
media thickness in OSA after CPAP, but however, CPAP has not been shown to 
decrease or stabilize plaques. Thus, causality between OSA and atherosclerosis has 
not been confirmed and further RCTs are needed to clarify whether CPAP could 
improve early signs of atherosclerosis and prevent the development of a clinically 
more severe form of CVD (Drager et al. 2007, Hoys et al. 2017, Hui et al. 2012). 
OSA has been associated with an increased risk of CVDs, particularly stroke, but 
an association between coronary artery disease (CAD), HF, atrial fibrillation (AF), 
peripheral artery disease (PAD) and type 2 diabetes (T2D) has also been suggested 
in addition to a higher prevalence of OSA in pulmonary hypertension (Javaheri et al. 
2013, Javaheri et al. 2017, Pamidi & Tasali 2012, Utriainen et al. 2013).  
2.2.1.1 Mechanisms 
The potential pathogenesis of CVDs in OSA is not completely understood, but it is 
likely multifactorial. Figure 2 summarizes the main mechanisms and physiological 
effects that could contribute to the development of CVDs in OSA. 
Intermittent hypoxemia. Intermittent hypoxemia is characterized by repetitive 
episodes of desaturation and re-oxygenation; it has been suggested to play a pivotal 
role in the pathogenesis of CVDs in OSA. The European Sleep Apnea Database 
study of over 11 000 subjects found an association between oxygen desaturation 
index (ODI) and prevalent hypertension independent of confounding factors 
(Tkacova et al. 2014), while a prospective study of patients with newly diagnosed 
OSA associated the severity of nocturnal oxygen desaturation with carotid artery 
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thickening and plaque occurrence (Baguet et al. 2005). Intermittent hypoxemia may 
trigger oxidative stress, systemic inflammation, endothelial dysfunction and 
sympathetic activation and it may promote glucose intolerance (Dewan et al. 2015). 
Treatment with CPAP has been shown to be effective in attenuating ODI (Iftikhar et 
al. 2017). 
Inflammation. Systemic inflammation has been shown to crucially contribute to 
the progress of atherosclerosis at all stages of atheroma formation and its thrombotic 
complications (Dempsey et al. 2010, Dewan et al. 2015). Intermittent hypoxemia has 
been linked with the activation of pro-inflammatory transcription factors, 
particularly nuclear factor kappa B (NF-KB), leading to the production of various 
inflammatory markers (Ryan et al. 2009). Tumor necrosis factor-α (TNF-α), 
interleukin (IL)-6, IL-8 and C-reactive protein (CRP) have been reported to be 
elevated in OSA patients. Observational studies have suggested that CPAP may 
reduce the levels of most of these markers (Xie et al. 2013, Peker & Balcan 2018). 
However, the association has not been confirmed in RCTs (Jullian-Desayes et al. 
2015, Peker & Balcan 2018). OSA and obesity may also have synergistic effects, 
since intermittent hypoxemia may affect macrophages in adipose tissue leading to 
increases in inflammatory markers (Javaheri et al. 2017). 
Vascular endothelial dysfunction. Endothelial dysfunction is characterized by 
increased adherence of inflammatory mediators to endothelial cells and imbalanced 
production of vasoactive hormones from the endothelium, including inhibition of 
nitric oxide (a vasodilator) and increased release of endothelin (a vasoconstrictor). 
Intermittent hypoxemia, oxidative stress and systemic inflammation, in addition to 
OSA-related obesity, hypertension and metabolic dysregulation, have been 
suggested to contribute to endothelial dysfunction. It may trigger vasoconstriction, 
hypercoagulability and the proliferation of vascular smooth muscle, predisposing to 
the development of CVDs (Budhiraja et al. 2007, Dempsey et al. 2010). 
Observational studies have suggested that CPAP could improve endothelial function, 
but however, the data of RCTs is scarce and not sufficient to support this conclusion 
(Peker & Balcan 2018).  
Oxidative stress. Intermittent hypoxemia has been shown to result in increased 
production of reactive oxygen species (ROS). Cells adapt to lower oxygen levels, 
which leads to increased production of ROS at the end of apneas and hypopneas 
when the oxygen levels are restored (Butt et al. 2010, Dewan et al. 2015). ROS may 
oxidize cellular products, proteins and lipids and result in endothelial dysfunction by 
decreasing the level of nitric oxide and increasing the release of endothelin (Butt et 
al. 2010). Furthermore, it may activate the renin-angiotensin-aldosterone system, 
leading to elevated plasma aldosterone levels and the development of hypertension 
(Dempsey et al. 2010). CPAP has been suggested to potentially reduce oxidative 
stress in observational studies, but the data of RCTs is scarce and future RCTs are 
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needed to clarify whether the association between OSA and oxidative stress is causal 
(Hoyos et al. 2017, Peker & Balcan 2018). 
Sympathetic nerve activity. Sympathetic nerve activity in OSA has been shown 
to also be elevated during the daytime by measurements of muscle sympathetic nerve 
activity and norepinephrine levels in plasma and urine. It has been shown to result 
in vasoconstriction with a consequent increase in BP and alterations in heart rate 
variability. Several etiological mechanisms have been suggested to be involved, 
including intermittent hypoxemia, increased activation of central and peripheral 
chemoreceptors, reduced baroreflex sensitivity and endothelial dysfunction (Butt et 
al. 2010, Dempsey et al. 2010). Several RCTs have shown that CPAP reduces muscle 
sympathetic nerve activity in addition to plasma and urinary catecholamines in OSA, 
indicating a causal relationship between OSA and sympathetic activation (Peker & 
Balcan 2018). 
Thrombosis. Platelet dysfunction and hypercoagulability have been shown to 
contribute to the development of atherothrombotic events and CVDs. A potential 
association between OSA and hypercoagulability has been suggested, including 
increased plasma fibrinogen levels, excessive platelet activity and decreased 
fibrinolytic capacity (Dempsey et al. 2010, Somers et al. 2008). However, the data 
of both observational studies and RCTs on the effectiveness of CPAP in reducing 
coagulation factors in OSA have been conflicting, and it is not clear whether the 
association between OSA and hypercoagulability is causal (Peker & Balcan 2018).  
Intrathoracic pressure changes. Repetitive respiratory efforts against the closed 
upper airway in OSA result in major negative pressure swings in the chest cavity, 
which increases venous return to the heart and transmural pressure of all 
intrathoracic structures. Ventricular function may consequently be impaired due to 
increased cardiac afterload, decreased diastolic function and alterations in the 
function of the autonomic system (Somers et al. 2008). Thin-walled atriums stretch 
easily as a response to the surrounding negative pressure, which may lead to 
stimulation of atrial mechanoreceptors and activation of atrial ion channels and 
contribute to the development of atrial arrhythmias (Javaheri et al. 2017). 
Insulin resistance. OSA has been suggested to associate with insulin resistance, 
a risk factor for atherosclerosis, potentially due to intermittent hypoxemia, sleep 
disruption and increased sympathetic nerve activity (Reutrakul & Mokhlesi 2017). 
The association appears to be at least partly independent of obesity and increasing 
OSA severity has been reported to correlate with an increasing level of insulin 
resistance (Hoyos et al. 2017, Kent et al. 2014a). Several RCTs have suggested that 
CPAP may improve insulin resistance in OSA patients without T2D (Lam et al. 
2010, Patil et al. 2019, Weinstock et al. 2012), although the results are not entirely 
consistent. One RCT showed a reduction in insulin resistance only among those 
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treated with weight loss alone or weight loss plus CPAP, but not among those treated 
with CPAP alone (Chirinos et al. 2014). 
Leptin. Leptin is an adipose tissue -derived hormone that regulates appetite, 
weight control and fat distribution and it may also act as a respiratory stimulant. 
Animal studies have demonstrated that chronic hyperleptinemia may increase BP, 
platelet aggregation and arterial thrombosis, but a causal link between leptin and 
CVDs has not been confirmed (Chen et al. 2015, Dempsey et al. 2010). OSA has 
been associated with leptin resistance, which is characterized by reduced anorexic 
effect of leptin despite having elevated leptin levels (Chen et al. 2015, Shechter 
2017). Some prospective studies have reported decreased leptin levels after CPAP 
independent of weight changes, but importantly, RCTs have not. Thus, it is not clear 
whether the link between OSA and leptin is causal (Balcan et al. 2020, Chen et al. 
2015, Shechter 2016).  
Ghrelin. Ghrelin is a hormone that is predominantly secreted from the stomach. 
It has a broad range of physiological effects on almost every system; it stimulates 
appetite in an antagonist manner to leptin, has other impacts on gastric functions in 
addition to anabolic effects, and increases release of several hormones, including 
growth hormone. It has been suggested that ghrelin may have cardioprotective 
effects, such as improvement of LVEF, reduced BP and attenuation of causes of 
atherosclerosis, but a causal link has not been confirmed (Lilleness & Frishman 
2016). Obesity is associated with decreased ghrelin levels, whereas most studies 
have shown increased ghrelin levels in OSA patients (Shechter 2017). The majority 
of prospective studies have suggested a reduction in ghrelin after CPAP (Shechter 
2016). However, the effect of CPAP on ghrelin has been studied less than that on 
leptin, and data from RCTs are lacking (Shechter 2016). 
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BP, blood pressure; HR, heart rate; LVEF, left ventricular ejection fraction; O2, oxygen; pCO2, partial 
pressure of carbon dioxide.  
Figure 2.  The main mechanisms and physiological effects that could contribute to the 
development of cardiovascular diseases (CVD) in obstructive sleep apnea (OSA). 
Based on the references: Coniglio & Mentz 2020, Bradley & Floras 2003, Javaheri et al. 
2017, Ryan et al. 2009, Sommers et al. 2008.  
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2.2.1.2 Hypertension 
It has been estimated that ≥30 % of those with hypertension have an AHI of ≥15 /h 
(Floras 2015, Javaheri et al. 2017), while approximately 30 to 70 % of OSA patients 
are likely to have hypertension (Patel et al. 2019). OSA is the most common 
secondary cause of resistant hypertension, and an AHI of ≥15 /h has been found in 
≥70 % of those with drug-resistant hypertension (Floras 2015, Patel et al. 2019). 
OSA may also result in unfavorable circadian pattern, since the prevalence of non-
dippers (<10 % decrease in the mean nocturnal BP from the mean daytime BP) and 
risers (an increase in nocturnal BP) has been greater in OSA than in healthy subjects. 
Both may contribute to impaired CVD outcome (Torres et al. 2015).  
Several population-based studies have shown an association between OSA and 
prevalent hypertension independent of other known CVD risk factors (Hou et al. 
2018). The Wisconsin Sleep Cohort Study, the Sleep Heart Health Study and the 
more recent HypnoLaus Study involving together >9000 subjects showed an 
independent 1.3–1.8-fold increased risk of prevalent hypertension in moderate to 
severe SDB compared to healthy controls (Heinzer et al. 2015, Nieto et al. 2000, 
Young et al. 1997a). One large study also found that every 1 /h-unit increase in 
AHI increased the risk of prevalent hypertension by 1 %, whereas every 10 % 
decrease in nocturnal SpO2 increased the risk by 13 % (Lavie et al. 2000). 
Furthermore, a few studies have suggested that OSA patients aged <60 years may 
be more likely to have prevalent hypertension than older patients (Bixler et al. 
2000, Haas et al. 2005, Sjöström et al. 2002), potentially since the risk factors for 
OSA or physiological responses to upper-airway conclusion may differ according 
to age (Haas et al. 2005). 
However, the results of population-based studies on incident hypertension have 
been rather conflicting, which may be at least partly explained by differences in 
cohort size, diagnostic methods for OSA and patient characteristics (Torres et al. 
2015). The Wisconsin Sleep Cohort Study showed that patients with mild OSA 
had a 2-fold (95 % CI 1.3–3.2) and those with moderate to severe OSA a 2.9-fold 
(95 % CI 1.5–5.6) increased 4-year risk of incident hypertension independent of 
confounding factors (Peppard et al. 2000b). Conversely, the Sleep Heart Health 
Study and the Vitoria Sleep Cohort study of elderly patients failed to show an 
independent association over follow-ups of 5 to 7.5 years (Cano-Pumarega et al. 
2011, O'Connor et al. 2009). A recent large meta-analysis further demonstrated 
that mild to moderate OSA was associated with a 1.2- to 1.3-fold and severe OSA 
with a 1.6-fold (95 % CI 1.3–1.9) increased risk of prevalent hypertension, while 
no significant results were found in terms of incident hypertension (Hou et al. 
2018). 
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2.2.1.3 Ischemic heart disease 
Mounting evidence from clinic- and population-based studies has suggested that 
OSA may be an independent risk factor for CAD (Hla et al. 2015, Marin et al. 2005, 
Peker et al. 2006). It has been estimated that approximately 38 % of patients with 
CAD have an AHI of ≥15 /h (Javaheri et al. 2017). The Sleep Heart Health Study 
found that the risk of prevalent CAD was 1.3-fold (95 % CI 1.0–1.6) greater among 
those with an AHI of >11 /h compared to controls (Shahar et al. 2001). Observational 
studies have suggested that OSA may be a trigger for nocturnal myocardial infarction 
(Kuniyoshi et al. 2008) or sudden cardiac death (Gami et al. 2013). 
A clinic-based study of over 300 subjects found that mild OSA was associated 
with an adjusted 5-fold (95 % CI 1.8–11.6) increased 7-year risk of incident CAD 
compared to healthy subjects (Peker et al. 2006), while another study of over 1600 
males found that severe OSA was associated with a 3-fold (95 % CI 1.2–7.5) higher 
10-year risk of cerebrovascular and cardiac events compared to healthy controls 
(Marin et al. 2005). Population-based studies have generally shown an independent 
1.1–2.6-fold greater risk of incident CAD in OSA or OSA subgroups. The 
Wisconsin Sleep Cohort Study showed a 3-fold (95 % CI 1.1–6.1) greater risk of 
CAD or HF in severe SDB over a follow-up of up to 24 years compared to healthy 
subjects (Hla et al. 2015), while the Sleep Heart Health Study found an increased 
9-year risk of incident CAD in SDB only in males aged ≤70 years (Gottlieb et al. 
2010). Another analysis of the same study population also found that moderate to 
severe SDB was associated with a 2-fold (95 % CI 1.1–2.5) increased risk of fatal 
CAD events only among males (Punjabi et al. 2009). However, a Finnish study of 
over 36 000 subjects did find a higher 15-year risk of CAD in females with OSA 
(Strausz et al. 2018).  
OSA has also been suggested to worsen prognosis in CAD patients treated with 
percutaneous coronary intervention (PCI) (Lee et al. 2016, Qu et al. 2018). The Sleep 
and Stent Study of 1311 CAD patients treated with PCI found that those with an AHI 
of ≥15 /h had a 1.6-fold increased 2-year risk (95 % CI 1.1–2.2) of major adverse 
cardiac and cerebrovascular events (Lee et al. 2016). A meta-analysis of prospective 
studies including 2465 CAD patients treated with PCI confirmed that the risk of 
cardiac events was 1.6–2-fold higher among those with OSA (Qu et al. 2018). 
2.2.1.4 Stroke 
It has been estimated that approximately 57 % of patients with stroke have moderate 
to severe OSA (Javaheri et al. 2017). A recent Finnish study reported that up to 93 
% of patients with acute ischemic stroke had at least mild sleep apnea and that the 
OSA severity actually progressed to moderate or severe in 69 % after a follow-up of 
6 months (Huhtakangas et al. 2018). A large meta-analysis showed that OSA 
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prevalence was higher among those with recurrent rather than initial stroke (Johnson 
& Johnson 2010). Furthermore, a study of 161 patients with acute stroke or transient 
ischemic attack (TIA) found no correlation between the location of neurological 
lesions and OSA, suggesting that OSA had preceded the stroke onset (Parra et al. 
2000). OSA patients with stroke have also shown to differ from those without stroke 
by being less sleepy and having a lower BMI (Arzt et al. 2005), and it has been 
suggested that sleep studies should be considered in all patients with acute stroke or 
TIA (Johnson & Johnson 2010, Kernan et al. 2014). 
Compared to controls without OSA, the Sleep Heart Health Study showed a 1.6-
fold (95 % CI 1.0–2.5) increased risk of prevalent stroke in patients with an AHI of 
>11 /h (Shahar et al. 2001), while the Wisconsin Sleep Cohort Study reported a 4-
fold (95 % CI 1.3–14.2) greater risk among those with moderate to severe OSA (Arzt 
et al. 2005). The former also found a dose-response relationship between OSA and 
incident stroke over a follow-up of 9 years among women with an AHI of >25 /h and 
all men (Redline et al. 2015), while the latter did not find an independent association 
after a 4-year follow-up (Arzt et al. 2005). However, the Spanish Vitoria Sleep study 
of elderly patients found a 2.5-fold (95 % CI 1.0–6.0) higher 6-year risk of incident 
stroke (Munoz et al. 2006), and a clinic-based study of 1022 subjects also reported a 
2-fold (95 % CI 1.1–3.5) increased 3-year risk of incident stroke or all-cause death 
compared to controls without OSA (Yaggi et al. 2005). Thus, the risk of stroke has 
been suggested to be approximately 2- to 4-fold higher in OSA. A large meta-
analysis of prospective cohort studies further confirmed that the risk of incident 
stroke was 2.2-fold (95 % CI 1.4–3.2) higher among severe OSA compared to those 
without OSA (Wang et al. 2013). 
OSA has also been associated with a worse prognosis in patients with stroke 
(Kaneko et al. 2003a, Martínez-García et al. 2009), including poorer functional 
outcomes, prolonged hospitalization and rehabilitation during the post-stroke period 
(Kaneko et al. 2003a), and potentially increased risk of death at least in those with 
moderate to severe OSA (Martínez-García et al. 2009). 
2.2.1.5 Peripheral artery disease 
PAD is a form of systemic atherosclerosis and it has been associated with an 
increased risk of CVD events and death (Hirsch et al. 2001). The prevalence of 
OSA has been unexpectedly high in patients with advanced PAD, since it was 
found in 50–85 % of PAD patients referred for revascularization (Szymanski et al. 
2019, Utriainen et al. 2013). Furthermore, OSA may be associated with a worse 
prognosis in these patients, since an observational study of 84 patients with PAD 
referred for revascularization showed that those with moderate to severe OSA had 
an independent 5-fold (95 % CI 1.9–13.9) greater risk of major adverse 
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cardiovascular and cerebrovascular events than controls without OSA (Utriainen 
et al. 2014). However, the current data on the prevalence of PAD in OSA patients 
is scarce. 
2.2.1.6 Heart failure 
The relationship between OSA and HF is likely bidirectional. HF-related hypoxemia 
and venous congestion may result in unstable respiratory control particularly in 
obese subjects (Javaheri et al. 2020a). Peripheral edema may accumulate in the neck 
area in a supine position, predisposing to supine-predominant OSA (Wang et al. 
2020). CSA and Cheyne-Stokes respiration may also lead to upper airway collapse 
(Javaheri et al. 2017). OSA may predispose to HF through negative intrathoracic 
pressure swings, intermittent hypoxemia, increased sympathetic nerve activity and 
endothelial dysfunction (Bradley & Floras 2003, Coniglio & Mentz 2020).  
It has been estimated that the prevalence of moderate to severe OSA is 
approximately 20 % in HF with reduced (HFrEF) and 23 % in HF with preserved 
ejection fraction (HFpEF) (Javaheri et al. 2017). HF patients with OSA rarely report 
EDS, which likely leads to underdiagnosis of OSA (Bradley & Floras 2003, Javaheri 
et al. 2017). The Sleep Heart Health Study found that an AHI of >11 /h was 
associated with over a 2-fold (95 % CI 1.2–4.6) greater independent risk of prevalent 
HF compared to healthy controls (Shahar et al. 2001), while every 10 /h-unit increase 
in AHI increased the 9-year risk of incident HF by 13 % in men but not in women 
(Gottlieb et al. 2010). It has been recommended that all HF patients with New York 
Heart Association class II–IV should be screened for OSA (Yancy et al. 2017). 
Observational studies have also suggested that the risk of death may be 2- to 3-
fold higher in chronic HFrEF (Jilek et al. 2011, Wang et al. 2007) and 1.6-fold higher 
in acute HFrEF among those with moderate to severe OSA compared to a lower AHI 
(Khayat et al. 2015). This could be at least partly due to increased sympathetic nerve 
activity in the awake state, which may predispose to premature mortality and sudden 
death in HF (Floras 2003). Conversely, a smaller study did not find a difference in 
the 4-year mortality risk between HFrEF patients with or without OSA; however, 
those treated with CPAP were not examined separately (Roebuck et al. 2004). 
2.2.1.7 Atrial fibrillation 
OSA may predispose to AF particularly through intermittent hypoxemia and 
recurrent negative intrathoracic pressure swings, which may lead to increases in both 
pre- and afterload of the right side of the heart due to increased venous return and 
pulmonary vasoconstriction. Right atrial and ventricular enlargement and leftward 
septal displacement during diastole may impair left ventricular filling, leading to 
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increases in left atrial volume. Thin-walled left atrium also stretches easily due to 
intrathoracic pressure changes, which may activate catecholamine-sensitive ion 
channels and produce electrical impulse inducing AF (Javaheri et al. 2017, Linz et 
al. 2018). A large observational study also showed that obesity and nocturnal 
hypoxemia were both independently associated with AF over a follow-up of up to 
15 years but only in patients aged <65 years (Gami et al. 2007).  
The prevalence of OSA in patients with AF has been estimated to be in the range 
of 21 to 74 % (Linz et al. 2018). A large observational study found a higher 
prevalence of OSA (49 vs. 33 %) based on the Berlin questionnaire in patients with 
AF undergoing cardioversion compared to high-risk patients with multiple other 
CVDs (Gami et al. 2004). The Sleep Heart Health Study showed that severe SDB 
was associated with an independent 4-fold (95 % CI 1.0–15.7) greater risk of 
nocturnal AF compared to subjects without SDB (Mehra et al. 2006). Furthermore, 
nocturnal AF or non-sustained ventricular tachycardia occurred 18-times (95 % CI 
5.3–58.4) more likely after a respiratory disturbance than normal breathing, although 
the absolute rate of observed arrhythmias was extremely low (Monahan et al. 2009). 
However, a smaller study found no significant association between OSA and AF 
when patients with AF were studied for OSA (Porthan et al 2004). 
Observational studies have also suggested that untreated OSA is associated with 
an increased risk of AF recurrence after cardioversion and cardiac ablation compared 
to treated patients (Fein et al. 2013, Kanagala et al. 2003, Neilan et al. 2013) and a 
higher risk of hospitalization and worse symptoms. No significant differences were 
observed in the risk of all-cause mortality or CVD events (Holmqvist et al. 2015).  
2.2.1.8 Pulmonary hypertension 
The prevalence of OSA in patients with pulmonary hypertension, defined as a mean 
pulmonary artery pressure of >25 mmHg, appears to be much higher compared to 
that in the general population (Javaheri et al. 2013). All types of SDB may occur in 
30–90 % of the patients (Wong et al. 2017). Particularly intermittent hypoxemia, 
negative intrathoracic pressure swings and endothelial dysfunction could result in 
the development of awake pulmonary hypertension directly by adverse remodeling 
of pulmonary arteries or myocardium or indirectly by e.g. systemic hypertension and 
left sided HF (Javaheri et al. 2013, Wong et al. 2017). The American College of 
Chest Physicians has recommended SDB to be assessed in all patients with 
established pulmonary hypertension (Atwood et al. 2004). 
Conversely, the prevalence of pulmonary hypertension in OSA remains 
uncertain (Javaheri et al. 2013), particularly since the inclusion and exclusion criteria 
of patients have varied between studies (Wong et al. 2017). A combined analysis of 
6 studies involving 519 OSA patients reported that pulmonary hypertension was 
Minna Myllylä 
 34
observed in 10 %, and its severity was mild in most cases (Javaheri et al. 2013). 
Severe pulmonary hypertension is not commonly met in OSA patients if other 
predisposing comorbidities, such as obesity or chronic obstructive pulmonary 
disease (COPD), do not exist (Javaheri et al. 2013, Wong et al. 2017).  
2.2.1.9 Type 2 diabetes 
The prevalence of T2D with OSA has been estimated to be up to 15–30 %, and 70 
% vice versa (Kent et al. 2014b, Reutrakul & Mokhlesi 2017). It has been suggested 
that OSA may be independently associated with prediabetic conditions, although 
obesity has been an important confounding factor in these associations (Hoyos et al. 
2017). T2D patients with OSA may also have worse glucose control than those 
without OSA (Pamidi & Tasali 2012). A few observational studies have suggested 
an association between increasing OSA severity and the risk of prevalent T2D (Kent 
et al. 2014b, Pamidi & Tasali 2012), although one study reported an increased risk 
only in those with severe OSA and EDS (Ronksley et al. 2009). Patients in the 
Wisconsin Sleep Cohort Study and the European Sleep Apnea Database study with 
moderate to severe OSA had an independent 2-fold increased risk of prevalent T2D 
compared to subjects without OSA (Kent et al. 2014b, Reichmuth et al. 2005).  
The association between OSA and incident T2D has been more controversial 
(Pamidi & Tasali 2012). A cohort study of over 1200 subjects reported that OSA was 
associated with an adjusted 1.4-fold (95 % CI 1.1–1.9) higher 3-year risk of T2D 
(Botros et al. 2009). A similar result was found in the Australian Busselton Health 
Study (Marshall et al. 2009), while the Wisconsin Sleep Cohort Study did not report 
an increase in the 4-year T2D risk in moderate to severe OSA (Reichmuth et al. 
2005). Two Swedish studies with >10-year follow-ups also showed mixed results, 
since one study found an increased risk only in women (Celen et al. 2010), while the 
other study showed a 4-fold (95 % CI 1.1–18.1) greater risk among males with an 
ODI of >5 /h (Lindberg et al. 2012). Overall, it is not clear whether OSA could 
predispose to T2D, and further large-scale studies are needed (Patil et al. 2019). 
2.2.2 Other comorbidities 
Depression and anxiety. OSA may be more prevalent in patients with depression, 
since its prevalence in this patient group has been approximately 50 % in clinic- and 
slightly over 7 % in population-based samples. However, the evidence regarding the 
prevalence of OSA in anxiety disorders other than posttraumatic stress disorder has 
been insufficient (Gupta et al. 2015). There are also data suggesting an increased 
prevalence of depression in OSA, which may contribute to EDS. A recent RCT of 
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CAD patients showed that depressive mood was more prevalent among those with 
OSA (29 vs. 19 %) and particularly in the present of sleepiness (Balcan et al. 2019).  
COPD. The prevalence of COPD in OSA has been estimated to be 10–55 %, 
while the prevalence of OSA in COPD has varied in the range of 5–85 % (Khatri & 
Ioachimescu 2016). An overlap of OSA and COPD has been associated with more 
severe nocturnal hypoxemia, a higher prevalence of pulmonary hypertension and a 
7-fold higher risk of all-cause mortality compared to OSA without COPD (Khatri et 
al. 2016, Lavie et al. 2007, McNicholas 2016). Furthermore, an observational study 
showed that the risk of all-cause mortality or hospitalization due to severe COPD 
exacerbation did not differ between CPAP-treated patients and those with COPD 
only (Marin et al. 2010). However, these findings remain to be confirmed in future 
RCTs (Khatri & Ioachimescu 2016, McNicholas 2016).  
Asthma. It has been suggested that patients with asthma may have up to 2-fold 
increased OSA risk, while the prevalence of asthma in patients with OSA has been 
estimated to be approximately 35 %. Asthma and OSA share several risk factors and 
a causal relationship has not been confirmed. However, it has been reported that OSA 
may worsen asthma control (Khatri & Ioachimescu 2016).  
Gastroesophageal reflux. A causal relationship between gastroesophageal reflux 
and OSA has not been confirmed, although OSA patients seem to have a higher 
prevalence of gastroesophageal reflux. Obesity has been the most important 
confounding factor in these associations (Zanation & Senior 2005).  
Cancer. Observational studies have suggested an association between OSA and 
cancer incidence potentially due to intermittent hypoxemia and sleep fragmentation, 
but a causal relationship has not been confirmed (Patil et al. 2019). The Wisconsin 
Sleep Cohort study showed that the 22-year risk of cancer mortality increased 
independently with increasing AHI (Nieto et al. 2012). One study showed an 
increased risk of prevalent cancer in OSA only among women (Pataka et al. 2019), 
while the other study demonstrated a greater 4.5-year cancer incidence only among 
males aged <65 years (Campos-Rodriguez et al. 2013). An association between OSA 
and prevalent or incident cancer was not, however, observed in two other large 
studies, although nocturnal SpO2 of <90 % did independently associate with 
smoking-related cancers (Christensen et al. 2013, Kendzerska et al. 2014). Overall, 
further studies on the subject are needed.  
2.3 Risk of motor vehicle accidents (MVAs) in OSA 
Several observational studies have suggested that patients with untreated OSA may 
have up to 2- to 7-fold greater risk of being involved in an MVA (Cassel et al. 1996, 
George 2001, Horstmann et al. 2000, Stoohs et al. 1994, Young et al. 1997b). Based 
on a meta-analysis of 10 studies with over 2200 subjects, the mean risk of MVAs 
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was estimated to be over 2-fold (95 % CI 1.2–4.9) greater in patients with than 
without OSA (Tregear et al. 2009). A Swedish observational study of 1478 subjects 
further confirmed that patients with OSA had a 2.5-fold (95 % CI) greater risk of 
objectively reported MVAs compared to control subjects from the general 
population (Karimi et al. 2015). It has been actually estimated that more than 800 
000 drivers had an OSA-related MVA in the United States in the year 2000 resulting 
in 1400 deaths and a cost of 15.9 billion United States dollars (Sassani et al. 2004).  
2.3.1 Potential predictors of MVAs 
Daytime sleepiness. Several studies have reported that the MVA risk only tended to 
increase with increasing ESS score (Horstmann et al. 2000, Mulgrew et al. 2008, 
Young et al. 1997b), but however, a significant association has been observed in 
those with an ESS score of ≥16 (Karimi et al. 2015). Overall, daytime sleepiness 
from any cause has been associated with an increased MVA risk and is estimated to 
be responsible for approximately 20 % of highway accidents (Garbarino et al. 2001). 
Furthermore, experiencing sleepiness while driving rather than sleepiness in general 
may be one of the most important factors in addition to previous MVAs and near-
miss accidents in the assessment of driving risk (Dwarakanath & Elliott 2019).   
OSA severity. Only a few studies have suggested a significant association 
between more severe AHI and the risk of MVAs (Tregear et al. 2009), while the 
majority have not (Karimi et al. 2015, Mulgrew et al. 2008, Stoohs et al. 1994). 
Nocturnal hypoxemia may be a potential risk factor for MVAs, but a specific 
threshold level for SpO2 has not been verified (Engleman et al. 1996, Tregear et al. 
2009). 
BMI. Several studies have found an association between a higher BMI and 
increased risk of MVAs (Tregear et al. 2009). Two observational studies reported 
that OSA patients with MVAs had a higher BMI 2 to 3 years before the accident 
compared to those without MVAs (Horstmann et al. 2000, Yamamoto et al. 2000). 
Another large observational study also showed a small but significant elevation in 
the risk of MVAs with increasing BMI (Mulgrew et al. 2008), and a study of 90 
CMV drivers found that those with a BMI of ≥30 kg/m2 had a higher MVA rate than 
leaner patients after adjustment for driving exposure (Stoohs et al. 1994).  
Other risk factors. The MVA risk has also been shown to be elevated in patients 
with long annual driving distances, a short self-reported sleep time of ≤5 h/night and 
use of hypnotic medication, in addition to younger age and male gender (Gonçalves 
et al. 2015, Karimi et al. 2015). Furthermore, it has been suggested that OSA could 
potentially predispose to changes in brain morphology and neural activation leading 
to cognitive impairment and negative consequences on fitness to drive (Morrell et 
al. 2010). A study of 120 subjects found that OSA was independently associated with 
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focal loss of grey matter in magnetic resonance imaging (MRI) compared to those 
without OSA (Morrell et al. 2010). Working memory speed measured by functional 
MRI has also been shown to be significantly slower in OSA (Thomas et al. 2005). 
As a response to cognitive challenges, increased brain activation in several brain 
regions has been detected in functional MRI among OSA patients, which may 
represent an adaptive compensatory recruitment response (Ayalon et al. 2006). 
2.4 Continuous positive airway pressure (CPAP) 
treatment of OSA 
2.4.1 Mechanism and physiological effects 
A CPAP device delivers a positive pressure to the airway throughout inspiration and 
expiration splinting the airways open and preventing them from collapsing. It 
reduces airway resistance and the work of breathing and consolidates sleep by 
decreasing the number of apnea-hypopnea episodes (Antonescu-Turcu & 
Parthasarathy 2010, Leech et al. 1992, Sullivan et al. 1981). A recent RCT meta-
analysis observed an 86 % decrease in AHI with CPAP compared to before 
treatment, and CPAP was found to be efficient in reducing AHI/ RDI despite the 
severity of OSA at baseline (Patil et al. 2019). CPAP has been shown to be more 
effective in reducing AHI than a placebo, conservative treatment, positional therapy 
or oral appliances (Gay et al. 2006, Ramar et al. 2015). However, since OSA is a 
chronic condition that rarely resolves except with substantial weight loss or 
successful corrective surgery, long-term use of CPAP is usually required (Patil et al. 
2019).  
Positive airway pressure also increases intrathoracic pressure, which may result 
in reduced cardiac preload (by decreased venous return to heart) and reduced 
afterload (by reduced left ventricular transmural pressure), improving cardiac output 
(Antonescu-Turcu & Parthasarathy 2010). It improves end-expiratory lung volume, 
leading to increased oxygen stores and tracheal traction, which improves the patency 
of the upper airway (Antonescu-Turcu & Parthasarathy 2010). Several RCTs have 
shown CPAP to decrease BP and heart rate, particularly due to reductions in 
sympathetic activation, and small RCTs have suggested that CPAP may improve 
LVEF in HFrEF (Peker & Balcan 2018). Figure 3 summarizes the main 
physiological effects of CPAP. 
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Figure 3.  Physiological effects of continuous positive airway pressure (CPAP). Reprinted from 
Respiratory care: the official science journal of the American Association for Respiratory 
Care (Antonescu-Turcu & Parthasarathy 2010) with permission from the American 
Association for Respiratory Care. 
However, CPAP may also result in ventilatory instability and the development of 
CSA during treatment in some OSA patients if the arterial pCO2 is reduced below 
the apnea threshold level (Antonescu-Turcu & Parthasarathy 2010). The task force 
of the European Respiratory Society has defined two different phenotypes of patients 
developing CSA during CPAP. CSA disappears with continued CPAP use in 
treatment-emergent CSA, while it does not disappear in treatment-persistent CSA 
(Randerath et al. 2017). A study of 675 OSA patients found that CSA was present in 
12 % during the first night with CPAP but declined to 7 % after 3 months of treatment 
(Cassel et al. 2011), suggesting disappearance of CSA in a significant proportion of 
patients. Sleep insufficiency, arousals, insomnia, adaptation of loop gain after 
resolution of upper airway obstruction, high CPAP pressure level and excessive 
mask leakage have been identified as factors that may predispose to the development 
of CSA during CPAP treatment (Randerath et al. 2017). 
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2.4.2 Evaluation of treatment 
CPAP is the primary treatment for OSA, especially among patients with an AHI of 
≥15 /h even in the absence of symptoms, but it is also recommended for milder OSA 
when the patient shows symptoms of EDS, has hypertension or other significant 
comorbidities, or impaired sleep-related quality of life (Chowdhuri et al. 2016, Gay 
et al. 2006, Loube et al. 1999, Patil et al. 2019, Sullivan et al. 1981). 
2.4.3 Types of CPAP and the use of bilevel positive airway 
pressure for OSA treatment 
A fixed pressure CPAP device delivers a constant air pressure (usually 4–20 cmH2O) 
throughout the respiratory cycle, whereas an auto-adjusting device assesses breath-
by-breath the minimum pressure required to maintain the patency of the airway. 
Thus, an auto-adjusting device increases or decreases the level of positive airway 
pressure in response to changes in airflow, circuit pressure or the resistance of the 
upper airway. Newer CPAP devices may also contain modified pressure profiles, 
which aim to reduce pressure during expiration to improve comfort of use (Bakker 
et al. 2019, Patil et al. 2019). Figure 4 shows an example of a CPAP device. 
According to a recent recommendation by the AASM, optimal CPAP pressure 
may be determined either by using an auto-adjusting device at home or by 
conventional in-laboratory titration, since no clinically relevant differences were 
found between the two strategies in terms of compliance, sleepiness or quality of life 
in OSA patients without significant comorbidities. Either auto-adjusting or fixed 
CPAP device may be used for ongoing treatment, although auto-adjusting device is 
often preferred due to cost-effectiveness, faster initiation of treatment and greater 
access to care, since laboratory environment is not required. It also enables the 
continuation of effective treatment without the guidance of health-care personnel, 
since it automatically adjusts the pressure to a required level in response to e.g. 
changes in body position or weight. However, treatment-related problems may not 
be identified as effectively as during an in-laboratory titration (Patil et al. 2019). 
As a difference to CPAP, a bilevel positive airway pressure device delivers a 
higher positive airway pressure during inspiration than expiration. It has not been 
recommended to be used instead of CPAP for routine OSA treatment due to a higher 
cost with no clinically relevant differences observed in compliance, residual AHI, 
sleepiness or sleep-related quality of life. However, it may be used in special cases, 
particularly if high pressure levels (>20 cmH2O) are required. A trial with bilevel 
positive airway pressure or modified pressure profile CPAP may also be suitable for 
some of those patients who do not adapt to CPAP due to its high pressure demands. 
Overall, SDB-related hypercapnia remains to be the most common indication for the 
use of bilevel positive airway pressure instead of CPAP (Patil et al. 2019). 
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Figure 4.  An example of a continuous positive airway pressure (CPAP) device with a humidifier. 
Reprinted with permission from ResMed Finland Oy. 
2.4.4 Compliance 
Adherence to CPAP has been shown to be comparable to adherence to other medical 
treatments (Bakker et al. 2019). An observational study of 639 OSA patients reported 
that 81 % had continued CPAP after 5 years and 70 % after 10 years (Kohler et al. 
2010). However, it has been estimated that 30 to 80 % of patients are not compliant 
with CPAP if a threshold of ≥4 h/day is used to define compliance (Sawyer et al. 
2011, Weaver & Grunstein 2008). The mean use of CPAP has been reported to be 
approximately 3 h/day among non-compliant patients and 6 h/day among those who 
are compliant (Sawyer et al. 2011). Patients with mild OSA have been reported to 
adhere to CPAP similar to those with a more severe disease (Bakker et al. 2019). A 
study of 77 mild OSA patients found that 62 % had continued CPAP for 6 months 
with a mean compliance of 5 h/day (Monasterio et al. 2001). Prolonged partial upper 
airway obstruction has also been shown to be treatable with CPAP with good 
adherence to treatment (Anttalainen et al. 2016b). 
2.4.4.1 Criteria for adequate compliance 
Adequate compliance with CPAP has usually been defined as CPAP use of ≥4 h/day, 
since several studies have shown that sleepiness and other OSA-related symptoms 
are generally improved by this level of adherence (Patil et al. 2019, Weaver et al. 
2007). Studies have traditionally accepted a patient to be compliant with CPAP if 
the device has been used ≥4 h/day for ≥70 % of the days monitored (Gay et al. 2006). 
However, patients are considered to benefit from CPAP in a dose-response manner 
and even a one-night withdrawal may reverse achieved improvements in daytime 
sleepiness and increase AHI (Weaver et al. 2007). The adequate use of CPAP may 
also vary between different clinical outcomes (Antic et al. 2011, Weaver et al. 2007). 
A study of 149 patients with severe OSA reported that sufficient treatment responses 
to self-reported sleepiness, objective sleepiness and functional status were achieved 
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with a CPAP use of 4, 6 and 7.5 h/day, respectively (Weaver et al. 2007), although 
improvement or normalization of these symptoms may still not be observed in all 
patients (Bakker et al. 2019). Overall, the majority of clinicians recommend CPAP 
to be used regularly for the entire night (Patil et al. 2019).  
2.4.4.2 Factors affecting and methods to improve compliance 
OSA and patient characteristics. CPAP adherence has not been consistently 
associated with age or gender (Kohler et al 2010, Weaver et al. 2007) and its 
association between subjective sleepiness or OSA severity has been relatively weak 
(Weaver & Grunstein 2008, Sawyer et al. 2011). A large observational study did, 
however, report that ODI was the only clinical variable independently linked to long-
term adherence (Kohler et al. 2010). Nasal anatomy or existence of comorbidities 
may also affect CPAP use (Sawyer et al. 2011). A smaller nasal cross-sectional area 
has been associated with poorer adherence (Sawyer et al. 2011). Psychiatric 
disorders have been suggested to affect a patient’s perception of OSA symptoms and 
CPAP-related side effects, although e.g. depression and anxiety may affect 
adherence differently. Tendencies to claustrophobia may preclude some patients 
from initiating CPAP, although they may not result in nonadherence. Future studies 
on the effects of psychiatric disorders and personality types on CPAP adherence are 
still needed (Sawyer et al. 2011). 
Remote monitoring. Compliance during the first few weeks has been shown to 
predict compliance in the long term, emphasizing the importance of patient follow-
up after the initiation of CPAP (Patil et al. 2019, Weaver & Grunstein 2008). An 
RCT of CAD patients showed that poor CPAP use at 1 month was an independent 
predictor of inadequate usage at 12 months (Chai-Coetzer et al. 2013). Patients 
have also been reported to overestimate their CPAP usage by approximately 1 
h/day (Sawyer et al. 2011). The AASM has recommended objective telemonitoring 
of CPAP compliance in addition to subjective assessment, while routine re-
evaluation of patients by sleep studies is not required. Patients with repetitive 
treatment-related difficulties can be identified through telemonitoring and are 
recommended to be followed more frequently than those who have been compliant. 
Adjustments to the device can be made, since data on residual AHI, potential mask 
leak and other CPAP settings are received (Patil et al. 2019). Overall, 
telemonitoring has been linked to improved or similar adherence to CPAP 
(Anttalainen et al. 2016a, Patil et al. 2019).  
CPAP-related side effects. Side effects have been estimated to occur in two-
thirds of patients (Sawyer et al. 2011). They may be mask-related (e.g. leak, facial 
irritation, sore eyes/ conjunctivitis), pressure-related (e.g. rhinitis, dryness of mouth 
or nose, rhinorrhea, headache, ear pain, pressure intolerance), equipment-related 
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(e.g. noise, spousal intolerance, equipment maintenance and cleaning) and other side 
effects (e.g. anxiety, insomnia, nocturnal awakenings) (Gay et al. 2006, Patil et al. 
2019). Side effects may result in sleep disruption and decreased quality of sleep, and 
their existence at 1 month has been shown to independently predict CPAP adherence 
at 12 months. Proper treatment of side effects during early-on treatment may, thus, 
improve long-term adherence (Chai-Coetzer et al. 2013, Patil et al. 2019). A recent 
meta-analysis showed that a nasal mask was associated with an increased treatment 
compliance compared to oronasal mask due to fewer side effects. The use of 
humidification was also associated with a reduction in side effects, although no 
significant difference was observed in CPAP adherence (Patil et al. 2019).  
Psychological factors and interventions. Behavioral determinants have actually 
been suggested to account for up to 20 % of the total variance in CPAP compliance 
(Bakker et al. 2019, Patil et al. 2019). A recent RCT meta-analysis reported that the 
use of different types of interventions soon after the initiation of CPAP was 
associated with improved compliance (Patil et al. 2019). Educational intervention 
has focused on providing general information on OSA, its harmful consequences and 
CPAP’s beneficial effects. Behavioral intervention has usually included cognitive 
behavioral therapy or motivational enhancement, whereas the identification of 
problems related to CPAP and their potential resolutions have been emphasized in 
troubleshooting intervention (Patil et al. 2019). 
2.5 Effects of CPAP treatment for OSA 
2.5.1 OSA symptoms and quality of life 
Several RCTs have shown a decrease in ESS score of 2–7 points after a 4- to 6-week 
treatment with CPAP, in addition to an improvement in objective sleepiness and 
functional outcomes compared to oral placebo treatment, subtherapeutic or sham 
CPAP (Batool-Anwar et al. 2016, Faccenda et al. 2001, Montserrat et al. 2001). An 
improvement in ESS has been reported also to remain over the long term (Batool-
Anwar et al. 2016, McEvoy et al. 2016). A recent RCT meta-analysis by the AASM 
confirmed a mean reduction of 2.4 scores in ESS after CPAP in addition to improved 
capacity to maintain wakefulness, particularly in sleepy OSA patients compared to 
no treatment. A reduction of ≥2 points in ESS with CPAP was demonstrated to fulfil 
the criteria of clinical significance (Patil et al. 2019). However, patients with other 
signs of sleepiness, tiredness or fatigue may also benefit from a trial with CPAP, 
despite having a low ESS score at baseline (Patil et al. 2019). 
The results of RCTs evaluating the effectiveness of CPAP on mood, 
neurocognitive functions and quality of life in moderate to severe OSA have been 
controversial (Batool-Anwar et al. 2016, Martínez-García et al. 2015, McEvoy et al. 
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2016). A recent RCT meta-analysis by the AASM confirmed a clinically significant 
association between CPAP and sleep-related quality of life but not on overall quality 
of life. No significant improvements were observed in neurocognitive functions and 
mood, although none of the studies specifically enrolled patients with depression, 
anxiety or deficits in neurocognitive functions. However, CPAP may have beneficial 
effects on depression in different OSA subgroups, since an RCT of CAD patients 
showed that a 3- to 12-month treatment with CPAP independently improved mood 
in sleepy and non-sleepy patients (Balcan et al. 2019). This finding was confirmed 
in a recent RCT meta-analysis of 4255 patients with CVD (Zheng et al. 2019).  
Emerging evidence has suggested that treatment of mild OSA with CPAP is 
likely to improve subjective sleepiness, whereas the data on neurocognition, mood 
and quality of life have been more controversial (Barnes et al. 2002, Batool-Anwar 
et al. 2016, Chowdhuri et al. 2016, Monasterio et al. 2001, Patil et al. 2019). Overall, 
further studies on the effectiveness of CPAP on symptoms in mild OSA are needed. 
A need also exists for studies on other OSA-related symptoms, such as nocturia, 
sexual dysfunction or insomnia, in all OSA patients (Patil et al. 2019). 
2.5.2 Weight management and metabolic outcomes 
Untreated OSA has been suggested to predispose to weight gain, even though 
increased attempts to breath against the closed airway during sleep have been 
associated with elevated nocturnal energy expenditure levels (Stenlöf et al. 1996). A 
study of 53 OSA patients reported that weight gain of 7–8 kg was observed in both 
genders over the year preceding OSA diagnosis compared to controls matched for 
age, gender, BMI and percent body fat (Phillips et al. 1999). Daytime fatigue, sleep 
fragmentation and hypoxemia may predispose to weight gain by decreased physical 
activity, increased caloric intake potentially due to changes in leptin and ghrelin 
levels, and alterations in the gut microbiome (Drager et al. 2015, Joosten et al. 2017). 
Thus, CPAP could have beneficial effects on weight maintenance. 
Conversely, a large RCT showed that each 1 h/day increase in CPAP adherence 
was actually associated with an increase of 0.4 kg in weight over a 6-month follow-
up (Quan et al. 2013). A meta-analysis of 25 RCTs involving 3181 OSA patients 
further confirmed a significant albeit a modest increase in weight among CPAP-
treated patients compared to controls (+0.4 vs. -0.1 kg) over a follow-up of 3 months. 
The BMI outcome was predicted only by baseline weight, while age, gender, OSA 
severity or CPAP adherence did not affect the results. However, most of the studies 
were not specifically designed to evaluate the effect of CPAP on BMI. Long-term 
RCTs are still needed, but overall, lifestyle interventions should be recommended 
for all overweight OSA patients initiating CPAP (Drager et al. 2015, Joosten et al. 
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2017). Table 2 summarizes the characteristics and results of the main studies 
investigating the association between CPAP treatment and weight changes. 
The mechanisms by which CPAP could contribute to weight gain are not entirely 
clear. CPAP reduces airway resistance and the work of breathing, which results in 
reduced nocturnal energy expenditure levels. A study of 63 patients with newly 
diagnosed OSA observed a small reduction in basal metabolic rate after a 3-month 
treatment with CPAP, even though energy intake levels and physical activity 
remained unchanged (Tachikawa et al. 2016). CPAP may also contribute to weight 
gain due to reduced sympathetic activation (Drager et al. 2015, Quan et al. 2013). 
Furthermore, it appears that CPAP has only minimal effect on increasing physical 
activity despite the improvements in fatigue and daytime sleepiness (Shechter 2017). 
Most RCTs have failed to show any significant improvement in fasting glucose 
or glycated hemoglobin by 2- to 6-month treatment with CPAP in patients with or 
without established T2D (Hoyos et al. 2012, Patil et al. 2019, Shaw et al. 2016, 
Sivam et al. 2012). The majority of the studies have involved mainly obese male 
patients with moderate to severe OSA and CPAP use of 3.3–4.3 h/day. It is not clear 
whether a better outcome could be observed in other patient groups or with higher 
adherence (Patil et al. 2019). RCTs are still needed to evaluate whether benefits in 
glucose metabolism could potentially occur during long-term treatment with CPAP 
(Hoyos et al. 2017). 
R
EVIEW
 O
F TH
E LITER
ATU
R
E 
 
45 
RANDOMIZED CONTROLLED TRIALS (RCTS) 
Comments 
Baseline: 45–75 y, ODI4 ≥12, 
CVD, ESS ≤15, SpO2 ≥80%;  
M: CPAP ≥4 h/d ↑  weight  
(0.4 kg) vs. control 
Baseline: ≥18 y, ODI ≥15, AHI 
<70, T2D; 
CPAP+UC vs. UC: ∆  in BMI, 
HbA1c NS 
Baseline: AHI ≥15, BMI ≥30; 
IR, trigly, CRP: ↓  in CPAP+WL, 
↓  in WL, ↔ in CPAP 
Groups: 1) OSA: F: AHI >10 + 
menopausal, M: AHI >15 + 
middle-aged, 2) Control: AHI <5 
Baseline: 30–65 y, AHI ≥15, 
RHTN; 
Baseline BMI higher in CPAP 
Baseline: >18 y, AHI ≥10; 
1 h/d ↑  in CPAP use ↑  weight 
by 0.4 kg 
Findings  
(∆  in BMI in kg/m2) 
CPAP+UC vs. UC: ∆  in 
BMI NS 
CPAP+UC: ↔ BMI (∆  
-0.3); 
UC: ↓  BMI (∆  -1.2) 
CPAP+WL or WL: ↓  
weight (both: -7 kg); 
CPAP: weight ↔ 
CPAP or sham CPAP: 
↔ BMI, abdominal and 
intra-hepatic adiposity 
CPAP vs. UC: ∆  in BMI 
NS (0.4 vs. 0.5) 
CPAP: ↑  weight vs. 
sham CPAP  
(0.4 vs. -0.7 kg) 
 
Adjustments 
Age, sex, weight, 
country, duration 
in study, PCI 
Weight change 
(HbA1c analysis) 
No adjustments 
Age, BMI;  
M and F analyzed 
separately 
No adjustments 
No adjustments 
Study 
duration 
(months) 
45 
6 
6 
2 
6 
6 
CPAP  
use (h/d) 
(mean) 
M: 3.3 
F: 3.2 
4.9 
4.0 
6.0 
6.0 
4.8 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 61–63 
AHI: 27–30 
BMI: 28–30 
Age: 62 
AHI: 26–28  
BMI: 33 
Age: 48–49 
AHI: 40–47 
BMI: 38–40 
Age: 52–58 
AHI: 32–42 (OSA) 
BMI: 27–31 
Age: 56 
AHI: 29 (median) 
BMI: 32 (median) 
Age: 53 
AHI: 41 
BMI: 32 
Subjects 
N=2483 
M: 2006 
F: 477 
N=298 
M: 192 
F: 106 
N=181 
M: 104 
F: 77 
N=81 
M: 41 
F: 40 
N=35 
M: 77% 
F: 33% 
N=812 
M: 65% 
F: 35% 
Author 
Ou  
et al. 2019 
(SAVE) 
Shaw  
et al. 
2016 
Chirinos  
et al. 2014 
Kritikou  
et al. 2013 
Pedrosa  
et al. 2013 
Quan  
et al. 2013 
(APPLES) 
Table 2.  Selected RCTs and observational studies investigating the association between CPAP treatment and weight changes in OSA patients. 
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RANDOMIZED CONTROLLED TRIALS (RCTS) 
Comments 
18-70 y, AHI ≥20, ESS ≤10; 
UC vs. CPAP: ∆  in BMI 
significant 
Baseline: 45–75 y, ODI4 >7.5, 
minimally symptomatic; 
CPAP vs. UC: ↑  BMI 
Baseline: ≥18 y, AHI ≥20 (<80), 
ODI3 ≥15, SpO2 ≥65% 
CPAP vs. sham CPAP: ↔ FG, 
visceral abdominal/ liver fat 
Baseline: >21 y, AHI ≥25, ODI 
≥20, BMI ≤35; 
CPAP vs. sham CPAP: ↔ FG, 
liver/ SC/ visceral abdominal 
Baseline: 18–75 y, AHÍ ≥15, IGT; 
CPAP + AHI ≥30 vs. sham 
CPAP: ↑  ISI, ↓  2-h OGTT 
Baseline: ≤60 y, AHI >30, BMI 
≤40, masked/ pre-HTN 
Findings  
(∆  in BMI in kg/m2) 
CPAP: ↔ BMI (∆  0.08); 
UC: ↓  BMI (∆  -0.3) 
CPAP: ↑  BMI (∆  0.1) 
UC: ↓  BMI (∆  -0.2) 
CPAP: ↔ BMI (∆  0.1) 
Sham CPAP: ↔ BMI  
(∆  0.1) 
CPAP vs. sham CPAP: 
∆  in BMI NS (∆  0.3) 
CPAP vs. sham CPAP: 
∆  in BMI NS 
CPAP vs. no CPAP: 
∆  in BMI NS (0 vs. 0.1) 
Adjustments 
No adjustments 
BMI, participating 
center, ODI, CV 
risk score 
No adjustments 
No adjustments 
AHI, BMI, sex, 
race, 2-h OGTT 
glucose level 
No adjustments 
Study 
duration 
(months) 
48 
6 
3 
2 
2 
3 
CPAP  
use (h/d) 
(mean) 
5.0 
(median) 
2.4 
3.6 
4.6 
4.8 
5.2 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 52 
AHI: 35-42 (median) 
BMI: 31 
Age: 58 
AHI: N/A 
BMI: 32–33 
Age: 49 
AHI: 40 
BMI: 31 
Age: 47 
AHI: 37 
BMI: 31 
Age: 54 
AHI: 44 
BMI: 39 
Age: 43 
AHI: 56 
BMI: 29 
Subjects 
N=723 
M: 619 
F: 104 
N=391 
M: 305 
F: 86 
N=65 
M: 65 
F: 0 
N=27 
M: 26 
F: 1 
N=50 
M: 21 
F: 29 
N=36 
M: 36 
F: 0 
Author 
Barbé  
et al. 2012 
Craig  
et al. 2012 
(MOSAIC) 
Hoyos  
et al. 2012 
Sivam  
et al. 2012 
Weinstock 
et al. 2012 
Drager  
et al. 2011b 
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RANDOMIZED CONTROLLED TRIALS (RCTS) 
Comments 
Baseline: 30–65 y, AHI ≥15, ESS 
>10 
Baseline: 18–80 y, AHI ≥15, 
RHTN 
Baseline: AHI ≥5–40, ESS >9 for 
those with AHI 5–20 
 
Baseline: AHI ≥5 + EDS or two 
other OSA-related symptoms 
Baseline: AHI >10, EDS 
OBSERVATIONAL STUDIES 
 
Baseline: AHI ≥15; 
Age/ AHI/ BMI for compliant and 
non-compliant 
 
 Findings  
(∆  in BMI in kg/m2) 
CPAP vs. sham CPAP: 
↓ BMI (∆  -0.3), MBS, 
SC/ visceral fat, HbA1c, 
trigly, cholesterol, LDL 
CPAP+UC vs. UC: ∆  in 
BMI NS 
CPAP+UC: ↓  weight 
(∆  -1.2 kg), BMI (∆  -0.4) 
UC/ OA: ↔ weight 
CPAP: ↔ BMI (∆  0.3); 
Sub-therapeutic CPAP: 
↔ BMI (∆  0.5) 
CPAP vs. sham CPAP: 
∆  in BMI NS  
(0.2 vs. -0.3) 
CPAP: ↔ BMI, energy 
expenditure, physical 
activity (1 week) 
Adjustments 
No adjustments 
 
No adjustments 
 
No adjustments 
 
No adjustments 
Smoking, BMI 
No adjustments 
Study 
duration 
(months) 
3 
3 
2.5 
3 
1.5 
9 
CPAP  
use (h/d) 
(mean) 
5.1 
5.6 
4.2 
5.1 
4.3 
6.3 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 46 
AHI: 48 
BMI: 32–34 
Age: 59 
AHI: 53 
BMI: 31 
Age: 45–47 
AHI: 19–24 
BMI: 27–28 
Age: 50–51 
AHI: 29–31 
BMI: 27 
Age: 54 
AHI: 54 
BMI: 32 
Age: 52 
AHI: 34–38 
BMI: 32–34 
Subjects 
N=86 
M: 77 
F: 9 
N=64 
M: 44 
F: 20 
N= 101 
M: 79 
F: 22 
N=46 
M: 37 
F: 9 
N=45 
M: 91% 
F: 9% 
N=41 
M: 35 
F: 6 
Author 
Sharma  
et al. 2011 
Lozano  
et al. 2010 
Lam  
et al. 2007 
Hui  
et al. 2006 
Montserrat 
et al. 2001 
Diamanti  
et al. 2013 
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48 OBSERVATIONAL STUDIES 
Comments 
Baseline: AHI ≥15; 
CPAP: ↑  insulin, IR, ↓  ghrelin, 
↔ leptin; ∆  in weight correlated 
with ∆  in insulin, IR  
Baseline: >18 y, AHI ≥5; 
Age/ AHI/ BMI for M and F; 
CPAP in M: ↑  LBM only in <60 y, 
↑  IGF-1 only in 40–60 y 
Baseline: AHI <15, symptoms; 
CPAP ≥4 h/d: ↑  insulin 
secretion capacity 
Baseline: ≥18 y, AHI ≥5; 
Groups: 1) CPAP: ≥4 h/d ≥70% 
of nights, 2) control: lower CPAP 
use; 
CPAP: none lost weight 
 
Baseline: AHI >20; 
CPAP: ↓  leptin (after 3–4 days); 
No CPAP: ↔ visceral/ SC fat 
(follow-up 36 days) 
Findings  
(∆  in BMI in kg/m2) 
CPAP: ↑  weight (∆  
1.6 kg), ↔ BMI (∆  0.6) 
CPAP: 40% gained 
≥2% of initial weight 
CPAP in M: ↑  BMI (∆  
0.5), WC, LBM, SC fat, 
IGF-1 
CPAP in F: ↔ BMI, SC 
fat, IGF-1, ↑  WC, LBM 
CPAP ≥4 h/d (n=31): ↔ 
BMI (∆  0.1), ↓  leptin, 
cholesterol, LDL 
CPAP vs. control: ∆  in 
BMI NS; 
CPAP: ↑  BMI in F 
(∆  0.6) or if initial BMI 
<30 (∆  0.4) 
CPAP + ↔ BMI: ↓  
visceral fat, ↔ SC fat 
CPAP + ↓  BMI: ↓  SC, 
visceral fat 
 
Adjustments 
No adjustments 
No adjustments 
No adjustments 
No adjustments 
No adjustments 
Study 
duration 
(months) 
6 
8 
2 
12 
6 
CPAP  
use (h/d) 
(mean) 
5.3 
5.9 
N/A 
N/A 
N/A 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 60 
AHI: 50 
BMI: 37 
Age: 51 
AHI: 46–49 
BMI: 30–31 
Age: 54 
AHI: 43 
BMI: 32 
Age: 55 
AHI: N/A 
BMI: 34–36 
Age: 46–51 
AHI: 53–64 
BMI: 29–31 
Subjects 
N=20 
M: 17 
F: 3 
N=78 
M: 67 
F: 11 
N=44 
M: 27 
F: 17 
N=228 
M: 64% 
F: 36% 
N=31 
M: 29 
F: 2 
Author 
Garcia  
et al. 2011 
Münzer  
et al. 2010 
Cuhadaroğlu 
et al. 2009 
Redenius  
et al. 2008 
Chin  
et al. 1999 
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OBSERVATIONAL STUDIES 
Comments 
Baseline: OSA, BMI ≥25; 
CPAP >4 vs. <4 h/d: more likely 
to ↓  weight >4.5 kg (43 vs. 0 %) 
Findings  
(∆  in BMI in kg/m2) 
CPAP >4 h/d: ↔ BMI 
(∆  -1.6); <4 h/d: ↔ BMI 
(∆  0.2) 
 
Adjustments 
No adjustments 
Study 
duration 
(months) 
6 
CPAP  
use (h/d) 
(mean) 
N/A 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 54–58  
AHI/ BMI: N/A 
Subjects 
N=32 
M: 22 
F: 10 
Author 
Loube  
et al. 1997 
↔, unchanged; ∆ , difference; AHI, apnea-hypopnea index; APPLES, the Apnea Positive Pressure Long-Term Efficacy Study; BMI, body mass index; 
CRP, C-reactive protein; CV, cardiovascular; CVD, cardiovascular disease; F, female; FG, fasting glucose; HbA1c, glycated hemoglobin; HTN, 
hypertension; IGF-1, serum insulin-like growth factor 1; IGT, impaired glucose tolerance; IR, insulin resistance; ISI, insulin sensitivity index; LBM, lean 
body mass; LDL, low-density lipoprotein; M, male; MBS, metabolic syndrome; N/A, not available; NS, not significant; OA, oral appliance; ODI, oxygen 
desaturation index; ODI3, oxygen desaturation index of ≥3%; ODI4, oxygen desaturation index of ≥4%; OGTT, oral glucose tolerance test; PCI, 
percutaneous coronary intervention, RHTN, resistant hypertension; SAVE, the Sleep Apnea Cardiovascular Endpoints study; SpO2, blood oxygen 
saturation level; SC, subcutaneous; T2D, type 2 diabetes; trigly, triglycerides; UC, usual care; WC, waist circumference; WL, weight loss. 
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2.5.3 Cardiovascular outcomes 
2.5.3.1 Hypertension and fatal and nonfatal cardiovascular disease 
events 
Most RCTs have shown a 2–3 mmHg reduction in mean 24-h systolic, diastolic and 
mean arterial BP after CPAP compared to sham CPAP or usual care (Patil et al. 2019, 
Peker & Balcan 2018). Long-term reductions in BP of this magnitude may reduce 
the risk of stroke and CAD by 4 to 8 %, having potential public health importance 
(Javaheri et al. 2017). CPAP may also normalize the nocturnal dipping pressure 
pattern, since ≥10 % decrease in the average BP has been reported during night 
compared to that during daytime (Javaheri et al. 2017, Peker & Balcan 2018). The 
effect of CPAP on BP may be reduced if the primary cause of hypertension is other 
than OSA or if consequent remodeling of the vascular structures has occurred in the 
long term (Javaheri et al. 2017). An RCT meta-analysis actually found that the 
decrease in BP after CPAP was greater in those aged <60 years (Pengo et al. 2020). 
Reductions of up to 4–5 mmHg in BP levels have been observed by CPAP in 
resistant hypertension (Javaheri et al. 2017, Peker & Balcan 2018). Patients with 
more severe OSA or higher treatment compliance may also particularly benefit from 
CPAP. The level of adherence needed to achieve significant antihypertensive 
response is not unequivocal; it has been recommended to be ≥4 h/day, but optimally 
>5–6 h/day (Javaheri et al. 2017). Non-sleepy or mildly sleepy patients have been 
suggested to benefit less from CPAP than those with sleepiness. A meta-analysis of 
4 RCTs involving 1206 patients with minimally symptomatic OSA showed a slight 
but clinically significant decrease of 1.4 mmHg in diastolic BP only among those 
who had used CPAP >4 h/day (Bratton et al. 2014, Patil et al. 2019). The data on the 
effect of CPAP on BP in mild to moderate OSA are scarce and controversial (Barnes 
et al. 2002, Lam et al. 2007, Patil et al. 2019). 
Long-term observational studies have independently associated CPAP with a 
reduced risk of CVDs (Patil et al. 2019, Peker & Balcan 2018). Conversely, RCTs 
have failed to confirm a significant association (Patil et al. 2019). The largest RTC 
in the field, the Sleep Apnea Cardiovascular Endpoints study, found no beneficial 
effect of CPAP on the secondary prevention of CVDs compared to usual care 
(McEvoy et al. 2016). However, subgroup analyses of RCTs involving non-sleepy 
OSA patients have found that CPAP use of ≥4 h/day may reduce the risk of stroke 
and cerebral events (McEvoy et al. 2016) or composite CVD events (Barbé et al. 
2012, Peker et al. 2016). A meta-analysis of 10 RCTs, of which one included CSA 
patients, did not find a difference in CVD outcome between the untreated and treated 
patients (Yu et al. 2017). A few RCT meta-analyses have shown an association 
between CPAP use of ≥4 h/day and a reduced risk of composite CVD events 
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(Abuzaid et al. 2017, Javaheri et al. 2020b, Khan et al. 2018). Since then, another 
RCT of non-sleepy OSA patients did not find a significant effect of CPAP on the 
secondary prevention of CVDs compared to usual care, even when those with CPAP 
use of ≥4 h/day were analyzed separately (Sánchez-de-la-Torre et al. 2020). 
Overall, RCTs have confirmed that CPAP is associated with a modest but 
clinically significant reduction in BP levels in moderate to severe OSA. Future RCTs 
are needed to clarify whether CPAP could reduce BP also in mild OSA. No 
recommendation was presented in a recent guideline of the AASM, on whether or 
not non-symptomatic OSA patients should be treated with CPAP to solely improve 
CVD outcome, since RCTs have failed to show a beneficial effect of CPAP as 
secondary prevention (McEvoy et al. 2016, Patil et al. 2019, Sánchez-de-la-Torre et 
al. 2020). Subgroup analyses of RCTs have suggested that CPAP use of ≥4 h/day 
may improve CVD outcome, particularly stroke (Javaheri et al. 2020b). Future RCTs 
of CVDs, with particular emphasis on adequate CPAP adherence and well-defined 
targeted outcomes, are needed before final conclusions can be made. Table 3 
summarizes the characteristics and results of the main studies investigating the 
associations between CPAP treatment, hypertension and CVD events.  
2.5.3.2 Heart failure, atrial fibrillation, peripheral artery disease          
and pulmonary hypertension 
Small RCTs of HFrEF patients have demonstrated that a 4- to 12-week treatment 
with CPAP may improve LVEF, myocardial sympathetic nerve function, heart rate 
and systolic BP in OSA (Egea et al. 2008, Hall et al. 2014, Kaneko et al. 2003b, Usui 
et al. 2005) and potentially myocardial energetics in those with an AHI of >20 /h 
(Hall et al. 2014). Only few RCTs have investigated the effect of CPAP in HFpEF 
patients with OSA (Peker & Balcan 2018). One RCT found an improvement in 
diastolic function after a 12-week treatment with CPAP (Arias et al. 2005), while the 
other RCT only found an association between CPAP use of ≥4 h/day and improved 
diastolic relaxation velocity after 12 months (Glantz et al. 2017). 
A few observational studies have suggested that CPAP may be associated with 
a better CVD outcome in patients with HF and OSA (Peker & Balcan 2018). One 
study showed a 50 % greater 2-year survival rate among HF patients whose OSA 
was treated (Javaheri et al. 2011), while the other study found an independent 2-fold 
(95 % CI 1.1–3.7) increased risk of death or hospitalization in HFrEF patients with 
untreated OSA compared to CPAP treatment (Kasai et al. 2008). Recent RCTs have 
not shown a beneficial effect of CPAP on the incidence of hospitalization for HF, 
although the mean use of CPAP has been <4 h/day (McEvoy et al. 2016, Sánchez-
de-la-Torre et al. 2020). Overall, observational studies and small RCTs have 
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suggested that CPAP may have some beneficial effects in HFrEF patients with OSA 
but larger RCTs and data on patients with HFpEF are needed (Peker & Balcan 2018). 
In patients with AF and OSA, observational studies have suggested that those 
treated with CPAP may be more likely to achieve a higher therapeutic success of 
cardioversion and cardiac ablation (Peker & Balcan 2018) and  less likely to develop 
more permanent forms of AF compared to patients without CPAP (Holmqvist et al. 
2015). One study reported that the AF recurrence rate one year after cardioversion 
did not differ between CPAP-treated patients and those without OSA (Kanagala et 
al. 2003). Three observational studies of AF patients also found that a 12- to 42-
month treatment with CPAP after pulmonary vein isolation, a type of cardiac 
ablation, was associated with a reduced risk of AF recurrence in OSA compared to 
those without CPAP (Naruse et al. 2013), while the risk did not differ from subjects 
without OSA (Fein et al. 2013, Neilan et al. 2013). CPAP has been actually 
recommended in all AF patients with OSA undergoing surgical or catheter ablation 
(Calkins et al. 2012). However, RCT data are lacking and definite conclusions of the 
effectiveness of CPAP in AF cannot be made (Peker & Balcan 2018). 
The current data investigating the effect of CPAP on progression and prognosis 
of PAD in conventionally and surgically treated patients is scarce and remains to be 
evaluated in further studies (Utriainen et al. 2013).  
It has been suggested that CPAP could reduce pulmonary artery pressure by 
decreasing left-sided filling pressures and improving left ventricle diastolic function 
and altered blood gases (Javaheri et al. 2013). However, studies evaluating the effect 
of CPAP on pulmonary hypertension have usually lacked invasive hemodynamic 
assessment, and the number of patients with significant pulmonary hypertension at 
baseline has been low. Two small RCTs involving patients without significant heart 
and lung diseases showed a significant reduction of 3–6 mmHg in pulmonary artery 
pressure after a 4- to 12-week treatment with CPAP. In both studies, pulmonary 
artery pressure was measured by echocardiography, and those who had pulmonary 
hypertension at baseline were shown to benefit the most from CPAP (Arias et al. 
2006, Javaheri et al. 2013, Sajkov et al. 2002). Overall, the data of RCTs is scarce 
and further RCTs evaluating the effect of CPAP on pulmonary hypertension with 
OSA are needed. 
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RANDOMIZED CONTROLLED TRIALS (RCTS) 
Comments 
Baseline: AHI ≥15, RHTN 
Baseline: 45–75 y, AHI 
≥15 (≤50), SpO2 ≥85%; 
CPAP vs. oxygen at 
night: ↓  24h MAP, DBP 
Baseline: 18–75 y, AHI 
≥15, ESS <18, RHTN; 
↑  CPAP use: ↓  24h 
MAP, SBP, DBP 
 
Baseline: 30–65 y, AHI 
≥15, RHTN; 
CPAP: ↔ nocturnal BP 
dipping* 
Baseline: ≤60 y, AHI >30, 
BMI ≤40, masked/ pre-
HTN;  
CPAP: ↓  masked (-34%)/ 
pre-HTN (-39%) 
Findings  
(∆  in BP in mmHg) 
CPAP vs. no CPAP 
∆  in ambulatory/ 
clinic BP levels NS 
CPAP vs. UC: ↓  24h 
MAP (∆  -2.4), DBP 
(∆  -2.8), ∆  in SBP 
NS 
CPAP vs. UC: ↓  24h 
MAP (∆  -3.1), DBP 
(∆  -3.2), ∆  in SBP 
NS, ↑  nocturnal BP 
dippers (36 vs. 22%)* 
CPAP vs. UC: ↓  
awake DBP (∆  -7.2), 
SBP (∆  -9.6), ∆  in 
nocturnal BP NS 
CPAP: ↓  24h DBP, 
SBP (both: ∆  -5); 
CPAP vs. no CPAP: 
↓  24h DBP, SBP 
Adjustments 
No adjustments 
CAD, BP, study 
site 
BP, AHI, ESS, 
CVD events, 
nocturnal BP 
dipper*/ riser 
No adjustments 
No adjustments 
Study 
duration 
(months) 
6 
3 
3 
6 
3 
CPAP  
use (h/d) 
(mean) 
4.8 
3.5 
 
5.0 
6.0 
5.2 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 61 
AHI: 41 
BMI: 33 
Age: 63–64 
AHI: 24–26 
BMI: 33–35 
Age: 56 
AHI: 40 
BMI: 34 
Age: 56 
AHI: 29 (median) 
BMI: 32 (median) 
  
 
Age: 43 
AHI: 56 
BMI: 29 
Subjects 
N=117 
M: 40% 
F: 60% 
N=281 
M: 209 
F: 72 
N=194 
M: 133  
F: 61 
N=35 
M: 77% 
F: 33% 
N=36 
M: 36 
F: 0 
Outcome 
HTN 
HTN 
HTN 
HTN 
HTN 
Author 
Muxfeldt  
et al. 2015 
Gottlieb  
et al. 2014 
Martínez-
García  
et al. 2013 
(HIPARCO) 
Pedrosa  
et al. 2013 
Drager  
et al. 2011b 
Table 3.  Selected randomized controlled trials (RCTs) and observational studies investigating the association between continuous positive airway 
pressure (CPAP) treatment, hypertension (HTN) and cardiovascular disease (CVD) events in obstructive sleep apnea (OSA) patients. 
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54 RANDOMIZED CONTROLLED TRIALS (RCTS) 
Comments 
Baseline: 18–70 y, AHI 
≥20, ESS ≤10 (non-
sleepy), HTN 
Baseline: 18–75 y, AHI 
>15, HTN; 
CPAP: ↓  24h BP, ↑  
nocturnal BP dippers* 
Baseline: 18–80 y, AHI 
≥15, RHTN; 
CPAP >5.8 h/d vs. UC: 
↓  24h DBP (-7 mmHg), 
SDB (-10 mmHg) 
 
Baseline: AHI ≥5–40, 
ESS >9 if AHI 5–20 
 
Baseline: 30–70 y, AHI 
≥10, HTN; 
CPAP use/ AHI did not 
correlate with ∆  in BP  
Baseline: AHI ≥5+EDS or 
two other symptoms; 
Therapeutic CPAP vs. 
sub-: ↓  nocturnal SBD 
Findings  
(∆  in BP in mmHg) 
CPAP: ↓  DBP, SBP 
(both: -2), best effect 
with CPAP >5.6 h/d 
CPAP vs. sham 
CPAP: ↓  24h DBP 
(∆  -1.3), SBD (∆  -2.1) 
CPAP vs. UC: ↓  24h 
DBP (-4.9 vs. 0.1), 
∆  in 24h SBP NS; 
CPAP: ↑  nocturnal 
BP dippers* 
Morning DBP: ↓  by 
CPAP (∆  -5.2), OA 
(∆  -2.8); other BPs ↔ 
Therapeutic CPAP 
vs. sub-: ∆  in 24h 
DBP/ SBP, nocturnal 
BP dippers* NS 
Therapeutic CPAP 
vs. sub-: ↓  24h MAP 
(∆  -3.8), DBP (∆      
-3.5), ∆  in SBP NS 
Adjustments 
AHI, T90, BMI, 
∆ in BMI, BP, 
follow-up time 
No adjustments 
No adjustments 
No adjustments 
No adjustments 
No adjustments 
Study 
duration 
(months) 
36 
3 
3 
2.5 
1 
3 
CPAP  
use (h/d) 
(mean) 
4.7 
4.4 
5.6 
4.2 
5.0 
5.1 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 56 
AHI: 45 
BMI: 32 
Age: 52 
AHI: 44 
BMI: 32 
Age: 59 
AHI: 53 
BMI: 31 
Age: 45–47 
AHI: 19–24 
BMI: 27–28 
Age: 55–58 
AHI: 58–60 
BMI: 34–36 
Age: 50–51 
AHI: 29–31 
BMI: 27 
Subjects 
N=359 
M: 299 
F: 60 
N=340 
M: 277 
F: 63 
N=64 
M: 44 
F: 20 
N= 101 
M: 79 
F: 22 
N=68 
M: 41 
F: 27 
N=46 
M: 37 
F: 9 
Outcome 
HTN 
HTN 
HTN 
HTN 
HTN 
HTN 
Author 
Barbé  
et al. 2010 
Durán-
Cantolla  
et al. 2010 
Lozano  
et al. 2010 
Lam  
et al. 2007 
Campos-
Rodriguez 
et al. 2006 
Hui  
et al. 2006 
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RANDOMIZED CONTROLLED TRIALS (RCTS) 
Comments 
Baseline: ODI4 >10, ESS 
<10 (non-sleepy), HTN 
Baseline: 30–75 y, ODI4 
>10, ESS >9 
 
Baseline: AHI ≥30, ESS 
≤10 (non-sleepy); CPAP: 
↔ BP non-dippers* 
Baseline: AHI ≥15, ESS 
≤10, ACS; 
CPAP ≥4 h/d vs. PS-
matched UC: ∆  in CVDs 
NS (HR 0.8) 
Baseline: ODI4 ≥12, ESS 
≤15, cerebral CVD/ CAD; 
CPAP ≥4 h/d vs. PS-
matched UC: ↓  cerebral 
CVD, stroke (HR 0.5-0.6) 
Baseline: AHI ≥15, ESS 
<10 (non-sleepy), CAD 
+newly RVN; 
CPAP ≥4 vs. <4 h/d or no 
CPAP: ↓  CVDs (HR 0.3) 
 
Findings  
(∆  in BP in mmHg) 
Therapeutic CPAP 
vs. sub-: ∆  in 24h 
DBP, SBP NS 
Therapeutic CPAP 
vs. sub-: ↓  24h MAP, 
DBP, SBP (∆  >-3)  
CPAP vs. sham 
CPAP: ∆  in 24h 
DBP, SBP NS 
CPAP+UC vs. UC: ∆  
in CVDs NS (16 vs. 
17%, HR 0.9), ↓  DBP 
(∆  >-3 after 24 to 48 
months) 
CPAP+UC vs. UC: ∆  
in CVDs (17 vs. 15%, 
HR 1.1), SBP, DBP 
NS 
CPAP vs. no CPAP: 
∆  in outcome NS (18 
vs. 22%, HR 0.8) 
Adjustments 
No adjustments 
No adjustments 
No adjustments 
Age, sex, ESS; 
obesity, DM, 
smoking, AHI, 
HTN, first 
episode of ACS 
Age, sex, ODI, 
BMI, ESS, CVD, 
DM, country 
Age, sex, AHI, 
BMI, smoking, 
LVEF, MI, HTN, 
DM, RVN, lung 
disease  
Study 
duration 
(months) 
1 
1 
1.5 
40 
44 
57 
CPAP  
use (h/d) 
(mean) 
5.2 
4.9 
5.0 
2.8 
3.3 
At 0.5 y: 
5.5; 
At 4 y: 
6.2 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 54 
AHI: N/A 
BMI: 33 
Age: 50–51 
AHI: N/A 
BMI: 35 
Age: 52–54 
AHI: 54–57 
BMI: 29 
Age: 60–61 
AHI: 36 
BMI: 29–30 
Age: 61 
AHI: 29–30 
BMI: 29 
Age: 66–67 
AHI: 28–29 
BMI: 28–29 
Subjects 
N=35 
M: 31 
F: 4 
N=118 
M: 118 
F: 0 
N=54 
M: 49 
F: 5 
N=1255 
M: 1058 
F: 197 
N=2687 
M: 2174 
F: 513 
N=144 
M: 105 
F: 39 
Outcome 
HTN 
HTN 
HTN 
HTN; CVD 
death/ event 
(in-hospital 
UAP/ TIA/ HF, 
MI, stroke)  
HTN; CVD 
death/ event 
(TIA, stroke, 
MI, in-hospital 
HF/ UAP)   
 
CVD death/ 
event (RVN, 
MI, stroke) 
Author 
Robinson  
et al. 2006 
Pepperell  
et al. 2002 
Barbé  
et al. 2001 
Sánchez-
de-la-Torre  
et al. 2020 
(ISAACC) 
McEvoy  
et al. 2016 
(SAVE) 
Peker  
et al. 2016 
(RICCADSA) 
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56 RANDOMIZED CONTROLLED TRIALS (RCTS) 
Comments 
Baseline: 45–75 y, AHI 
≥15, HTN, CAD, ESS <15; 
CPAP vs. no CPAP: 
improved HTN control 
Baseline: <75 y, AHI ≥20, 
first-ever stroke 
Baseline: ≥65 y, ODI4 
>7.5, ESS ≥9 
 
Baseline: 18–70 y, AHI 
≥20, ESS ≤10 (non-
sleepy); 
CPAP≥4 h/d vs. UC: ↓  
HTN, CVD outcome 
Baseline: 45–75 y, ODI4 
>7.5, minimal symptoms; 
CPAP ≥4 vs. <4 h/d: ∆  in 
risk of CVD death NS 
Findings  
(∆  in BP in mmHg) 
CPAP vs. no CPAP: 
↓  SBP (-8 vs. -3), ∆  
in CVD death/ event 
NS (2.8 vs. 13.5%) 
CPAP+UC vs. UC: ↓  
fatal CVDs (0 vs. 
10%), ∆  in all CVDs 
NS (11 vs. 25%) 
CPAP+UC vs. UC: ∆  
in outcome NS; 
CPAP: ↔ DBP, SBP; 
UC: ↓  SBP 
CPAP vs. UC: ∆  in 
HTN, CVD outcome 
NS 
CPAP vs. UC: ∆  in 
HTN, risk of CVD 
death NS 
Adjustments 
No adjustments 
No adjustments 
Study center, 
ESS, functionality 
Hospital site 
BMI, participating 
center, ODI, CVD 
risk score 
Study 
duration 
(months) 
36 
68 
12 
48 
6 
CPAP  
use (h/d) 
(mean) 
4.5 
5.3 
2.2 
(n=102) 
5.0 
(median) 
2.4 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 62–63 
AHI: 28–29 
BMI: 28 
Age: 64–66 
AHI: N/A 
BMI: 29–30 
Age: 71 
AHI: 28–29  
 (median) 
BMI: 34 
Age: 52 
AHI: 35–42  
 (median) 
BMI: 31 
Age: 58 
AHI: N/A 
BMI: 32–33 
Subjects 
N=73 
M: 60 
F: 13 
N=126 
M: 89 
F: 37 
N=278 
M: 229 
F: 49 
N=723 
M: 619 
F: 104 
N=391 
M: 305 
F: 86 
Outcome 
HTN; CVD 
death/ event 
(MI, stroke, 
RVN, in-
hospital HF)  
CVD death/ 
event (CAD 
event, 
stroke) 
HTN; CVD 
event (AP, 
stroke, MI, 
AF, PAD) 
HTN; CVD 
death/ event 
(TIA, stroke, 
MI, AR, in-
hospital HF/ 
UAP) 
HTN; 
Calculated 
5-y risk of 
CVD death 
Author 
Huang  
et al. 2015 
Parra  
et al. 2015 
McMillan  
et al 2014 
(PREDICT) 
Barbé  
et al. 2012 
Craig  
et al. 2012 
(MOSAIC) 
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RANDOMIZED CONTROLLED TRIALS (RCTS) 
Comments 
Baseline: ≥18 y, AHI ≥10 
 
OBSERVATIONAL STUDIES 
 
Baseline: CAD+RVN; 
Groups: 1) CPAP (AHI 
≥15, ESS ≥10), 2) No 
OSA (AHI <5) 
 
Baseline: ≥60 y, AHI ≥20; 
CPAP ≥4 (n=24) vs. <4 
h/d (n=12): ↓  outcome (4 
vs. 17%) 
Baseline: AHI ≥5, CAD 
+PCI; 
AHI ≥15 vs. CPAP: 2-fold 
↑  risk of RVN (adjusted) 
Groups: 1) control: AHI 
<10, 2) OSA: AHI ≥10 
(CPAP: ≥4, untreated: <4 
h/d or no CPAP) 
 
Findings  
(∆  in BP in mmHg) 
CPAP vs. sham 
CPAP: ∆  in outcome 
NS 
CPAP vs. no OSA:  
∆  in outcome NS (23 
vs. 16%; no effect of 
level of CPAP use) 
CPAP vs. no CPAP: 
↓  outcome (14 vs. 
56%) 
CPAP vs. no CPAP: 
∆  in outcome NS 
CPAP vs. control: ∆  
in outcome NS; 
Untreated vs. control: 
2.8-fold ↑  risk 
Adjustments 
No adjustments 
Age, sex, LVEF 
AHI, BMI, HTN, 
MI, lung disease, 
DM, RVN, smoking 
No adjustments 
Age, sex, BMI, 
CVD, smoking, 
HTN, DM, PCI, 
DLP 
Age, BMI, HTN, 
DM, AF 
Study 
duration 
(months) 
6 
57 
60 
58 
82 
CPAP  
use (h/d) 
(mean) 
4.2 
At 0.5 y: 
5.5; 
At 4y: 
6.0 
N/A 
N/A 
N/A 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 51–52 
AHI: N/A 
BMI: 32 
Age: 62–63 
AHI: 32 
 (No OSA: 3) 
BMI: 26–30 
Age: 71–73 
AHI: 36–45 
BMI: 31 
Age: 54–56 
AHI: 10–46 
BMI: 28–30 
Age: 52–59 
AHI: 24–43    
 (Control: 4) 
BMI: 32–38 
Subjects 
N=1098 
M: 719 
F: 379 
N=267 
M: 221 
F: 46 
N=130 
M: 104 
F: 26 
N=390 
M: 328 
F: 62 
N=967 
M: 0 
F: 967 
Outcome 
Adverse and 
serious 
adverse 
CVD events 
CVD death/ 
event (MI, 
RVN, stoke) 
CVD death/ 
event (MI, 
stroke, ACS 
+RVN) 
CVD death/ 
event (RVN, 
stroke, stent 
clot, MI) 
CVD event 
(stroke, 
CAD) 
Author 
Kushida  
et al. 2012 
(APPLES) 
Peker  
et al. 2017 
(RICCADSA) 
Ou  
et al. 2015 
Wu  
et al. 2015 
Campos-
Rodriguez 
et al. 2014 
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58 OBSERVATIONAL STUDIES 
Comments 
Groups: 1) control: AHI 
<10, 2) OSA: AHI ≥10 
(CPAP: ≥4, untreated: <4 
h/d or no CPAP) 
 
Baseline: ≥18 y, MI; 
Groups: 1) OSA: AHI ≥5 
(CPAP vs. no CPAP), 2) 
no OSA: AHI <5 
Baseline: ≥65 y; Groups: 
1) Control: AHI <15, 2) 
OSA: AHI ≥15 (CPAP: 
≥4, untreated: <4 h/d or 
no CPAP); 
↑  CPAP use: ↓ outcome 
Baseline: AHI ≥5; 
CPAP: AHI ≥5+EDS/ AHI 
≥15 
Baseline: AHI ≥5, 
CAD+PCI 
 
Findings  
(∆  in BP in mmHg) 
CPAP vs. control: ∆  
in outcome NS 
 
CPAP vs. no OSA: 
∆  in outcome NS; 
No CPAP vs. no 
OSA: ↑  CVD event 
CPAP vs. control: ∆  
in outcome NS;  
Untreated AHI ≥30 
vs. control: 2.3-fold 
↑  risk (whereas AHI 
15–29: NS) 
CPAP vs. untreated: 
↓  risk of outcome, 
also in mild OSA 
(both: HR 0.36) 
CPAP vs. untreated: 
↓  CVD death (3 vs. 
10%), ∆  in CVD 
event NS 
Adjustments 
Age, BMI, HTN, 
CVD, DM 
Age, sex, BMI, 
DM, packs-year, 
DLP 
 
Age, sex, BMI, 
CVD, DM, ESS, 
smoking, sleep 
study, clinic, 
DLP 
Age, sex, BMI, 
CVD, malignant 
disorders, HTN, 
COPD, nicotine 
use, DM, DLP 
No adjustments 
Study 
duration 
(months) 
72 
72 
69 
72 
60 
CPAP  
use (h/d) 
(mean) 
6.0 
6.1 
6.4 
N/A 
N/A 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 52–64 
AHI: 17–61 
 (Control: 4) 
BMI: 33–39 
Age: 58–59 
AHI: 21–22 
 (No OSA) 
BMI: 26–27 
Age: 70–72 
AHI: 21–59 
 (Control: 7) 
BMI: 32–35 
Age: 55–58 
AHI: 15–31 
BMI: 29–31 
 
Age: 64 
AHI: 39–50 
BMI: 33–35 
Subjects 
N=1116 
M: 0 
F: 1116 
N=186 
M: 160 
F: 26 
N=939 
M: 601 
F: 338 
N=449 
M: 384 
F: 65 
N=371 
M: 325 
F: 46 
Outcome 
CVD death 
(stroke, MI, 
HF, AR) 
CVD event 
(MI, RVN) 
CVD death 
(MI, HF, 
stroke) 
CVD death 
(MI, stroke)/ 
event (MI, 
stroke, ACS 
+RVN) 
CVD death/ 
event (MI, 
RVN, severe 
AP, stroke) 
Author 
Campos-
Rodriguez 
et al. 2012 
Garcia-Rio 
et al. 2012 
Martínez-
García  
et al. 2012 
Buchner  
et al. 2007 
Cassar  
et al. 2007 
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OBSERVATIONAL STUDIES 
Comments 
Baseline: AHI >15; 
CPAP ≥5 y vs. untreated: 
↓  all CVD deaths+ 
events (18 vs. 31%) 
Groups: 1) Healthy, 2) 
Untreated OSA (AHI ≥5), 
3) CPAP (AHI >30 or 
≥5+EDS, usage >4 h/d) 
Baseline: AHI ≥20, TIA/ 
stroke 
Baseline: CAD, AHI ≥15 
Groups: 1) Not treated, 
2) Treated (CPAP/ UAS) 
Findings  
(∆  in BP in mmHg) 
CPAP ≥5y vs. 
untreated: ↓  CVD 
deaths (2 vs. 15%), 
∆ in CVD events NS 
CPAP vs. healthy: ∆  
in CVD death/ event 
NS 
 
Untreated vs. CPAP: 
↑  CVD event (36 vs. 
7%; 5-fold ↑  risk) 
 
Treated vs. not 
treated: ↓  outcome 
(24 vs. 58%, HR 0.2) 
Adjustments 
Age, sex, BMI, 
AHI, smoking, 
alcohol use, 
CVD 
Age, CVD, HTN, 
DLP, smoking, 
alcohol use, BP, 
medication, DM 
AF, HTN, ICS, 
BMI, smoking, 
DM, cognition, 
DLP, CAD, FGN  
Age, AHI, DLP, 
BMI, smoking, 
HTN, LVEF, DM 
Study 
duration 
(months) 
90 
120 
18 
87 
CPAP  
use (h/d) 
(mean) 
N/A 
N/A 
5.7 
5.7 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 50–53 
AHI: 37–48 
BMI: 30–31 
Age: 50 
AHI: 18–43 
 (Healthy: 1) 
BMI: 28–31 
Age: 73 
AHI: 37 
BMI: 27 
Age: 57 
AHI: 29–34 
BMI: 28 
Subjects 
 
N=168 
M: 155 
F: 13 
N=1274 
M: 1274 
F: 0 
N=51 
M: 63% 
F: 37% 
N=54 
M: 53 
F: 1 
Outcome 
CVD death/ 
event (HTN, 
stroke, heart 
event) 
CVD death/ 
event (MI, 
stroke, ACS 
+RVN) 
CVD event 
(AP, MI, 
stroke) 
CVD death/ 
event (ACS, 
RVN, HF) 
Author 
Doherty  
et al. 2005 
Marin  
et al. 2005 
Martínez-
García  
et al. 2005 
Milleron  
et al. 2004 
↔, unchanged; ∆ , difference; ACS, acute coronary syndrome; AF, atrial fibrillation; AHI, apnea-hypopnea index; AP, angina pectoris; APPLES, the Apnea 
Positive Pressure Long-Term Efficacy Study; AR, arrhythmia; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; DBP, diastolic BP; DM, 
diabetes mellitus; DLP, dyslipidemia; F, female; FGN, fibrinogen; HF, heart failure; ICS, internal carotid stenosis; ISAACC, Impact of Sleep Apnea syndrome in 
the evolution of Acute Coronary syndrome, Effect of intervention with CPAP; LVEF, left ventricular ejection fraction; M, male; MAP, mean arterial BP; MI, 
myocardial infarction; N/A, not available; NS, not significant; OA, oral appliance; ODI, oxygen desaturation index; ODI4, oxygen desaturation index of ≥4%; PAD, 
peripheral artery disease; PCI, percutaneous coronary intervention; PS, propensity score matched; RHTN, resistant hypertension; RVN, revascularization; SAVE, 
the Sleep Apnea Cardiovascular Endpoints study; SBP, systolic BP; SpO2, blood oxygen saturation level; T90, percentage of time spent under SpO2 of 90 %; 
TIA, transient ischemic attack; UAP, unstable angina pectoris; UAS, upper airway surgery; UC, usual care. 
* Nocturnal BP dippers: ≥10 % decrease in the average BP during night compared to that during daytime. 
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2.5.4 All-cause mortality 
Observational studies have suggested a beneficial effect of CPAP on all-cause 
mortality, particularly CVD deaths (Patil et al. 2019). A large observational study of 
1010 male OSA patients found no difference in the 10-year risk of CVD death 
between CPAP use of >4 h/day and subjects without OSA (Marin et al. 2005). A 
similar result was shown in a smaller study of males over a follow-up of 7.5 years 
(Doherty et al. 2005). A beneficial effect of CPAP on preventing CVD deaths in 
females was reported in a large, long-term study (Campos-Rodriguez et al. 2012), 
while another study showed reduced all-cause mortality in middle-aged and elderly 
males, but not at all in females (Jennum et al. 2015). It has also been suggested that 
OSA patients with CPAP use of >6 h/day may have a higher 5-year survival rate 
compared to those with lower CPAP usage (Campos-Rodriguez et al. 2005).  
Conversely, RCTs have not confirmed a significant association between CPAP 
and all-cause mortality (Patil et al. 2019). Two large RCTs of OSA patients with 
established CVD and minimal sleepiness at baseline found no significant difference 
in all-cause mortality over follow-ups of 3 to 4 years between patients treated with 
CPAP or usual care, although the mean use of CPAP was <4 h/day (McEvoy et al. 
2016, Sánchez-de-la-Torre et al. 2020). Similar results were found in two other RCTs 
involving non-sleepy patients, although in both of these studies the number of deaths 
was only <10 per group (Barbé et al 2012, Peker et al. 2016).  
Overall, a meta-analysis of observational studies involving 2340 patients found 
a 60 % lower risk of all-cause mortality in CPAP-treated patients compared to 
controls (Patil et al. 2019). However, since RCTs have failed to confirm a significant 
association, the existing data is insufficient to support a beneficial effect of CPAP 
on all-cause mortality. Further RCTs with adequate CPAP compliance are needed.  
2.5.5 MVAs 
A reduced risk of MVAs after CPAP has been shown in several observational studies 
(Barbé et al. 2006, Karimi et al. 2015, Walia et al. 2019). Most of the studies have 
involved middle-aged, obese male patients with moderate to severe OSA. A meta-
analysis of nine studies involving 1976 patients reported that MVA risk was reduced 
by 65–78 % after CPAP in observation periods of 6 months to 5 years before and 
after treatment (Tregear et al. 2010), although one study found a decrease in MVAs 
also in healthy controls (Barbé et al. 2006). However, only a minority of studies have 
provided objective data on MVAs (Tregear et al. 2010). One study actually found 
that patients subjectively reported only one-third of their objectively measured 
MVAs, implying their reluctance to disclose their MVA history (Findley et al. 2000). 
Table 4 summarizes the characteristics and results of the main studies investigating 
the association between CPAP treatment and risk of MVAs.  
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OBJECTIVE DATA ON MVAS 
Comments 
Baseline: AHI ≥15; 
MVAs: medical costs 
from clinical records 
Baseline: DL; 
MVAs: police-reported; 
Groups: 1) CPAP ≥4 h/d, 
2) CPAP <4 h/d 
Baseline: AHI ≥10 (no 
OSA in controls);  
MVAs: definition N/A, 
from the database of the 
Ministry of Transportation 
of Ontario 
 
Baseline: OSA 
MVAs: property damage 
>$500/ personal injury, 
from State DMV records 
Findings  
 
CPAP: ↔ MVAs (∆   
-0.8%), usage ≥4 vs. 
<4 h/d did not affect 
CPAP ≥4 h/d: ↓  
MVAs (∆  -5.1 /1000 
person years); 
CPAP <4 h/d: ↑  
MVAs (∆  5.6 /1000 
person years) 
CPAP: ↓  MVAs (∆  
-0.14 /driver /year),  
∆  from controls NS; 
No CPAP vs. control: 
↑ MVAs (∆  0.14 
/driver /year) 
CPAP: ↓  MVAs (∆   
-0.07 /driver /year); 
No CPAP: ↔ MVAs 
(both 0.07 /driver 
/year) 
Factors 
controlled for  
(if compared to 
controls) 
N/A 
Groups: ∆  in 
driving 
exposure NS 
Matched for 
age, sex, DL 
class 
Matched for 
age, sex; ∆  in 
weight NS 
Study 
duration 
(months) 
B: 12 
A: 12 
B: 60 
A: 42 
B: 36 
A: 36 
B: 24 
A: 24 
CPAP  
use (h/d) 
(mean) 
5.3 
≥4 h/d: 
5.8 
<4 h/d: 
1.4 
5.9 †  
7.2 †  
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 56 
AHI: 54 
BMI: 31 
Age: 56–57 
AHI: 22–30 
BMI: 30–31 
Age: 52 
AHI: 54 
BMI: 36 
(Controls: N/A) 
Age: 54–60 
AHI: 38 
BMI: N/A 
Subjects 
N=373 
M: 315 
F: 58 
N=567 * 
M: 425 
F: 142 
N=420 
M: N/A 
F: N/A 
N=50 
M: 43 
F: 7 
Study  
design 
OBS Study; 
B-A 
OBS Study; 
B-A 
OBS Study; 
B-A + 
Case-control 
OBS Study; 
B-A + 
Case-control 
Author 
Catalá  
et al. 2016 
Karimi  
et al. 2015 
George 
2001 
Findley  
et al. 2000 
Table 4.  Selected studies investigating the association between continuous positive airway pressure (CPAP) treatment and risk of motor vehicle 
accidents (MVAs) in obstructive sleep apnea (OSA) patients. Studies with subjective and objective MVA data are categorized separately. 
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62 SUBJECTIVE DATA ON MVAS 
Comments 
Baseline: OSA; MVAs/ 
near-misses due to 
drowsy driving; 1-point ↓  
in ESS ↓  drowsy driving 
by 14% 
Baseline: ODI4 ≥12, ESS 
≤15, cerebrovascular 
disease/ CAD; 
MVA/ near-miss: drowsy 
driving/ personal injury 
Baseline: ≥65 y, ODI4 
>7.5, ESS ≥9 
MVAs: definition N/A 
Baseline: DL; Groups: 1) 
AHI ≥5 (n=291 with 
CPAP), 2) no OSA; 
↑ MVAs in untreated 
OSA: ESS ≥11, AHI ≥40 
Baseline: DL; Groups: 1) 
AHI >20 + CPAP, 2) no 
OSA;  
MVAs: damage >$500/ 
personal injury 
Findings  
 
Drowsy driving: ↓  by 
8.8% in PAP ≥4 h/d, 
by 6% in lower usage 
(usage not predictive) 
CPAP+UC vs. UC:  
∆  in MVAs NS (RR 
0.8) 
CPAP+UC vs. UC:  
∆  in MVAs NS  
(MVA data for n=150) 
CPAP: ↓  MVAs by 
14%, ∆  from no 
OSA NS; Untreated 
vs. no OSA: ↑  
MVAs (12 vs. 5%) 
↓  MVAs in CPAP 
(RR 0.41) and in no 
OSA (RR 0.49), ∆  in 
MVAs NS 
Factors 
controlled for  
(if compared to 
controls) 
N/A 
N/A 
N/A 
Matched for 
age 
BMI, alcohol 
intake, ESS; 
Matched for 
age, sex 
Study 
duration 
(months) 
10 
44 
12 
B: 60 
A: 60 
B: 24 
A: 24 
CPAP  
use (h/d) 
(mean) 
N/A 
3.3 
2.2  
(n=102) 
N/A 
5.9 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 56 
AHI: 23 
BMI: 33 
Age: 61 
AHI: 29–30 
BMI: 29 
Age: 71 
AHI: 28–29 
(median) 
BMI: 34 
Age: 46 
AHI: 44 (OSA) 
BMI: 23–27 
Age: 46–49 
AHI: 60 (OSA) 
BMI: 27–33 
Subjects 
N=2059 
M: 1124 
F: 935 
N=2687 
M: 2174 
F: 513 
N=278 
M: 229 
F: 49 
N=1216 
M: 1216 
F: 0 
N=160 
M: 156 
F: 4 
Study  
design 
OBS Study; 
B-A 
Randomized 
controlled 
trial 
Randomized 
controlled 
trial 
OBS Study; 
B-A + 
Case-control 
OBS Study; 
B-A + 
Case-control 
Author 
Walia  
et al. 2019 
McEvoy  
et al. 2016 
(SAVE) 
McMillan  
et al. 2014 
(PREDICT 
Komada  
et al. 2009 
Barbé  
et al. 2006 
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SUBJECTIVE DATA ON MVAS 
Comments 
Groups: 1) OSA: AHI ≥10 
(n=85 with CPAP), 2) no 
OSA;  
MVAs: material damage/ 
personal injury 
Baseline: DL; 
MVA: definition N/A 
MVA: definition N/A 
MVA: definition N/A 
Baseline: 25–65 y, DL, 
EDS, CPAP indicated; 
MVAs: definition N/A 
Baseline: AHI >5, 
symptoms; 
Sleep-related MVAs with 
(major)/ without (minor) 
injury, near-misses 
Findings  
 
CPAP: ↓  MVAs  
(∆  -7.9 /million km); 
Untreated vs. no 
OSA: ↑  MVAs (12 
vs. 3%); 
 
CPAP: ↓  MVAs (82 
vs. 10%), near-
misses (33 vs. 0%) 
CPAP: ↓  MVAs, 
near-misses 
CPAP: ↓  MVAs, 
near-misses (data for 
n=547) 
CPAP: ↓  MVAs  
(∆  -7 /million km) 
CPAP: ↓  near-misses 
(∆  -0.8/ 10 000 
miles), ↔ major, 
minor MVAs 
Factors 
controlled for  
(if compared to 
controls) 
Driving 
exposure; 
Matched for 
age, sex 
N/A 
N/A 
N/A 
Driving 
exposure 
Driving 
exposure 
Study 
duration 
(months) 
B: 36 
A: 15 
B: 24 
A: 24 
B: 6 
A: 6 
B: 12 
A: 12 
B: 60 
A: 12 
B: 60 
A: 24 
CPAP  
use (h/d) 
(mean) 
N/A 
N/A 
N/A 
6.0 
 
6.1 
(n=37) 
 
5.1 
(n=62) 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 57 
AHI: N/A 
BMI: 32 
Age: 50 
AHI: N/A (>50) 
BMI: 29 
Age: 49 
AHI: 43 
BMI: N/A 
Age: 57 
AHI: 35 
BMI: 34 
Age: 49 
AHI: 39 
BMI: 32 
Age: 53 
AHI: 47 
BMI: N/A 
Subjects 
N=160 
M: 90% 
F: 10% 
N=39 
M: 39 
F: 0 
N=316 
M: 234 
F: 82 
N=893 
M: 87% 
F: 13% 
N=59 
M: 59 
F: 0 
N=215 
Sex: N/A 
 
Study  
design 
OBS Study; 
B-A 
OBS Study; 
B-A 
OBS Study; 
B-A 
OBS Study; 
B-A 
 
OBS Study; 
B-A 
OBS Study; 
B-A 
Author 
Horstmann 
et al. 2000 
Yamamoto 
et al. 2000 
Scharf  
et al. 1999 
Krieger  
et al. 2000 
Cassel  
et al. 1996 
Engleman 
et al. 1996 
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SUBJECTIVE DATA ON MVAS 
Comments 
MVAs: definition N/A 
Findings  
 
CPAP: ↓  MVAs (42 
vs 0%), near-misses 
(64 vs. 0%) 
 
Factors 
controlled for  
(if compared to 
controls) 
N/A 
 
Study 
duration 
(months) 
B: 36 
A: 11 
CPAP  
use (h/d) 
(mean) 
N/A 
Age (y), AHI (/h), 
BMI (kg/m2) 
(mean values in 
groups) 
Age: 46 
AHI: N/A 
BMI: N/A 
Subjects 
N=14 
M: 14 
F: 0 
Study  
design 
OBS Study; 
B-A 
Author 
Minemura 
et al. 1993 
↔, unchanged; ∆ , difference; A, after; AHI, apnea-hypopnea index; B, before; BMI, body mass index; CVD, cardiovascular disease; DL, driver’ s 
license; ESS, Epworth Sleepiness Scale; F, female; HTN, hypertension; M, male; N/A, not available; ODI4, oxygen desaturation index of ≥4%; PAP, 
positive airway pressure; RR, risk ratio; SpO2, blood oxygen saturation level; UC, usual care. 
* Only patients treated with CPAP included. 
†  The level of CPAP usage subjectively measured. 
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2.5.5.1 Evaluation of fitness to drive 
The American Thoracic Society has defined a high-risk driver as a subject with 
moderate to severe daytime sleepiness (e.g. falling asleep unintentionally during 
daily activities) in addition to a recent MVA or near-miss MVA related to sleepiness, 
fatigue or inattention. Driving risk and possible non-OSA causes of EDS (e.g. use of 
alcohol or sedatives, sleep restriction, neurological disorders) should be evaluated in 
all patients with suspected or confirmed OSA. High-risk drivers should be warned 
about the potential risk associated with driving. A sleep study and further initiation 
of CPAP in confirmed OSA should be performed in less than one month to reduce 
driving risk. Patients should be followed after the initiation of CPAP to reassess the 
risk of driving and to ensure compliance with treatment (Strohl et al. 2013). 
A revision of Annex III of the European Union Directive on Driving Licenses 
was established in 2014 based on the recommendations from a Working Group 
established by the Transport and Mobility Directorate of the European Commission 
(Commission Directive 2014/85/EU, McNicholas et al. 2013). The new Directive 
was subjected to mandatory implementation by all Member States starting in 
December 2015. It states that moderate to severe OSAS as an AHI of ≥15 /h is a risk 
of driving due to its association with EDS. Drivers with suspected moderate to severe 
OSAS shall be referred for further authorized medical advice before a driving license 
may be issued and they may be advised not to drive until the diagnosis is confirmed. 
Driving licenses may be issued to drivers with confirmed moderate to severe OSAS 
if sleepiness is improved and an authorized medical practitioner has confirmed that 
the control of OSAS and compliance with appropriate treatment is adequate. During 
treatment, drivers with moderate to severe OSAS shall be subject to medical review 
at intervals not exceeding 3 years for group 1 drivers and 1 year for group 2 drivers 
to ensure treatment compliance, continuation of good vigilance and to reassess the 
need for continuing treatment (Commission Directive 2014/85/EU).  
Additional recommendations from the Working Group defined EDS as ESS of 
≥15 scores. A driving license may be recovered by drivers advised not to drive in the 
absence of EDS after a 2- to 4-week treatment with CPAP with adequate compliance, 
defined as CPAP use of ≥4 h/day on ≥70 % of days. Residual AHI for professional 
drivers should be <10 /h. Driving may be authorized for drivers with untreated, mild 
OSA if the driver does not report on EDS or recent MVAs, has no hypertension 
requiring ≥2 medications and if BMI is <35 kg/m2 (McNicholas et al. 2013). 
However, the assessment of sleepiness by ESS has been insufficient for 
identifying high-risk drivers, since it is prone to bias and patients may underrate their 
sleepiness. Objective tests are not well suited to be performed on a large scale, 
although they may be particularly useful if sleepiness continues during treatment. 
The use of MSLT in the assessment of driving ability has been criticized, since 
patients do not aim to fall asleep while driving, and the reliability of MWT to match 
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real-life driving performance has also been questioned (Bonsignore et al. 2016, 
Dwarakanath & Elliott 2019, McNicholas et al. 2013, Strohl et al. 2013). 
Furthermore, the use of AHI or BMI alone in the assessment of fitness to drive is not 
recommended, since patients with similar AHI may differ regarding the severity of 
EDS, and the specificity of BMI to predict MVAs has been poor (McNicholas et al. 
2013, Strohl et al. 2013). It is also not clear how moderate or severe OSA should be 
suspected or how good compliance, treatment effectiveness or good vigilance should 
be determined. The European Respiratory Society has established a task force to 
provide practical recommendations considering these issues. Overall, new tools to 
assess fitness to drive are needed (Bonsignore et al. 2016). 
2.5.6 Economic impact 
Untreated OSA has been associated with increased healthcare utilization and costs 
(Kapur et al. 2017). Based on cost-effectiveness analyses, CPAP has been shown to 
be cost-effective in OSA treatment compared to no treatment (Patil et al. 2019). A 
study of 373 OSA patients reported CPAP to be cost-effective as of the second year 
in patients with CPAP use of ≥4 h/day but not in those with lower usage (3357 vs. 
5959 €). Costs related to the OSA diagnosis and the initiation of CPAP, particularly 
if in-laboratory titration was required, are likely to explain why CPAP was not cost-
effective right from the beginning. Total costs included in the analysis consisted of 
direct health-care costs (treatment for diseases and MVAs), direct non-health-care 
costs (patient transport costs, costs of medical care covered by private health 
insurance schemes) and indirect costs (loss of work productivity) (Català et al. 2016). 
The main result was consistent with a previously published study of the British 
National Health Service (Guest et al. 2008). However, there are no studies evaluating 
the cost-effectiveness of CPAP and outcomes on BP levels, suggesting that CPAP 
might be even more cost-effective than previously estimated (Patil et al. 2019). 
2.6 Alternative treatment options for OSA 
2.6.1 Lifestyle interventions 
The clinical practice guideline from the American Thoracic Society has 
recommended that overweight and obese OSA patients should be treated with 
conventional lifestyle intervention such as a reduced-calorie diet, increased physical 
activity and/ or behavioral guidance (Hudgel et al. 2018). The Wisconsin Sleep 
Cohort Study reported that a 10 % weight loss resulted in a 26 % reduction in AHI 
over a follow-up of 4 years (Peppard et al. 2000a), and an RCT meta-analysis of 410 
patients with mild to moderate OSA further confirmed that lifestyle interventions 
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reduced weight by 14 kg and AHI by 16 /h (Mitchell et al. 2014). Weight loss has 
been shown to affect non-supine AHI to a greater extent than supine AHI; thus, non-
positional OSA may be converted to positional OSA (Joosten et al. 2017).  
The combination of weight loss and CPAP has been more effective than CPAP 
treatment alone (Joosten et al. 2017). An RCT of 146 obese patients with moderate 
to severe OSA found that weight loss and weight loss plus CPAP were associated 
with significant reduction in weight (both -7 kg) over 6 months, while CPAP alone 
was not (Chirinos et al. 2014). In a 2-year study of 31 obese males with OSA, CPAP 
plus weight loss similarly did not contribute to greater results than weight loss alone 
(Kajaste et al. 2004). Exercise has been shown to reduce AHI regardless of weight 
changes in mild to moderate OSA (Peppard & Young 2004). An RCT meta-analysis 
found that reduction in AHI did not differ between exercise training or CPAP in 
comparison to controls (mean change in AHI -17 /h vs. -25 /h) (Iftikhar et al. 2017).  
However, only a minority of OSA patients have achieved a normal AHI of <5 /h 
by conventional lifestyle interventions (Joosten et al. 2017). An RCT of 63 obese 
males with moderate to severe OSA found that a normal AHI was achieved only in 
17 % after a 9-week very low-calorie diet (Johansson et al. 2009). Another RCT of 
72 overweight patients with mild OSA showed that 63 % had achieved a normal AHI 
after a 12-month very low-calorie diet with supervised lifestyle counseling, but the 
prevalence had decreased to 32 % at 60 months and did not differ from controls 
treated with usual care (17 %) (Tuomilehto et al. 2009, Tuomilehto et al. 2013).  
2.6.2 Positional therapy for positional OSA 
It has been suggested that 50 to 60 % of OSA patients have positional OSA, usually 
defined as an AHI of ≥5 /h with ≥50 % increase in AHI in supine position compared 
to non-supine positions. The non-supine AHI may be either <5 /h (supine-isolated 
OSA) or ≥5 /h (supine-predominant OSA). Patients with positional OSA have been 
reported to be more likely younger, male and have a lower BMI than those with non-
positional OSA (Joosten et al. 2012, Kim et al. 2016, Srijithesh et al. 2019). 
Positional therapy aims to avoid sleeping in a supine position, e.g. by tennis ball 
sewn onto the back of a shirt, waistband or positional alarms (Srijithesh et al. 2019). 
The AASM has recommended positional therapy as an effective secondary treatment 
for positional OSA. It may also be a supplement to primary therapies if non-supine 
AHI is low, and the correction of OSA by position has been verified in a sleep study 
(Epstein et al. 2009). An RCT meta-analysis of 323 patients with mainly moderate 
OSA reported that CPAP was more effective in reducing AHI than positional 
therapy, while no difference was found in ESS. Positional therapy reduced both AHI 
and ESS more effectively compared to no treatment. Common side effects included 
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sleep disturbances and back and chest pain. However, RCTs on long-term adherence 
are needed, since most of the RCTs have been short-term (Srijithesh et al. 2019).  
2.6.3 Oral appliances 
A majority of the oral appliances, termed mandibular advancement devices (MADs), 
aim to enlarge the pharyngeal airway by pulling the lower jaw forward (Ramar et al. 
2015, Sutherland et al. 2014). Based on the AASM and American Academy of 
Dental Sleep Medicine, CPAP should generally be the first-line treatment alternative 
for OSA. MADs have been used as a first-line treatment option in patients with mild 
to moderate OSA who prefer MADs over CPAP or as a secondary alternative in 
those with more severe OSA who do not tolerate CPAP (Epstein et al. 2009, Ramar 
et al. 2015). A combination of CPAP and MAD may be beneficial in selected patients 
to improve CPAP compliance, since MAD may prevent mouth opening, leaks and 
chin retrusions and reduce CPAP’s pressure requirements (Sutherland et al. 2014). 
MADs have been shown to improve daytime sleepiness and sleep parameters 
compared to a placebo or inactive devices (Ramar et al. 2015). The impact of MADs 
on AHI appears to be similar to CPAP in mild OSA, whereas CPAP is more effective 
in reducing AHI in moderate to severe OSA (Ramar et al. 2015). The effect of CPAP 
on BP has been studied in more detail, although mounting evidence suggests that 
MADs may reduce BP, at least in selected patients (Lam et al. 2007, Ramar et al. 
2015). Compliance with MAD appears to be greater than that with CPAP and it 
appears to remain in the long term. Side effects may also lead to discontinuation of 
treatment less frequently (de Almeida et al. 2005, Ramar et al. 2015).  
Custom-prepared titratable devices that allow the anterior repositioning to be 
increased over weeks are preferred over non-custom devices (Ramar et al. 2015). 
Patient follow-up during treatment is recommended to identify potential side effects 
and to reassure treatment response with a sleep study (Ramar et al. 2015), since an 
AHI of <10 /h may be achieved only in 52 % of the patients (Ferguson et al. 2006). 
Younger age, lower BMI and female gender may result in better treatment outcome. 
MAD-related side effects are usually transient: mouth dryness, excessive salivation, 
tooth pain, gum irritation, pain in temporomandibular joint and headaches. Long-
term use of MADs may result in small but significant dental changes, such as 
decreases in overbite and overjet, changes in anterior-posterior occlusion and 
reduced number of occlusal contacts, compared to CPAP (Ramar et al. 2015).  
2.6.3.1 Bariatric surgery 
Bariatric surgical procedures, which aim to increase malabsorption and/ or caloric 
restriction, have been associated with greater weight loss and reductions in AHI 
REVIEW OF THE LITERATURE 
 69 
compared to conventional weight loss interventions (Joosten et al. 2017). Bariatric 
surgery is generally recommended to be considered in those who have failed to lose 
weight by conventional interventions and have a BMI of ≥40 kg/m2 without 
complications or a BMI of ≥35 kg/m2 with obesity-related comorbidities (e.g. OSA, 
T2D, hypertension) (Mechanick et al. 2008).  
A meta-analysis of 12 uncontrolled trials involving 342 patients showed that 
BMI was reduced by 18 kg/m2 and AHI by 38 /h after 17 months of bariatric surgery, 
but only 38 % had achieved an AHI of ≤15 /h. These patients were younger and had 
a lower BMI than those with a higher residual AHI (Greenburg et al. 2009). An RCT 
of 60 obese patients with moderate to severe OSA found that bariatric surgery was 
more likely to result in an AHI of <15 /h compared to those treated with conventional 
weight loss program (27 vs. 7 %), while no differences were observed in pressure 
requirements or adherence in patients continuing CPAP (Dixon et al. 2012). 
Overall, only a minority of patients have been shown to be cured of OSA after 
bariatric surgery; thus, most of the patients will require continued treatment for OSA. 
The possible attenuation of the disease should always be verified by a postoperative 
sleep study (Mechanick et al. 2008). One study showed that 45 % of the patients had 
achieved an AHI of <5 /h 1-year after bariatric surgery (Peromaa-Haavisto et al. 
2017), while the prevalence has been approximately 40 % two years after bariatric 
surgery depending on the amount of achieved weight loss (Mechanick et al. 2008).  
2.6.3.2 Upper airway surgery 
Reconstructive upper airway surgery includes a variety of different procedures 
regarding the nasal (e.g. septoplasty, nasal polypectomy, nasal valve surgery), oral/ 
oro-/ nasopharyngeal (e.g. tonsillectomy, adenoidectomy, uvulopalatoplasty), 
hypopharyngeal (e.g. tongue reduction, tongue advancement) and laryngeal (e.g. 
epiglottoplasty, hyoid suspension) areas. Maxillary and mandibular advancement, in 
which the patency of the upper airway is enhanced in several areas, may improve 
OSA similarly to CPAP. Bypassing the upper airway with a tracheostomy naturally 
leads to elimination of OSA. The majority of other upper airway surgical procedures 
rarely cure OSA but may improve symptoms and other outcomes. Laser-assisted 
uvulopalatoplasty is not recommended for OSA treatment (Epstein et al. 2009).  
As a primary treatment for OSA, evaluation of upper airway surgery may be 
considered in mild OSA with severe obstructing anatomy that could be corrected by 
a surgical procedure. As a secondary treatment for OSA, it may be considered in 
patients with residual OSA during CPAP or MAD treatment, patients who do not 
tolerate CPAP or MAD, or as an adjunct therapy if obstructive anatomy is likely to 
reduce the adherence to OSA treatment. A follow-up sleep study is recommended to 
reassure adequate treatment response after surgical treatment (Epstein et al. 2009). 
 70
3 AIMS 
The aims of the present study were to evaluate: 
1) whether CPAP treatment is associated with a reduced risk of nonfatal and 
fatal CVD outcomes compared to untreated controls in order to comprehend 
at which level of adherence this could be achieved and to further investigate 
whether the results differ in terms of specific outcomes 
2) the impact of CPAP treatment on weight changes at the cohort and individual 
levels and to identify patient characteristics associated with significant 
weight change, particularly those at high risk for significant weight gain 
3) the impact of CPAP on the incidence of police-reported MVAs compared 
between before and after treatment and between the CPAP-treated patients 
and untreated controls and to determine the potential effect of the level of 
CPAP adherence on the results 
4) the level of long-term adherence to CPAP at the cohort and individual levels 
and to identify patient characteristics associated with significant change in 
adherence 
5) the potential changes in the self-administered ESS and GHQ-12 
questionnaires during long-term CPAP treatment 
6) the effectiveness of AHI in the assessment of high-risk patients for adverse 
outcomes 
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4 MATERIALS AND METHODS 
Original publications I, IV and V present the data from study I, original publication 
II the data from study II, and original publication III the data from study III.  
4.1 Study subjects  
4.1.1 CPAP-treated patients (studies I–III) 
From the discharge database of the Turku University Hospital (Turku, Finland), 2489 
patients who had commenced CPAP treatment for OSAS during the years 2002–
2006 were identified. Of these patients, 1116 had continued the treatment for ≥5 
years. Patients without available cardiorespiratory polygraphy data (N=52) or with 
<4 follow-up visits (N=34) were excluded. These remaining 1030 patients formed 
the group of CPAP-treated patients without any further selection in studies I and III. 
Those who had engaged in bariatric surgery before or during CPAP treatment (N=7) 
were additionally excluded in study II in order to more reliably evaluate the 
association between CPAP and weight changes (Figure 5).  
4.1.2 Control patients (studies I, III) 
The control group was identified among 2359 OSAS patients who had commenced 
CPAP treatment at the Turku University Hospital (Turku, Finland) during 2002–
2009 but who discontinued the treatment within 5 years despite their doctor’s advice 
(Figure 5). Patients without available cardiorespiratory polygraphy data were 
excluded (N=83). The remaining 2276 patients had used CPAP for a median of 8.9 
(IQR 28.6) months. Among these patients, the best-matched control for each CPAP-
treated patient was determined according to gender, age and AHI. The pairwise-
matched control patients (N=1030) had used CPAP for a median of 4.0 (IQR 16.0) 
months prior to the study’s initiation. 
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Figure 5.  Flowchart of the recruitment of the continuous positive airway pressure (CPAP) treated 
obstructive sleep apnea syndrome (OSAS) patients in studies I–III and their controls 
matched for age, gender and apnea-hypopnea index (AHI) in studies I and III. Modified 
with permission from original publications I–II. 
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4.2 Methods 
4.2.1 Study designs (studies I–III) 
All the studies consisted of a retrospective, observational, single-center cohort of 
CPAP-treated patients (studies I–III) and their pairwise-matched controls (studies I 
and III). Study I used a matched case-control study design to compare the incidence 
of nonfatal and fatal CVD events between CPAP-treated patients and controls. Study 
II explored the development of BMI and adherence during CPAP treatment and 
studied them at the cohort and the individual levels. Study III determined the 
incidence of MVAs in CPAP-treated patients by using both before-after and case-
control study designs. 
4.2.2 Sleep studies (studies I–III) 
All included patients underwent cardiorespiratory polygraphy prior to the initiation 
of CPAP treatment. OSAS was diagnosed either by a cardiorespiratory polygraphy 
in the hospital (Embla, Somnologica Software, Flaga hf. Medical Devices, 
Reykjavik, Iceland) or by an ambulatory device at home (Embletta, Somnologica 
Software, Flaga hf. Medical Devices, Reykjavik, Iceland). Electroencephalography 
was not recorded during polygraphy. OSAS diagnosis was based on the Chicago 
criteria in the majority of the patients, while the 2007 AASM criteria were used for 
those patients diagnosed with OSAS during 2007 to 2009 (Iber et al. 2007, The 
Report of an American Academy of Sleep Medicine Task Force 1999). The sleep 
studies were scored by a pulmonologist or a clinical neurophysiologist.  
Categories of OSAS severity were defined according to the AHI: an AHI of <5 
/h (normal), an AHI of ≥5 but <15 /h (mild OSAS), an AHI of ≥15 but <30 /h 
(moderate OSAS), and an AHI of ≥30 /h (severe OSAS) (The Report of an American 
Academy of Sleep Medicine Task Force 1999). CPAP treatment was generally 
recommended for patients with an AHI of ≥15 /h (Chowdhuri et al. 2016, Gay et al. 
2006, Loube et al. 1999, Patil et al. 2019, Sullivan et al. 1981). The need for 
treatment was assessed individually in patients with a lower AHI, according to the 
patients’ symptoms and clinical findings strongly suggestive for OSAS.  
During the data collection of the studies I and III, AHI was confirmed to be 
measured during treatment among 3 of the patients with an AHI of <5 /h reported in 
study II and was corrected in studies I and III. The prevalence of moderate and severe 
disease among CPAP-treated patients was slightly higher in studies I and III 
compared to study II for the same reason. Study III additionally determined the 
following characteristics for those CPAP-treated patients and controls who had an 
MVA from the electronic medical records, if available: oxygen desaturation index 
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of ≥4 % (ODI4), or alternatively of ≥5 % if ODI4 was not reported, mean and 
minimum SpO2 and the percentage of time spent under SpO2 of 90 %. 
4.2.3 Questionnaires (studies I–III) 
The scores of the self-administered ESS (Johns 1991) (Appendix 1) and GHQ-12 
(Goldberg et al. 1997) (Appendix 2) questionnaires were generally evaluated both 
at the commencement of CPAP and at follow-up visits and entered into the electronic 
medical records. Data on baseline ESS and GHQ-12 scores were determined for the 
patients from the electronic medical records, if available. Study II determined the 
individual trends (slopes) of ESS and GHQ-12 development over time for those 
patients who had ≥3 available measurements during CPAP treatment. Study III 
evaluated the mean change in ESS during treatment for those CPAP-treated patients 
who had an MVA by comparing the first and last available values. 
4.2.4 Baseline comorbidity (studies I–III) and cardiovascular 
disease risk factors (study I) 
The following baseline variables were examined from the electronic medical 
records: age, gender, BMI and smoking status (defined as current smoker, ex-smoker 
or never smoker). Diagnoses of asthma, COPD, T2D (fasting glucose of ≥7.0 
mmol/l, use of insulin and/ or oral antidiabetics), IFG (fasting glucose of 6.1–6.9 
mmol/l), AF and psychiatric disorders, including depression, anxiety and psychotic 
disorder, were gathered from a diagnosis database of the Turku University Hospital. 
All diagnoses of the patients recorded during hospital visits are preserved in this 
database. The diagnoses of the patients were also verified from the electronic 
medical records during the manual collection of other patient data (studies I–III). 
Data on lipid concentrations in serum (including triglycerides, total cholesterol, 
low-density lipoprotein and high-density lipoprotein cholesterol) and the history of 
hypertension and CVD were determined in order to more reliably evaluate the 
association between CPAP treatment and CVD risk (study I). The patients’ 
laboratory test results were derived from a separate database of the Turku University 
Hospital, which includes all patient laboratory tests performed during hospital visits. 
Among those patients who did not have available values, data on serum lipid 
concentrations were examined manually from the electronic medical records, since 
the tests may have been ordered by general practitioners prior to the referral to a 
pulmonologist. Only serum lipid concentrations measured within 6 months before or 
after the initiation of CPAP treatment were included. Hypertension was defined as 
BP >140/90 mmHg and/ or use of antihypertensive medication. CVD included 
coronary, cerebral or peripheral artery diseases. An internist diagnosed CAD by 
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clinical symptoms and findings and/ or exercise testing or coronary angiography. A 
neurologist confirmed the diagnosis of stroke by computerized tomography or MRI. 
PAD was assessed by ankle-brachial index. The history of hypertension and CVD 
was also included in studies II and III. 
4.2.5 Study follow-up  
4.2.5.1 CPAP-treated patients (studies I–III) 
The follow-up of the CPAP-treated patients started from the commencement of 
CPAP treatment in all the studies. CPAP follow-up visits occurred approximately 
three times during the first year and after habituation every second year.  
Study I followed the CPAP-treated patients until the first nonfatal or fatal CVD 
event, all-cause death, CPAP withdrawal or the last CPAP follow-up visit before the 
end of 2014. The median follow-up time was 8.7 (IQR 2.8) years with a mean 
number of follow-up visits of 8.4 ± 2.2 per patient. The follow-up of the CPAP-
treated patients in study II ended with CPAP withdrawal, or the last CPAP follow-
up visit before the end of 2011. The mean follow-up period was 6.6 ± 1.2 years with 
a mean number of follow-up visits of 7.4 ± 2.1 per patient. Study III followed the 
CPAP-treated patients until CPAP withdrawal, or the last follow-up visit before the 
end of 2014. The median follow-up time was 9.0 (IQR 2.5) years with a mean 
number of follow-up visits of 8.4 ± 2.2 per patient. CPAP-treated patients were also 
screened for MVAs for 9 years prior to CPAP to compare MVAs before and after 
treatment. 
4.2.5.2 Control patients (studies I, III) 
Studies I and III started the follow-up of controls from the last CPAP follow-up visit. 
Study I followed control patients until the first nonfatal or fatal CVD event, all-cause 
death or until the end of 2014. The median follow-up time was 6.2 (IQR 4.1) years. 
In study III, control patients were followed until all-cause death or the end of 2014. 
The median follow-up time was 6.5 (IQR 3.9) years. Controls were also screened for 
MVAs for 6.5 years prior to CPAP in order to determine whether the incidence had 
changed over time.  
4.2.6 CPAP adherence and other treatment options for OSA 
(studies I–III) 
All patients were treated with a fixed pressure CPAP device. An auto-adjusting 
device may have been used at the beginning of the treatment in the assessment of 
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optimal treatment pressure (cmH2O). Treatment pressure and CPAP usage (h/day) 
were recorded by an inbuilt counter clock on the CPAP device. The CPAP use was 
determined from the device at every follow-up visit undertaken during the study and 
entered into the electronic medical records. The data on CPAP treatment were 
derived from a sleep database of the Department of Pulmonary Diseases at the Turku 
University Hospital. The database was updated at every follow-up visit. The mean 
usage hours across the whole CPAP treatment period (including missed days of use) 
were determined for each patient to evaluate long-term adherence. Those with a 
mean CPAP usage of ≥4 h/day were considered compliant with the treatment. Study 
II additionally determined short-term adherence by calculating the mean usage hours 
from the initiation of treatment either until the first follow-up visit or, alternatively, 
the 6-month follow-up visit when the habituation to treatment took longer period of 
time. 
CPAP-treated patients who had engaged in bariatric surgery before or during 
CPAP treatment (studies I–III) and controls who had been submitted to bariatric 
surgery or commenced MAD treatment during the study follow-up (studies I and III) 
were identified from the electronic medical records. A physician and a trained nurse 
gave overweight patients instructions for weight loss at the commencement of 
treatment in all the studies. According to the patient’s motivation, further diet and 
lifestyle counseling by a dietician were arranged but were not systematically offered 
to all patients. 
4.2.7 Follow-up data on body mass index (studies II–III) 
BMI was calculated by dividing weight in kilograms by the square of height in 
meters (kg/m2). The patients’ weight was measured during visits by a nurse. BMI 
was generally determined both at the commencement of CPAP treatment and at 
follow-up visits and entered into the electronic medical records. Study II determined 
the individual trends (slopes) of BMI development during treatment for each CPAP-
treated patient based on the BMI measurements recorded at baseline and follow-up 
visits. Study III evaluated the mean change in BMI during treatment for those CPAP-
treated patients who had an MVA by comparing the first and last available values. 
4.2.8 The definition of cardiovascular disease events 
(study I) and the data on deaths (studies I, III) 
A composite CVD event consisted of nonfatal and fatal CVD events. A nonfatal 
CVD event included angina pectoris (stable or unstable), CAD diagnosed by 
angiography and invasively treated, nonfatal myocardial infarction and nonfatal 
stroke. CVD events were diagnosed in special health care by a cardiologist or an 
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internist according to international guidelines. Coronary angiography data of the 
patients were gathered from a cardiological angiography database of the Turku 
University Hospital with a cardiologist’s guidance. The database included the 
following data on performed coronary angiographies: date, indication (elective vs. 
acute angiography), number of occluded coronary arteries, treatment decision 
(invasively vs. conservatively treated) and the type of procedure if invasively treated 
(PCI, coronary artery bypass grafting or heart valve procedure). All acutely 
performed angiographies with ≥1 occluded coronary artery (myocardial infarction, 
unstable angina pectoris) were included regardless of the treatment decision (either 
invasively or conservatively treated). Those electively performed angiographies with 
≥1 occluded coronary artery in addition to a need for invasive treatment procedure 
were also included as a nonfatal CVD event (CAD diagnosed and invasively treated). 
The Turku University Hospital is the only hospital in the region performing surgical 
and interventional cardiology procedures with an emergency department and an 
intensive cardiac care unit.  
Fatal CVD events were based on the 10th revision of the International Statistical 
Classification of Diseases and Related Health Problems (ICD-10), a medical 
classification list by the World Health Organization (World Health Organization, 
2004). Diseases of the circulatory system as determined by the ICD-10 (diagnoses 
I00–I99) that had led to death were included as fatal CVD events. The underlying 
cause of death was confirmed by an autopsy or documented disease history. All 
nonfatal and fatal strokes and nonfatal cardiac (CAD diagnosed by angiography and 
invasively treated, nonfatal angina pectoris or myocardial infarction) and fatal 
cardiac (death from ischemic heart disease) events were analyzed separately in 
additional analyses. Data on all-cause deaths before the end of 2014 were derived 
from the national registry maintained by Statistics Finland and were acknowledged 
in the follow-up durations of controls. All-cause mortality, death from CVD and 
death from cancer were analyzed separately in additional analyses. 
4.2.9 Data on MVAs (study III) 
All MVAs reported to the police and notified to the national registry maintained by 
Statistics Finland during the study follow-up were identified. Only accidents 
resulting in personal injury and involving the study subject as the actual driver were 
included. Data on accident conditions were provided. According to the data 
protection practices of Statistics Finland, small groups consisting of a few 
individuals may not be utilized; thus, the number of patients was either reported as 
approximate values or referred to as being ‘low’ in these cases. 
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4.3 Statistical analyses 
Data analyses were performed using IBM SPSS Statistics version 22.0 or 25.0 (IBM 
Corporation, Armonk, NY, USA) (studies I–III), R Core Team 2013 (R: A language 
and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria) (study II) or SAS 9.4 (SAS Institute Inc., Cary, NC, USA) (study 
III) software packages. Normally distributed continuous variables were presented as 
mean values and standard deviations (SD), and not normally distributed variables as 
median values and interquartile ranges (IQR). Means and medians were compared 
by the independent-samples T test or the one-way analysis of variance (ANOVA) 
and the Mann–Whitney U test, respectively, and categorical variables by the χ2 test. 
The linear relationship between two continuous random variables was assessed by 
the Spearman correlation coefficient (study II). P values of <0.05 were considered 
statistically significant. 
4.3.1 Study I 
The Cox regression model was used to evaluate the association between CPAP and 
the risk of CVD events, all-cause mortality and death from cancer by comparing 
CPAP-treated patients to untreated controls. For the basic Cox regression models, 
individual follow-up time was always calculated from the initiation of CPAP in 
CPAP-treated patients and from the last CPAP follow-up visit in controls. Time to 
the endpoint was determined in patients who had a specific endpoint (CVD event/ 
death from all-cause or cancer). In case of multiple CVD events, only the first event 
was considered. CPAP-treated patients who did not have an endpoint were followed 
until CPAP withdrawal or the last CPAP follow-up visit before the end of 2014. 
Controls who did not have a CVD event as an endpoint were followed until all-cause 
death or the end of 2014, while those who did not have all-cause death as an endpoint 
were followed until the end of 2014. Similarly, those controls who did not have death 
from cancer as an endpoint were followed until death from other causes or the end 
of 2014. 
Additional analyses were performed by using a modified Cox regression model 
to more reliably compare the incidence of CVD death, all-cause death and death from 
cancer between the CPAP-treated patients and controls. The main inclusion criterion 
for the CPAP-treated patients was continuation of treatment for ≥5 years, which 
naturally favors CPAP-treated patients over controls in terms of death survival rates, 
since they were followed from the initiation of treatment. Thus, in those analyses 
where a composite CVD event or death was the endpoint, follow-up duration of 
controls was modified from that of the basic Cox regression models. Individual 
follow-ups of those controls who had a fatal endpoint were increased by 5 years in 
the modified Cox regression analyses where a composite CVD event was the 
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endpoint, whereas in the analyses of CVD death, all-cause death or death from 
cancer, individual follow-ups of all the 1030 controls were increased by 5 years.  
The adjusted basic/ modified models were generally adjusted for the following 
confounding covariates, in addition to CPAP treatment: gender, age, AHI, BMI, IFG/ 
T2D, COPD, hypertension and CVD at baseline. As an exception, the adjusted model 
for stroke also included AF (all diagnoses of AF before the end of 2014) and the 
model for all-cause mortality the prevalence of psychiatric disorders at baseline. In 
further analyses, the adjusted model of the effect of smoking on the risk of CVDs 
included data on active/ former smoking and/ or a history of COPD instead of COPD 
alone. Data on serum cholesterol concentrations and the ESS score at baseline did 
not affect the hazard ratios (HR) of the CPAP-treated patients and were thus omitted 
from the final adjusted basic/ modified models. In unadjusted models, each covariate 
was computed separately in the model. HRs and 95 % CIs were used to determine 
the associations between the studied covariates and time to the endpoint. In terms of 
continuous covariates, HRs represented the risk associated with every one-unit 
increase in the studied covariate (e.g. one-year increase in age or one kg/m2 increase 
in BMI). 
Additional analyses by Cox regression model were performed to evaluate the 
association between the level of CPAP use and the risk of CVD events, all-cause 
mortality and death from cancer. These analyses compared CPAP-treated patients 
with CPAP use of >6 h/day, >4 but ≤6 h/day, or ≤4 h/day to controls. Furthermore, 
the effect of the level of CPAP adherence on the risk of having a composite CVD 
event or a nonfatal cardiac event was analyzed separately for those who had 
(secondary prevention) or did not have established CVD at baseline (primary 
prevention). Additional analyses were also performed separately for CPAP-treated 
patients and controls. In terms of composite CVD events, CPAP-treated patients with 
CPAP use of >6 h/day were compared to those with ≤6 h/day. Among controls, an 
AHI of ≥15 /h was compared to a lower AHI regarding the risk of a composite CVD 
event, CVD death or all-cause mortality. 
Unadjusted Kaplan–Meier curves with data censored at the time of the end of 
follow-up were used to visually compare the risk of having a composite CVD event, 
nonfatal stroke or nonfatal cardiac event between CPAP-treated patients and 
controls. Among controls, survival free time from all-cause mortality was shown in 
unadjusted Kaplan-Meier curves for those with an AHI of ≥15 /h or less.  
4.3.2 Study II 
The patients’ measurements of BMI and CPAP usage were assessed in relation to 
time starting from the initiation of CPAP. Based on these consecutive measurements, 
individual slopes of both BMI (kg/m2/year) and CPAP usage (h/day/year) were 
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determined for each patient by using the linear mixed model. Ascending slopes of 
BMI or CPAP usage were associated with gaining weight or increasing use of CPAP, 
respectively, whereas descending slopes were associated with the opposite. The 
accuracy of a single slope is dependent on the number of measurements available 
and the within-patient variation between the sequential measurements. The mean 
number of measurements were 7.4 ± 1.7 measurements of BMI and 6.5 ± 1.8 
measurements of CPAP usage during treatment for each CPAP-treated patient.  
The Bayesian hierarchical model for linear trend and the Markov Chain Monte 
Carlo simulation were used to account for the uncertainty related to individual trends, 
including the effect of within-patient variation, and to identify those individuals who 
had a significant constant change in BMI or CPAP adherence. For each patient, 5000 
lines were simulated through the measurement points, and the trend of these lines 
was evaluated individually at the posterior probability level of >90 %. These 5000 
lines thus represented the possible trends of development in each patient (the 
posterior distribution of trends) based on real data. Patients with >4500 ascending or 
descending slopes of the total simulated 5000 slopes (>90 %) were defined as having 
a significant increase or decrease, respectively, in BMI or CPAP adherence during 
treatment. Patients with fewer ascending or descending slopes did not have a 
significant change. Due to the model uncertainty and the within-patient variation, 
patients with a similar slope value may have been divided either into the subgroups 
of ‘significant change’ or ‘no significant change’ according to the Bayesian 
Hierarchical model and Monte Carlo simulation (Figure 6).  
Patients with a significant change in BMI or CPAP adherence were further 
profiled by the multivariate logistic regression analysis to evaluate potential 
predictors of change. These models were always adjusted for age, gender, AHI, BMI, 
ESS and GHQ-12 scores, the prevalence of IFG/ T2D, hypertension, CVD, 
psychiatric disorders and current smoking at baseline in addition to the ESS and 
GHQ-12 slopes. The models regarding significant changes in adherence were 
additionally adjusted for the prevalence of asthma at baseline, short-term CPAP 
usage and the BMI slope, whereas the models regarding significant changes in BMI 
were additionally adjusted for the CPAP adherence slope. The results were reported 
as ORs and 95 % CIs.  
The individual slope values of BMI and CPAP usage in addition to ESS and 
GHQ-12 scores (change of score/ year) determined by the linear mixed model, were 
used to evaluate the annual change in these variables. The average annual change at 
the cohort level was reported for all the CPAP-treated patients with available data. 
Additionally, the slope values of BMI and CPAP usage were also reported at the 
individual level for the following subgroups: patients with no significant change, 
patients with a significant increase and patients with a significant decrease in BMI 
or CPAP adherence. Further analyses also determined the prevalence of patients with 
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a significant change in BMI or CPAP adherence for those CPAP-treated patients 
who had a composite CVD event or an MVA in studies I and III.  
 
Figure 6.  These examples show that two patients may have a similar slope value, but the 
statistical accuracy of the slope depends on the number of measurements available and 
the variation between sequential measurements. Only patients 1 and 3 had a significant 
change in CPAP usage based on the Bayesian Hierarchical model and Monte Carlo 
simulation at the probability level of >90 %. Reprinted with permission from original 
publication II. 
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4.3.3 Study III 
The Poisson regression was used for the comparison of MVA incidences between 
study groups. The individual follow-up time of each patient was taken into account 
in the analysis. The incidence of MVAs was reported per 1000 person years and the 
risk for having an MVA as risk ratios (RR) and 95 % CIs. CPAP-treated patients 
were compared before–after treatment and to controls. The effect of the level of 
CPAP use (≥4 or ≥6 h/day) on the incidence of MVAs was determined separately. 
Among controls, the MVA incidence was also determined separately for those who 
had not used MAD after CPAP. Cox regression model was also used to evaluate the 
associations between the incidence of MVAs and potential predictors, including age, 
gender, BMI, smoking and AHI. 
4.4 Ethical aspects 
According to the national regulations, ethical committee's consideration was not 
required owing to the retrospective nature of the studies. The registry-based study 
design was approved by the Office of the Data Protection Ombudsman, Finland. 
Data gathering and analyses were performed with the permission of the Turku 
University Hospital. 
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5 RESULTS 
5.1 Characteristics of the patients at baseline 
5.1.1 Study II 
Of the 1023 included CPAP-treated patients, 76 % were male, the mean age was 56 
± 10 years and the mean AHI 34 ± 23 /h. Compared to men, women differed in 
several aspects by being older, more obese, by having a milder OSA and a higher 
prevalence of psychiatric disorders (Table 5). A correlation between AHI and age 
was not observed (R2 = −0.01, p=0.7).   
5.1.2 Studies I, III 
CPAP-treated patients and the 1030 pairwise-matched controls did not differ in terms 
of gender, age or AHI, but differences in comorbidities were observed (Table 6). 
Moderate to severe OSA was diagnosed in 76 % of the CPAP-treated patients and 
77 % of controls (p=0.9; Figure 7), and the majority of the patients in both groups 
were middle-aged (Figure 8) and obese (BMI >30 kg/m2, 67 vs. 60 %, respectively, 
p=0.001; Figure 9). EDS (ESS ≥11) was reported more frequently by CPAP-treated 
patients than controls (39 vs. 30 %, p<0.001), although the majority of the patients 
in both groups were non-sleepy.  
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Table 5.  Comparison of the characteristics between the CPAP-treated male and female patients 
at baseline (N=1023). Modified with permission from original publication II. 
 Male       
(N=775) 
Female 
(N=248) 
P Total 
(N=1023) 
Patient characteristics     
    Age, years (mean, SD) 54.7 ± 9.7 58.2 ± 9.8 <0.001 55.6 ± 9.8 
    BMI, kg/m2 (mean, SD) 33.1 ± 5.9 34.9 ± 7.6 <0.001 33.5 ± 6.4 
OSA and questionnaires     
    AHI, events/h (mean, SD) 35.7 ± 23.2 27.4 ± 21.7 <0.001 33.7 ± 23.1 
    ESS score (mean, SD) 9.5 ± 4.7 9.0 ± 4.7 0.1 9.4 ± 4.7 
    GHQ-12 score (mean, SD) 3.1 ± 3.6 4.0 ± 3.6 0.002 3.3 ± 3.6 
Comorbidity and lifestyle     
    IFG/ T2D (N, %) 324 (41.8) 88 (35.5) 0.08 412 (40.3) 
    Hypertension* (N, %) 586 (75.6) 197 (79.4) 0.2 783 (76.5) 
    CVD† (N, %) 48 (6.2) 7 (2.8) 0.04 55 (5.4) 
    Asthma (N, %) 68 (8.8) 32 (12.9) 0.06 100 (9.8) 
    COPD (N, %) 40 (5.2) 6 (2.4) 0.07 46 (4.5) 
    Psychiatric disorder‡ (N, %) 98 (12.6) 63 (25.4) <0.001 161 (15.7) 
    Current smoking (N, %) 179 (23.1) 45 (18.1) 0.1 224 (21.9) 
 
Data are presented as N (%) or mean ± standard deviation (SD). AHI, apnea-hypopnea index; BMI, 
body mass index; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway 
pressure; CVD, cardiovascular disease; ESS, Epworth Sleepiness Scale (data available for 977 
patients); GHQ-12, General Health Questionnaire (data available for 908 patients); IFG, impaired 
fasting glucose; T2D, type 2 diabetes.  
 
* Blood pressure greater than 140/90 mmHg and/ or use of antihypertensive medication. 
† Coronary artery disease, myocardial infarction, angina pectoris, stroke, intracranial atherosclerosis 
or peripheral artery disease. 
‡ Depression, anxiety or psychotic disorder. 
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Table 6.  Comparison of the characteristics between the CPAP-treated patients and controls at 
baseline. Modified with permission from original publication I. 
 CPAP-treated 
(N=1030) 
Controls 
(N=1030) 
P 
Patient characteristics    
    Male gender (N, %) 781 (75.8) 781 (75.8) 0.1 
    Age, years (mean, SD) 55.6 ± 9.8 56.4 ± 11.1 0.1 
    BMI, kg/m2 (median, IQR) 32.7 (8.1) 31.5 (7.9) <0.001 
OSA and questionnaires    
    AHI, events/h (median, IQR) 28.0 (33.0) 27.0 (28.0) 0.1 
    ESS score (mean, SD) 9.4 ± 4.7 8.3 ± 4.7 <0.001 
    GHQ-12 score (median, IQR) 2.0 (5.0) 2.0 (6.0) 0.1 
Comorbidity and lifestyle    
    IFG/ T2D (N, %) 416 (40.4) 363 (35.2) 0.02 
    Hypertension* (N, %) 788 (75.6) 724 (70.3) 0.001 
    CVD† (N, %) 56 (5.4) 130 (12.6) <0.001 
    Asthma (N, %) 102 (9.9) 97 (9.4) 0.7 
    COPD (N, %) 47 (4.6) 78 (7.6) 0.004 
    Psychiatric disorder‡ (N, %) 162 (15.7) 189 (18.3) 0.1 
    Smoking (N, %) 
        Current 
        Ex-smoker 
 
227 (22.0) 
668 (35.7) 
 
296 (28.7) 
355 (34.5) 
<0.001§ 
 
Data are presented as N (%) or mean ± standard deviation (SD) or median and interquartile range 
(IQR). AHI, apnea-hypopnea index; BMI, body mass index; COPD, chronic obstructive pulmonary 
disease; CPAP, continuous positive airway pressure; CVD, cardiovascular disease; ESS, Epworth 
Sleepiness Scale (data available for 981 CPAP-treated patients and 986 controls); GHQ-12, 
General Health Questionnaire (data available for 912 CPAP-treated patients and 947 controls); IFG, 
impaired fasting glucose; T2D, type 2 diabetes.  
 
*, †, ‡ Definitions are provided in Table 5. 
§ P-value for the trend. 
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Figure 7.  Comparison of the obstructive sleep apnea severity groups according to apnea-
hypopnea index (AHI) between the CPAP-treated patients and controls. 
 
Figure 8.  Comparison of the age groups between the CPAP-treated patients and controls. 
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Figure 9.  Comparison of the body mass index (BMI) groups between the CPAP-treated patients 
and controls. 
 
5.2 OSA treatment 
5.2.1 CPAP treatment and adherence (studies I–III) 
In studies I and III, the median use of CPAP was 6.4 (IQR 2.3) h/day for the 1030 
CPAP-treated patients over a median follow-up of 9 years. Of the patients, 598 (58 
%) had used CPAP >6 h/day, 315 (31 %) 4–6 h/day, and only 117 (11 %) <4 h/day 
(median use of 2.9, IQR 1.3 h/day) during the follow-up. Before the initiation of the 
study, controls had used CPAP for a median of 0.7 (IQR 2.6) h/day during a median 
treatment period of 4 (IQR 16) months. 
Study II evaluated CPAP adherence in more detail. CPAP usage was 5.2 ± 2.0 
h/day in the short term and 6.0 ± 1.8 h/day in the long term for the 1023 CPAP-
treated patients. Shor-term adherence was determined from the initiation of treatment 
either until the first follow-up visit or alternatively the 6-month follow-up visit. The 
mean change in adherence at the cohort level was 11 ± 12 min/day per year over a 
mean follow-up of 7 years. A weak positive correlation was found between AHI and 
long-term CPAP usage hours (R2 = 0.11, p=0.001), and a weak negative correlation 
between the mean CPAP usage and ESS score slopes (R2 = -0.13, p <0.001). At the 
individual level, 76 % of the patients showed no significant change, whereas 11 % 
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had a significant increase (an average of 30 ± 8 min/day per year) and 13 % a 
significant decrease (an average of 8 ± 9 min/day per year) in CPAP adherence 
(Figures 10–11). Gender differences were not observed in the groups with 
significant increase or decrease in adherence. 
The multivariate logistic regression analysis showed that significant increase 
in CPAP adherence was associated with the presence of psychiatric disorder or a 
higher BMI at baseline in addition to increases in weight or the GHQ-12 score 
during treatment. A weak association was observed between increasing AHI and 
significant increase in CPAP adherence (Table 7). Compared to the rest of the 
cohort, patients with an average CPAP use of >8 h/day (N=115) were more obese, 
had a more severe OSA based on AHI and a higher prevalence of psychiatric 
disorders and hypertension at baseline. No differences were found in terms of age, 
gender, other comorbidities (Table 8), or the mean ESS or GHQ-12 slopes (-0.7 ± 
0.7 vs. -0.6 ± 0.7, p=0.2, and -0.2 ± 0.7 vs. -0.2 ± 0.6, p=0.3 change of score/ year, 
respectively). 
5.2.2 Bariatric surgery, lifestyle counselling and mandibular 
advancement device treatment (studies I–III) 
Study II excluded CPAP-treated patients who had engaged in bariatric surgery before 
or during CPAP treatment (N=7) from the study. In studies I and III, 12 (1 %) of the 
CPAP-treated patients and 9 (1 %) of controls had engaged in bariatric surgery 
(p=0.5) and were included in the analyses. Of the control patients, 65 (6 %) had used 
MAD treatment after CPAP.  
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Figure 10. Mean annual change in CPAP adherence over a mean treatment period of 7 years at 
the individual level (N=1023). Modified with permission from original publication II. 
 
Figure 11.  Individual development of CPAP adherence in relation to the usage at the beginning of 
treatment (N=1017). Reprinted with permission from original publication II. 
Minna Myllylä 
 90
Table 7.  Associations between clinical characteristics and significant change in CPAP adherence 
determined by the multivariate logistic regression analysis. Modified with permission 
from original publication II. 
 Significant increase in    
CPAP adherence*  
Significant decrease in 
CPAP adherence*  
OR (CI 95 %) P OR (CI 95 %) P 
Patient characteristics     
    Age, years  1.02 (1.0–1.0) 0.3 0.98 (1.0–1.0) 0.2 
    Male gender 0.98 (0.5–1.8) 1.0 0.80 (0.5–1.4) 0.4 
    BMI, kg/m2  1.07 (1.0–1.1) 0.001 0.94 (0.9–1.0) 0.006 
OSA and questionnaires     
    AHI, events/h  1.01 (1.0–1.0) 0.04 1.00 (1.0–1.0) 0.5 
    ESS score  0.86 (0.8–0.9) <0.001 0.99 (0.9–1.1) 0.8 
    GHQ-12 score  1.19 (1.1–1.3) <0.001 1.10 (1.0–1.2) 0.02 
Comorbidity and lifestyle     
    IFG/ T2D 1.20 (0.7–2.0) 0.5 0.93 (0.6–1.5) 0.8 
    Hypertension† 1.84 (0.9–3.8) 0.09 0.92 (0.5–1.6) 0.8 
    CVD‡ 1.06 (0.4–2.9) 0.9 0.52 (0.1–2.2) 0.4 
    Asthma 0.83 (0.4–1.9) 0.7 0.87 (0.4–1.9) 0.7 
    Psychiatric disorder§ 3.30 (1.8–6.0) <0.001 0.70 (0.3–1.4) 0.3 
    Current smoking 1.41 (0.8–2.4) 0.2 0.64 (0.4–1.1) 0.1 
Follow-up characteristics     
    BMI slope|| 2.94 (1.7–5.2) <0.001 0.26 (0.1–0.5) <0.001 
    Short-term CPAP usage# 0.89 (0.8–1.0) 0.04 0.75 (0.7–0.8) <0.001 
    ESS slope|| 0.46 (0.3–0.7) 0.001 1.21 (0.8–1.8) 0.4 
    GHQ-12 slope|| 2.47 (1.6–3.9) <0.001 1.28 (0.8–2.0) 0.3 
 
Data are presented as odds ratios (ORs) and 95 % confidence intervals (95 % CIs). Abbreviations 
are presented in Table 5. 
 
* Patients with an ascending (significant increase) or a descending (significant decrease) trend in 
adherence over a mean treatment period of 7 years at the posterior probability level of >90 %.  
†, ‡, § Definitions are provided in Table 5. 
|| Annual change in BMI, ESS (N=948) or GHQ-12 (N=948) score over a mean CPAP treatment 
period of 7 years. 
# Mean CPAP usage from the commencement of CPAP either until the first follow-up visit or 
alternatively until the 6-month follow-up visit (including missed days of use) (N=1017). 
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Table 8.  Comparison of the baseline characteristics between the patients with an average CPAP 
use of >8 h/day and the rest of the cohort. 
 CPAP use of >8 h/day 
(N=115) 
The rest of the cohort 
(N=908) 
P 
Patient characteristics    
    Age, years (mean, SD) 57.0 ± 9.4 55.4 ± 9.9 0.1 
    Male gender (N, %) 82 (71.3) 693 (76.3) 0.2 
    BMI, kg/m2 (mean, SD) 35.8 ± 6.9 33.2 ± 6.3 <0.001 
OSA and questionnaires    
    AHI, events/h (mean, SD) 41.8 ± 26.2 32.7 ± 22.5 <0.001 
    ESS score (mean, SD) 8.9 ± 5.2 9.4 ± 4.6 0.3 
    GHQ-12 score (mean, SD) 4.2 ± 4.3 3.2 ± 3.5 0.005 
Comorbidity and lifestyle    
    IFG/ T2D (N, %) 53 (46.1) 359 (39.5) 0.2 
    Hypertension* (N, %) 99 (86.1) 684 (75.3) 0.01 
    CVD† (N, %) 6 (5.2) 49 (5.4) 0.9 
    Asthma (N, %) 15 (13.0) 85 (9.4) 0.2 
    COPD (N, %) 4 (3.5) 42 (4.6) 0.6 
    Psychiatric disorder‡ (N, %) 30 (26.1) 131 (14.4) 0.001 
    Current smoking (N, %) 22 (19.1) 202 (22.2) 0.4 
 
Data are presented as N (%) or mean ± standard deviation (SD). Abbreviations are presented in 
Table 5. 
 
*, †, ‡ Definitions are provided in Table 5. 
 
5.3 The association between CPAP treatment and 
the risk of cardiovascular diseases (study I) 
At baseline, the CPAP-treated patients and controls did not differ in terms of gender, 
age or AHI, but other differences in CVD risk factors were observed (Table 6). 
CPAP-treated patients had a higher BMI and a higher prevalence of IFG/ T2D and 
hypertension than controls, whereas CVD, COPD and smoking were more common 
among controls. CAD was the most common CVD at baseline in both groups (3 % 
in CPAP-treated patients and 7 % in controls) (Table 9). Clinically relevant 
differences in serum lipid concentrations were not observed (Table 10). 
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Among all patients, those with an AHI of ≥15 /h (N=1573) had a higher median 
BMI (33, IQR 8 vs. 31, IQR 8 kg/m2), a higher prevalence of hypertension (76 vs. 
64 %), CVD (10 vs. 6 %) and IGT/ T2D (40 vs. 30 %) in addition to older age (57 ± 
11 vs. 54 ± 0.4 years) at baseline compared to those with an AHI of <15 /h (N=487) 
(p <0.05). Among controls, an AHI of ≥15 /h (N=788) was associated with a 1.7-
fold (95 % CI 1.0–2.7, p=0.03) increased risk of all-cause mortality over a mean 
follow-up of 6.2 years independent of confounding factors compared to a lower AHI. 
Similarly, an unadjusted 2.4-fold (95 % CI 1.6–3.7, p<0.001) increased risk of 
composite CVD events was observed; however, the adjusted analyses of composite 
CVD events (HR 1.46, 95 % CI 0.9–2.3, p=0.1) and CVD deaths (HR 2.02, 95 % CI 
1.0–4.2, p=0.06) showed only a tendency towards increased risk.  
The survival of the controls free from all-cause mortality is shown in adjusted 
Kaplan-Meier curves according to AHI (Figure 12). 
 
Table 9.  Comparison of the prevalence of cardiovascular diseases between the CPAP-treated 
patients and controls at baseline. Modified with permission from original publication I. 
 CPAP-treated    
(N=1030) 
Controls            
(N=1030) 
P 
Cardiovascular diseases (N, %) 56 (5.4) 130 (12.6) <0.001 
    Coronary artery disease 34 69 <0.001 
    Myocardial infarction 6 18 0.01 
    Angina pectoris 3 5 0.5 
    Stroke 10 25 0.01 
    Intracranial atherosclerosis 1 0 0.3 
    Peripheral artery disease 2 13 0.004 
 
Data are presented as N or N (%). CPAP, continuous positive airway pressure. 
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Table 10.  Comparison of the lipid concentrations in serum between the CPAP-treated patients and 
controls at baseline. 
Lipid concentrations, mmol/l CPAP-treated (N=1030) Controls (N=1030) P 
Total cholesterol* (mean, SD) 5.1 ± 1.0 5.0 ± 1.1 0.009 
LDL cholesterol (median, IQR) 2.9 (1.1) 2.8 (1.2) 0.004 
HDL cholesterol (mean, SD) 1.3 ± 0.4 1.3 ± 0.4 0.4 
Triglycerides† (median, IQR) 1.6 (1.1) 1.6 (1.1) 0.2 
 
Data are presented as mean ± standard deviation (SD) or as median and interquartile range (IQR). 
CPAP, continuous positive airway pressure; HDL, serum high-density lipoprotein (data available for 
787 CPAP-treated patients and 715 controls); LDL, serum low-density lipoprotein (data available 
for 773 CPAP-treated patients and 703 controls). 
 
* Total cholesterol level in serum (data available for 845 CPAP-treated patients and 738 controls). 
† Triglyceride level in serum (data available for 776 CPAP-treated patients and 708 controls). 
 
Figure 12.  Survival free time from all-cause mortality among control patients with an AHI of ≥15 /h 
(orange, N=788) or <15 /h (green, N=242). 
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5.3.1 All CVD deaths 
In the basic Cox regression model, CPAP treatment was associated with a decreased 
risk of fatal CVD events after adjustment for confounding factors when all CVD 
deaths of the patients, including 33 deaths in CPAP-treated patients and 106 deaths 
in controls, were analyzed separately (HR 0.23, CI 95 % 0.2–0.3, p <0.001). The 
association remained significant in the adjusted modified model (HR 0.53, 95 % CI 
0.4–0.8, p=0.003). However, a subgroup analysis revealed that the beneficial impact 
of CPAP was shown only in those patients who had used CPAP for >6 h/day (HR 
0.39, 95 % CI 0.2–0.7, p=0.001) (Table 11). The most common cause of CVD death 
was ischemic heart disease (Figure 13). 
Table 11.  Adjusted hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) predicting the 
time to death from cardiovascular diseases (CVDs) (N=139) among the CPAP-treated 
patients and controls. Modified with permission from original publication I. 
 Basic adjusted model*
 † Modified adjusted model* † 
HR CI 95% P HR CI 95% P 
Male gender 1.61 1.0–2.5 0.04 1.60 1.0–2.5 0.04 
Age, years 1.08 1.1–1.1 <0.001 1.08 1.1–1.1 <0.001 
BMI, kg/m2 1.02 1.0–1.1 0.2 1.02 1.0–1.1 0.2 
AHI, events/h 1.01 1.0–1.0 0.001 1.01 1.0–1.0 <0.001 
CVD‡ 3.33 2.2–4.9 <0.001 2.99 2.0–4.4 <0.001 
Hypertension§ 1.69 0.9–3.0 0.08 1.68 0.9–3.0 0.08 
IFG/ T2D 1.42 1.0–2.0 0.05 1.42 1.0–2.0 0.048 
COPD 1.16 0.7–1.9 0.6 1.21 0.7–2.0 0.4 
CPAP treatment 
    >6 h/day# 
    >4, but ≤6 h/day# 
    ≤4 h/day# 
0.23 
0.17 
0.27 
0.51 
0.2–0.3 
0.1–0.3 
0.1–0.5 
0.2–1.1 
<0.001 
<0.001 
<0.001 
0.09 
0.53 
0.39 
0.62 
1.2 
0.4–0.8 
0.2–0.7 
0.3–1.2 
0.5–2.6 
0.003 
0.001 
0.1 
0.7 
 
AHI, apnea-hypopnea index; BMI, body mass index; COPD, chronic obstructive pulmonary disease; 
CPAP, continuous positive airway pressure; IFG, impaired fasting glucose; T2D, type 2 diabetes. 
 
* The model was adjusted for gender, age, BMI, AHI, CVD, hypertension, IFG/ T2D, COPD and 
CPAP treatment (CPAP vs. controls). 
† In the modified model, the follow-up of all the controls was increased by 5 years from that of the 
basic model in order to compare the incidence of deaths between the groups more reliably.  
‡ Coronary artery disease, myocardial infarction, angina pectoris, stroke, intracranial atherosclerosis 
or peripheral artery disease. 
§ Blood pressure greater than 140/90 mmHg and/ or use of antihypertensive medication. 
# Mean CPAP usage over a median treatment period of 9 years (including missed days of use). 
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Figure 13.  All cardiovascular disease deaths of the CPAP-treated patients (N=33) and controls 
(N=106) including death from ischemic heart disease (IHD), cardiomyopathy (CM), 
aortic dissection (AD), aneurysm (AA), stroke or other causes (cardiac arrhythmias, 
heart valve diseases, other cerebrovascular diseases than stroke, systemic 
atherosclerosis, complicated hypertension or thrombophlebitis of deep veins). 
5.3.2 All strokes 
Of the CPAP-treated patients, 47 had a nonfatal and 3 a fatal stroke. The 
corresponding incidences for controls were 60 and 4, respectively. CPAP-treatment 
was associated with a reduced risk of nonfatal and fatal strokes both in the basic (HR 
0.60, 95 % CI 0.4–0.9, p=0.01) and the modified (HR 0.59, 95 % CI 0.4–0.9, 
p=0.008) Cox regression models. The association was independent of confounding 
factors in both analyses (Table 12).  
The association between CPAP treatment and a reduced risk of stroke remained 
significant both in the unadjusted (HR 0.56, 95 % CI 0.4–0.8, p=0.003) and adjusted 
basic Cox regression model (HR 0.60, 95 % CI 0.4–0.9, p=0.01) after fatal strokes 
were excluded from the analysis and nonfatal strokes (N=107) were analyzed 
separately (Table 13). Survival rates free from nonfatal stroke are shown in 
unadjusted Kaplan–Meier curves (Figure 14).  
Subgroup analyses showed that only those patients who had used CPAP for >4 
but ≤6 h/day were associated with a reduced risk of nonfatal and fatal stroke (HR 
0.38, 95 % CI 0.2–0.7, p=0.005) or nonfatal stroke alone (HR 0.41, 95 % CI 0.2–0.8, 
p=0.01) in comparison to controls, while patients with a higher or lower CPAP usage 
were not (Tables 12–13). However, when the model was adjusted only for AF, a 
significant association between patients with CPAP use of either >4 but ≤6 h/day 
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(HR 0.65, 95 % CI 0.4–1.0, p=0.047) or >6 h/day (HR 0.41, 95 % CI 0.2–0.8, 
p=0.009) and a reduced risk of stroke was observed compared to controls, but not 
among those with CPAP use of ≤4 h/day (HR 0.42, 95 % CI 0.2–1.2, p=0.09).  
Table 12.  Adjusted hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) predicting the 
time to nonfatal and fatal stroke (N=114) among the CPAP-treated patients and controls. 
 
 
Adjusted basic model* † Adjusted modified model* † 
HR CI 95% P HR CI 95% P 
Male gender 1.39 0.9–2.2 0.2 1.37 0.9–2.2 0.2 
Age, years 1.07 1.0–1.1 <0.001 1.07 1.0–1.1 <0.001 
BMI, kg/m2 1.00 1.0–1.0 0.8 1.00 1.0–1.0 0.9 
AHI, events/h 1.00 1.0–1.0 0.6 1.00 1.0–1.0 0.6 
CVD‡ 3.69 2.4–5.8 <0.001 3.73 2.4–5.8 <0.001 
Hypertension§ 1.63 0.9–2.9 0.1 1.61 0.9–2.9 0.1 
AF 1.14 0.7–1.8 0.6 1.16 0.7–1.8 0.5 
IFG/ T2D 1.32 0.9–1.9 0.2 1.33 0.9–2.0 0.2 
COPD 0.72 0.3–1.5 0.4 0.73 0.3–1.5 0.4 
CPAP treatment 
 >6 h/day# 
 >4, but ≤6 h/day# 
 ≤4 h/day# 
0.60 
0.72 
0.38 
0.61 
0.4–0.9 
0.5–1.1 
0.2–0.8 
0.2–1.5 
0.01 
0.1 
0.006 
0.3 
0.59 
0.71 
0.38 
0.61 
0.4–0.9 
0.5–1.1 
0.2–0.7 
0.2–1.5 
0.008 
0.1 
0.005 
0.3 
 
AF, atrial fibrillation (all diagnoses before the end of 2014, N=314); AHI, apnea-hypopnea index; 
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive 
airway pressure; CVD, cardiovascular disease; IFG, impaired fasting glucose; T2D, type 2 diabetes.  
 
* In the modified model, the follow-up was increased by 5 years from that of the basic model in 
those controls who had fatal stroke in order to compare the incidence of fatal events between the 
groups more reliably. 
† The model was adjusted for gender, age, BMI, AHI, CVD, hypertension, AF, IFG/ T2D, COPD and 
CPAP treatment (CPAP vs. controls). 
‡, §, # Definitions are provided in Table 11. 
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Table 13.  Unadjusted and adjusted hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) 
predicting the time to nonfatal stroke (N=107) among the CPAP-treated patients and 
controls. 
 
 
Unadjusted basic model*  Adjusted basic model† 
HR CI 95% P HR CI 95% P 
Male gender 1.19 0.7–1.9 0.5 1.32 0.8–2.1 0.3 
Age, years 1.08 1.1–1.1 <0.001 1.06 1.0–1.1 <0.001 
BMI, kg/m2 0.99 1.0–1.0 0.6 1.00 1.0–1.0 0.9 
AHI, events/h 1.00 1.0–1.0 0.8 1.00 1.0–1.0 0.6 
CVD‡ 6.98 4.6–10.6 <0.001 3.76 2.4–6.0 <0.001 
Hypertension§ 2.28 1.3–3.9 0.003 1.47 0.8–2.6 0.2 
AF 2.36 1.6–3.6 <0.001 1.23 0.8–1.9 0.4 
IFG/ T2D 1.78 1.2–2.6 0.003 1.45 1.0–2.2 0.07 
COPD 1.43 0.7–2.9 0.3 0.77 0.4–1.6 0.5 
CPAP treatment 
 >6 h/day# 
 >4, but ≤6 h/day# 
 ≤4 h/day# 
0.56 
0.66 
0.40 
0.43 
0.4–0.8 
0.4–1.0 
0.2–0.8 
0.2–1.2 
0.003 
0.06 
0.008 
0.1 
0.60 
0.73 
0.41 
0.52 
0.4–0.9 
0.5–1.1 
0.2–0.8 
0.2–1.4 
0.01 
0.2 
0.01 
0.2 
 
AF, atrial fibrillation (all diagnoses before the end of 2014, N=314); AHI, apnea-hypopnea index; 
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive 
airway pressure; CVD, cardiovascular disease; IFG, impaired fasting glucose; T2D, type 2 diabetes.  
 
* Each covariate was computed separately in the model. 
† The model was adjusted for gender, age, BMI, AHI, CVD, hypertension, AF, IFG/ T2D, COPD and 
CPAP treatment (CPAP vs. controls). 
‡, §, # Definitions are provided in Table 11. 
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Figure 14.  Survival free time from nonfatal stroke (N=107) among the CPAP-treated patients 
(orange, N=1030) and controls (green, N=1030). 
5.3.3 All cardiac events 
A nonfatal cardiac event was observed in 86 of the CPAP-treated patients and 66 of 
controls, while death from ischemic heart disease was found in 11 and 50 of the 
patients, respectively. The association between CPAP and the risk of nonfatal and 
fatal cardiac events was not significant in the modified Cox regression model after 
adjustment for confounding factors (HR 0.78, 95 % CI 0.6–1.0, p=0.1) (Table 14). 
A subgroup analysis found that the association became significant when patients 
with CPAP use of >6 h/day were compared to controls (HR 0.70, 95 % CI 0.5–1.0, 
p=0.04). However, when all nonfatal cardiac events (N=152) were analyzed 
separately, a significant association was not observed regardless of the level of CPAP 
use (Table 14). Furthermore, no effect of CPAP was found on the primary 
prevention of nonfatal cardiac events, since excluding those CPAP-treated patients 
and controls who had an established CVD at baseline (N=186) did not change the 
results. Survival free time from nonfatal cardiac events is shown in unadjusted 
Kaplan–Meier curves (Figure 15). 
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Table 14.  Adjusted hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) predicting the 
time to nonfatal and fatal cardiac events (N=213) or nonfatal cardiac events alone 
(N=152) among the CPAP-treated patients and controls. 
 Nonfatal and fatal cardiac event Nonfatal cardiac event 
Adjusted basic     
model* † 
Adjusted modified 
model* † 
Adjusted basic  
model* † 
HR CI 95% P HR CI 95% P HR CI 95% P 
Male gender 1.56 1.1–2.2 0.02 1.57 1.1–2.3 0.01 1.74 1.1–2.7 0.01 
Age, years 1.07 1.0–1.1 <0.001 1.07 1.0–1.1 <0.001 1.06 1.0–1.1 <0.001 
BMI, kg/m2 1.02 1.0–1.0 0.1 1.02 1.0–1.0 0.1 1.02 1.0–1.1 0.1 
AHI, events/h 1.00 1.0–1.0 0.9 1.00 1.0–1.0 0.8 0.99 1.0–1.0 0.1 
CVD‡ 4.22 3.1–5.8 <0.001 4.04 2.9–5.6 <0.001 4.06 2.8–6.0 <0.001 
Hypertension§ 1.53 1.0–2.4 0.06 1.53 1.0–2.4 0.07 1.68 1.0–2.8 0.06 
IFG/ T2D 1.83 1.4–2.4 0.02 1.73 1.3–2.3 <0.001 1.61 1.2–2.3 0.005 
COPD 1.62 1.1–2.4 0.02 1.55 1.0–2.3 0.03 1.65 1.0–2.7 0.04 
CPAP treatment 
 >6 h/day# 
 >4, but ≤6 h/day# 
 ≤4 h/day# 
0.72 
0.65 
0.91 
0.50 
0.5–1.0 
0.5–0.9 
0.6–1.3 
0.2–1.1 
0.02 
0.01 
0.6 
0.08 
0.78 
0.70 
1.00 
0.56 
0.6–1.0 
0.5–1.0 
0.7–1.5 
0.3–1.2 
0.1 
0.04 
1.0 
0.1 
1.10 
1.01 
1.36 
0.74 
0.8–1.5 
0.7–1.5 
0.9–2.1 
0.3–1.7 
0.6 
1.0 
0.2 
0.5 
 
Abbreviations are presented in Table 11. 
 
* In the modified model, the follow-up was increased by 5 years from that of the basic model in 
those controls who had fatal cardiac event in order to compare the incidence of cardiac deaths 
between the groups more reliably. 
† The model was adjusted for gender, age, BMI, AHI, CVD, hypertension, IFG/ T2D, COPD and 
CPAP treatment (CPAP vs. controls). 
‡, §, # Definitions are provided in Table 11. 
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Figure 15.  Survival free time from nonfatal cardiac events (N=152) among the CPAP-treated 
patients (orange, N=1030) and controls (green, N=1030). 
5.3.4 Composite CVD events 
A composite of nonfatal and fatal CVD events occurred in 14 % (N=148) of the 
CPAP-treated patients and in 19 % (N=194) of controls. Of these events, 22 and 79 
were fatal, respectively. Stroke was the most common nonfatal CVD event in both 
groups (Figure 16). Coronary angiography was performed for 42 of the total 81 
nonfatal CAD events (52 %) among the CPAP-treated patients and for 29 of the total 
60 events (48 %) among controls (p=0.7) (Table 15). CPAP was independently 
associated with a decreased risk of a composite of nonfatal and fatal CVD events in 
the basic Cox regression model compared to controls (HR 0.64, CI 95 % 0.5–0.8, p 
<0.001). The association remained significant in the modified model (HR 0.69, 95 
% CI 0.5–0.9, p=0.001). The strongest risk factor was previous CVD in both analyses 
and also hypertension, IFG/ T2D, male gender and older age remained independent 
risk factors while AHI did not (Table 16). 
A subgroup analysis of the modified adjusted model revealed that the association 
between CPAP and improved CVD outcome existed only among those who had used 
CPAP for >6 h/day (N=598; HR 0.64, 95 % CI 0.5–0.8, p=0.002) when compared to 
controls. No associations were observed among the two groups of patients with lower 
CPAP use (Table 16), although a statistically significant difference was achieved 
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when those two groups were combined, and CPAP use of ≤6 h/day (N=432) was 
compared to controls (HR 0.75, 95 % CI 0.6–1.0, p=0.045) (Figure 17). Importantly, 
a significant association was observed between CPAP use of >4 h/day and the 
primary prevention of CVDs, since CPAP use of >4, but ≤6 h/day (HR 0.68, 95 % 
CI 0.5–1.0, p=0.04) or >6 h/day (HR 0.50, 95 % CI 0.4–0.7, p<0.001) were both 
associated with a reduced risk of a composite CVD event (N=241 CVD events) after 
those with established CVD at baseline (N=186) were excluded from the modified 
model. The model was adjusted for gender, age, BMI, AHI, the prevalence of 
hypertension, IFG/ T2D and COPD at baseline. CPAP did not have an effect on the 
secondary prevention of CVDs, but however, the analysis likely lacked statistical 
power, since only 186 patients had CVD at baseline, and the model failed to show 
any significant associations between the studied covariates and the CVD outcome.  
The unadjusted risk of a composite CVD event did not differ between the CPAP-
treated patients with CPAP use of >6 or ≤6 h/day (HR 0.82, CI 95 % 0.6–1.1, p=0.2). 
Additional analyses were also conducted to evaluate the effect of smoking on the 
CVD risk in more detail. CPAP was associated with a decreased risk of a composite 
CVD event compared to controls in the adjusted modified Cox regression model (HR 
0.68, 95 % CI 0.5–0.9, p=0.001), even though the data on active/ former smoking 
and/ or the prevalence of COPD were included as a covariate in the analysis in 
addition to gender, age, BMI, AHI, the prevalence of CVD, hypertension and IFG/ 
T2D at baseline. Furthermore, excluding active/ former smokers and/ or those with 
COPD (N=1252) did not change the results (HR 0.57, 95 % CI 0.4–0.8, p=0.006). 
Of the 1023 CPAP-treated patients in study II, 146 patients had a composite 
CVD event. Of these events, 74 % occurred in patients with no significant change, 
12 % in patients with a significant increase and 14 % in those with a significant 
decrease in CPAP adherence over a mean follow-up of 7 years. Similarly, 82 % of 
those who had a composite CVD event had no significant change in BMI, while 10 
% had a significant increase and 8 % a significant decrease in BMI.  
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Figure 16.  First occurred nonfatal cardiovascular disease events in the CPAP-treated patients 
(N=126) and controls (N=115) including stroke, coronary artery disease (CAD), angina 
pectoris (AP) and myocardial infarction (MI). Modified with permission from original 
publication I. 
Table 15.  Coronary angiography data on incident nonfatal coronary artery disease (CAD) events 
of the patients. Reprinted with permission from original publication I. 
Coronary angiography data CPAP-treated    
(N=42/1030) 
Controls            
(N=29/1030) 
Total 
(N=71/2060)                    
Findings in angiography    
    CAD diagnosed and invasively treated 17 10 27 
    Unstable angina pectoris 8 4 12 
    Nonfatal myocardial infarction 17 15 32 
Number of occluded coronary arteries    
    Three arteries or the left main 11 7 18 
    Two arteries 13 8 21 
    One artery 18 14 32 
Treatment    
    Percutaneous coronary intervention 26 22 48 
    Coronary artery bypass grafting 11 4 15 
    Heart valve procedure 3 0 3 
    Conservative treatment 2 3 5 
Data are presented as N. CPAP, continuous positive airway pressure. 
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Table 16.  Hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) predicting the time to the 
first nonfatal or fatal cardiovascular disease event (N=342) among the CPAP-treated 
patients and controls. Modified with permission from original publication I. 
 
 
 
Basic model* Modified model* 
Adjusted HR† Unadjusted HR‡ Adjusted HR† 
HR CI 95% P HR CI 95% P HR CI 95% P 
Male gender 1.42 1.1–1.9 0.01 1.25 1.0–1.6 0.09 1.39 1.1–1.8 0.02 
Age, years 1.06 1.0–1.1 <0.001 1.08 1.1–1.1 <0.001 1.06 1.0–1.1 <0.001 
BMI, kg/m2 1.01 1.0–1.0 0.3 1.01 1.0–1.0 0.2 1.01 1.0–1.0 0.2 
AHI, events/h 1.00 1.0–1.0 0.7 1.01 1.0–1.0 0.04 1.00 1.0–1.0 0.9 
CVD§ 4.09 3.1–5.3 <0.001 7.60 6.0–9.8 <0.001 3.69 2.8–4.8 <0.001 
Hypertension|| 1.58 1.1–2.2 0.008 2.63 1.9–3.6 <0.001 1.57 1.1–2.2 0.009 
IFG/ T2D 1.47 1.2–1.8 0.001 1.92 1.5–2.4 <0.001 1.39 1.1–1.7 0.005 
COPD 1.36 1.0–1.9 0.07 2.56 1.9–3.5 <0.001 1.26 0.9–1.8 0.2 
CPAP treatment 
 >6 h/day# 
 >4, but ≤6 h/day# 
 ≤4 h/day# 
0.64 
0.61 
0.71 
0.62 
0.5–0.8 
0.5–0.8 
0.5–1.0 
0.4–1.0 
<0.001 
<0.001 
0.03 
0.07 
0.55 
0.51 
0.66 
0.51 
0.4–0.7 
0.4–0.7 
0.5–0.9 
0.3–0.9 
<0.001 
<0.001 
0.008 
0.01 
0.69 
0.64 
0.77 
0.67 
0.5–0.9 
0.5–0.8 
0.6–1.1 
0.4–1.1 
0.001 
0.002 
0.1 
0.1 
Current smokerα – – – 0.98 0.8–1.3 0.9 – – – 
Cholesterolα – – – 0.72 0.6–0.8 <0.001 – – – 
ESS scoreα – – – 0.98 1.0–1.0 0.2 – – – 
 
AHI, apnea-hypopnea index; BMI, body mass index; COPD, chronic obstructive pulmonary disease; 
CPAP, continuous positive airway pressure; CVD, cardiovascular disease; ESS, Epworth 
Sleepiness Scale (data available for 981 CPAP-treated patients and 986 controls); IFG, impaired 
fasting glucose; T2D, type 2 diabetes. 
 
* In the modified model, the follow-up was increased by 5 years from that of the basic model in 
those controls who had CVD death in order to compare the incidence of deaths between the groups 
more reliably. 
† The model was adjusted for gender, age, BMI, AHI, CVD, hypertension, IFG/ T2D, COPD and 
CPAP treatment (CPAP vs. controls). 
‡ Each covariate was computed separately in the model.  
§ Coronary artery disease, myocardial infarction, angina pectoris, stroke, intracranial atherosclerosis 
or peripheral artery disease. 
 || Blood pressure greater than 140/90 mmHg and/ or use of antihypertensive medication. 
# Mean CPAP usage over a median treatment period of 9 years (including missed days of use). 
α History of COPD instead of smoking was used in the final adjusted model in order to better 
elucidate the amount of exposure. Data on serum cholesterol concentrations (mmol/l; data available 
for 845 CPAP-treated patients and 738 controls) and ESS score did not affect the HR of the CPAP-
treated patients and were thus omitted from the final adjusted model. 
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Figure 17.  Survival free time from a composite of nonfatal and fatal cardiovascular disease (CVD) 
events (N=342) among the CPAP-treated patients with CPAP use of >6 (orange, N=598) 
or ≤6 h/day (black, N=432) and controls (green, N=1030). The follow-up duration was 
increased by 5 years in those controls who had fatal CVD event. Modified with 
permission from original publication I. 
5.4 The association between CPAP treatment,   
all-cause and cancer mortality (study I) 
During follow-up, 77 of the CPAP-treated patients and 215 of controls had died from 
any cause. The most common underlying causes of death were CVD and cancer 
(Table 17). CPAP treatment was associated with a reduced risk of all-cause mortality 
independent of confounding factors both in the basic (HR 0.26, 95 % CI 0.2–0.3) 
and the modified Cox regression model (HR 0.60, 95 % CI 0.5–0.8) (both: p <0.001).  
A subgroup analysis of the adjusted modified Cox regression model showed that 
the association was, however, significant only among those who had used CPAP for 
>6 h/day (HR 0.49, 95 % CI 0.3–0.7, p <0.001) in comparison to controls. The most 
significant associations were found between all-cause mortality and male gender, 
established CVD and psychiatric disorder. Every 1 /h-unit elevation in AHI 
increased the risk by 1 %. (Table 18). A higher ESS score was associated with a 
lower risk of death in unadjusted analyses (HR 0.9–1.0, p <0.05), but the association 
did not remain significant after adjustment for confounding factors. 
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Table 17.  Underlying cause of death of the CPAP-treated patients (N=77) and controls (N=215) 
during the study follow-up. All deaths of the patients were included. 
Underlying cause of death CPAP treated (N, %) Controls (N, %) 
Cardiovascular disease 33 (42.9) 106 (49.3) 
Cancer 20 (26.0) 50 (23.3) 
Pulmonary or neurological disease 7 (9.1) 17 (7.9) 
Accident/ suicide/ chronic alcohol misuse 10 (13.0) 31 (14.4) 
Unclear cause 3 (3.9) 4 (1.9) 
Other cause 4 (5.2) 7 (3.3) 
 
Table 18.  Adjusted hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) predicting the 
time to death from all-causes among the CPAP-treated patients and controls. 
 
 
Basic adjusted model* † Modified adjusted model* † 
HR CI 95% P HR CI 95% P 
Male gender 2.29 1.6–3.3 <0.001 1.95 1.4–2.7 <0.001 
Age, years 1.09 1.1–1.1 <0.001 1.09 1.1–1.1 <0.001 
BMI, kg/m2 1.03 1.0–1.0 0.02 1.03 1.0–1.0 0.01 
AHI, events/h 1.01 1.0–1.0 <0.001 1.01 1.0–1.0 <0.001 
CVD‡ 2.27 1.7–3.1 <0.001 2.04 1.5–2.7 <0.001 
Hypertension§ 1.07 0.8–1.5 0.7 1.15 0.8–1.6 0.4 
IFG/ T2D 1.36 1.1–1.7 0.02 1.33 1.0–1.7 0.02 
COPD 1.53 1.1–2.1 0.02 1.65 1.2–2.3 0.002 
Psychiatric disorder|| 2.02 1.5–2.8 <0.001 2.07 1.5–2.8 <0.001 
CPAP treatment 
 >6 h/day# 
 >4, but ≤6 h/day# 
 ≤4 h/day# 
0.26 
0.20 
0.28 
0.43 
0.2–0.3 
0.1–0.3 
0.2–0.4 
0.2–0.8 
<0.001 
<0.001 
<0.001 
0.004 
0.60 
0.49 
0.68 
1.1 
0.5–0.8 
0.3–0.7 
0.4–1.0 
0.6–1.9 
<0.001 
<0.001 
0.07 
0.8 
Abbreviations are presented in Table 16.  
 
* The model was adjusted for gender, age, BMI, AHI, CVD, hypertension, IFG/ T2D, COPD, 
psychiatric disorder and CPAP treatment (CPAP vs. controls). 
† In the modified model, the follow-up of all controls was increased by 5 years from that of the basic 
model in order to compare the incidence of deaths between the groups more reliably.  
‡, §, # Definitions are provided in Table 16. 
|| Depression, anxiety or psychotic disorder. 
Minna Myllylä 
 106
Death from cancer occurred in 20 of the CPAP-treated patients and 50 of controls. 
The most common cancers leading to death included gastroenterological cancers 
(N=30, 43 %), urological/ gynecological cancers (N=16, 23 %), hematological 
cancers/ lymphoma (N=8, 11 %) and lung cancers (N=8, 11 %). A significant 
association between CPAP treatment and a reduced risk of death from cancer was 
not observed in the modified Cox regression model after adjustment for confounding 
factors (HR 0.76, 95 % CI 0.4–1.3, p=0.3). The association remained insignificant 
regardless of the level of CPAP use. The strongest predictors of cancer mortality 
were COPD, male gender and older age (Table 19).  
Table 19.  Adjusted hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) predicting the 
time to death from cancer among the CPAP-treated patients and controls. 
 
 
Basic adjusted model* † Modified adjusted model* † 
HR CI 95% P HR CI 95% P 
Male gender 1.98 1.0–3.8 0.04 1.95 1.0–3.8 0.045 
Age, years 1.11 1.1–1.1 <0.001 1.11 1.1–1.1 <0.001 
BMI, kg/m2 1.05 1.0–1.1 0.03 1.04 1.0–1.1 0.04 
AHI, events/h 1.01 1.0–1.0 0.2 1.01 1.0–1.0 0.2 
CVD‡ 1.63 0.9–3.0 0.1 1.45 0.8–2.7 0.2 
Hypertension§ 0.77 0.4–1.5 0.4 0.77 0.4–1.4 0.4 
IFG/ T2D 1.14 0.7–1.9 0.6 1.17 0.7–1.9 0.5 
COPD 2.65 1.5–4.7 0.001 2.70 1.5–4.8 0.001 
CPAP treatment 
 >6 h/day# 
 >4, but ≤6 h/day# 
 ≤4 h/day# 
0.27 
0.25 
0.30 
0.32 
0.2–0.5 
0.1–0.5 
0.1–0.7 
0.1–1.3 
<0.001 
<0.001 
0.003 
0.1 
0.76 
0.70 
0.85 
0.92 
0.4–1.3 
0.3–1.4 
0.4–1.9 
0.2–3.9 
0.3 
0.3 
0.7 
0.9 
Abbreviations are presented in Table 16.  
 
* The model was adjusted for gender, age, BMI, AHI, CVD, hypertension, IFG/ T2D, COPD and 
CPAP treatment (CPAP vs. controls). 
† In the modified model, the follow-up of all controls was increased by 5 years from that of the basic 
model in order to compare the incidence of deaths between the groups more reliably.  
‡, §, # Definitions are provided in Table 16. 
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5.5 The association between CPAP treatment and 
body mass index (study II) 
At baseline, the mean BMI was 34 ± 6 kg/m2, and 67 % of the 1023 CPAP-treated 
patients were obese (BMI >30 kg/m2). Those aged ≤40 years (N=59) had a 
significantly higher BMI than older patients (37 ± 9 vs. 33 ± 6 kg/m2, p <0.001). A 
positive correlation between AHI and BMI was also shown (R2 = 0.24, p <0.001). 
The mean change in BMI during CPAP treatment was 0.06 ± 0.4 kg/m2 per year 
over a mean follow-up of 7 years at the cohort level. At the individual level, 84 % of 
the patients showed no significant change, whereas 10 % had a significant increase 
(an average of 0.6 ± 0.4 kg/m2 per year) and 6 % a significant decrease (an average 
of 0.5 ± 0.4 kg/m2 per year) in BMI during treatment (Figures 18–19). Differences 
were observed between the patients with a significant increase in BMI and the rest 
of the cohort (Table 20). 
In the multivariate logistic regression analysis, male gender, current smoking, a 
higher BMI, younger age and a higher GHQ-12 score at baseline in addition to an 
ascending GHQ-12 slope were associated with a significant increase in BMI during 
CPAP treatment. The odds of having a significant decrease in BMI was decreased 
by an ascending CPAP adherence slope, while no other associations were observed 
(Table 21).  
5.6 The association between CPAP treatment and 
daytime sleepiness and psychological distress 
(study II) 
The majority of the 1023 CPAP-treated patients were non-sleepy, since EDS (ESS 
≥11) was reported only by 37 % of the patients. The mean ESS and GHQ-12 scores 
were 9 ± 5 and 3 ± 4, respectively. Women had a higher GHQ-12 score compared to 
men, but no gender difference was observed in ESS score at baseline (Table 5). 
Correlation between AHI and ESS (R2 = 0.05, p=0.1) or GHQ-12 (R2 = −0.04, p=0.3) 
score was not observed, whereas BMI correlated weakly with ESS (R2 = 0.11, 
p=0.001) and GHQ-12 (R2 = 0.09, p=0.007) scores.  
After a mean follow-up of 7 years, the mean ESS and GHQ-12 slopes of the 
cohort were both slightly descending (ESS slope −0.6 ± 0.7 and GHQ-12 slope −0.2 
± 0.6 change of score/year), suggesting that daytime sleepiness and psychological 
distress tended to reduce during CPAP treatment for the majority of the patients. 
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Figure 18.  Mean annual change in body mass index (BMI) over a mean CPAP treatment period of 
7 years at the individual level (N=1023). Modified with permission from original 
publication II. 
 
Figure 19.  Individual body mass index (BMI) development during CPAP treatment in relation to the 
BMI at the beginning of treatment. Reprinted with permission from original publication 
II. 
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Table 20.  Comparison of the baseline characteristics between the patients with a significant 
increase in body mass index (BMI) and the rest of the cohort. 
 Significant increase in 
BMI* (N=103) 
The rest of the cohort 
(N=920) 
P 
Patient characteristics    
    Age, years (mean, SD) 50.9 ± 9.5 56.1 ± 9.7 <0.001 
    Male gender (N, %) 89 (86.4) 686 (74.6) 0.008 
    BMI, kg/m2 (mean, SD) 40.0 ± 5.9 32.8 ± 6.0 <0.001 
OSA and questionnaires    
    AHI, events/h (mean, SD) 38.8 ± 26.3 33.1 ± 22.7 0.02 
    ESS score (mean, SD) 10.0 ± 4.3 9.3 ± 4.7 0.2 
    GHQ-12 score (mean, SD) 4.1 ± 4.0 3.2 ± 3.5 0.04 
Comorbidity and lifestyle    
    IFG/ T2D (N, %) 57 (55.3) 355 (38.6) 0.001 
    Hypertension† (N, %) 89 (86.4) 694 (75.4) 0.01 
    CVD‡ (N, %) 9 (8.7) 46 (5.0) 0.1 
    Asthma (N, %) 7 (6.8) 93 (10.1) 0.3 
    COPD (N, %) 3 (2.9) 43 (4.7) 0.4 
    Psychiatric disorder§ (N, %) 21 (20.4) 140 (15.2) 0.2 
    Current smoking (N, %) 35 (34.0) 189 (20.5) 0.002 
 
Data are presented as N (%) or mean ± standard deviation (SD). AHI, apnea-hypopnea index; BMI, 
body mass index; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway 
pressure; CVD, cardiovascular disease; ESS, Epworth Sleepiness Scale (N=977); GHQ-12, 
General Health Questionnaire (N=908); IFG, impaired fasting glucose; T2D, type 2 diabetes.  
 
* Patients with an ascending trend in BMI over a mean CPAP treatment period of 7 years at the 
posterior probability level of >90%.  
† Blood pressure greater than 140/90 mmHg and/ or use of antihypertensive medication. 
‡ Coronary artery disease, myocardial infarction, angina pectoris, stroke, intracranial atherosclerosis 
or peripheral artery disease. 
§ Depression, anxiety or psychotic disorder. 
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Table 21.  Associations between the clinical characteristics and significant change in BMI during 
CPAP treatment determined by the multivariate logistic regression analysis. Modified 
with permission from original publication II. 
 
 
Significant increase in BMI*  Significant decrease in BMI*  
OR (CI 95 %) P OR (CI 95 %) P 
Patient characteristics     
    Age, years 0.96 (0.9–1.0) 0.01 1.03 (1.0–1.1) 0.1 
    Male gender 5.13 (2.2–11.8) <0.001 2.12 (0.9–5.0) 0.09 
    BMI, kg/m2  1.18 (1.1–1.2) <0.001 0.97 (0.9–1.0) 0.3 
OSA and questionnaires     
    AHI, events/h  1.00 (1.0–1.0) 0.5 1.01 (1.0–1.0) 0.4 
    ESS score  1.02 (1.0–1.1) 0.6 0.91 (0.8–1.0) 0.05 
    GHQ-12 score  1.10 (1.0–1.2) 0.03 1.11 (1.0–1.2) 0.09 
Comorbidity and lifestyle     
    IFG/ T2D 0.98 (0.6–1.7) 0.9 0.69 (0.3–1.4) 0.3 
    Hypertension† 1.48 (0.7–3.0) 0.3 0.71 (0.3–1.4) 0.3 
    CVD‡ 1.98 (0.8–5.1) 0.2 2.14 (0.7–6.9) 0.2 
    Psychiatric disorder§ 0.85 (0.4–1.7) 0.7 0.36 (0.1–1.3) 0.1 
    Current smoking 1.80 (1.0–3.1) 0.04 1.62 (0.8–3.4) 0.2 
Follow-up characteristics     
    CPAP adherence slope|| 2.12 (0.5–8.3) 0.3 0.03 (0.0–0.1) <0.001 
    ESS slope|| 1.47 (0.9–2.3) 0.1 0.69 (0.4–1.2) 0.2 
    GHQ-12 slope|| 1.76 (1.1–2.8) 0.02 1.12 (0.6–2.2) 0.8 
 
Data are presented as odds ratios (ORs) and 95 % confidence intervals (95 % CIs). Abbreviations 
are presented in Table 20. 
 
* Patients with an ascending (significant increase) or a descending (significant decrease) trend in 
BMI over a mean CPAP treatment period of 7 years at the posterior probability level of >90 %. 
†, ‡, § Definitions are provided in Table 20. 
|| Annual change in CPAP adherence, ESS (N=948) or GHQ-12 score (N=948) over a mean CPAP 
treatment period of 7 years. 
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5.7 The association between CPAP treatment and 
MVAs (study III) 
5.7.1 CPAP-treated patients before and after the initiation  
of CPAP treatment 
Of the 1030 CPAP-treated patients, MVAs were registered in 30 patients before and 
39 patients after CPAP. The observation period in both was 9 years on average. Of 
the latter, 3 MVAs occurred after a several months’ break from CPAP and were thus 
excluded from the analyses. Two patients had multiple accidents. The incidence of 
MVAs per 1000 person years was 3.2 (95 % CI 2.3–4.6) before and 3.9 (95 % CI 
2.8–5.3) after CPAP (Figure 20). Risk for having an MVA did not differ between 
the after and before treatment groups (RR 1.2, 95 % CI 0.7–1.9, p=0.5).  
CPAP usage did not differ between those who had or did not have an MVA 
(median 6.4, IQR 2.2 vs. 6.4, IQR 2.3 h/day, p=0.8). Furthermore, the MVA 
incidence did not differ when patients with CPAP use of ≥4 h/day were compared 
before-after (Figure 20) or to those with lower usage. Patients with CPAP use of ≥6 
h/day similarly did not differ from those who had used it for <6 h/day (Figure 21). 
Of the 36 CPAP-treated patients with MVA after CPAP in study III, 14 % had a 
significant increase, 11 % a significant decrease, while 75 % had no significant 
change in adherence over a mean follow-up of 7 years in study II. A significant 
increase and decrease in BMI were similarly observed in 28 % and <9 % of the 
patients, respectively, while the majority had no significant change. The ESS (-0.5 ± 
0.5 vs. -0.6 ± 0.7 score/ year, p=0.5) or the GHQ-12 (-0.1 ± 0.5 vs. -0.2 ± 0.6, p=0.5) 
slopes over a mean follow-up of 7 years in study II did not differ between those who 
had or did not have an MVA. Overall, a mean increase of 1.2 ± 3.7 kg/m2-units in 
BMI and a mean decrease of 3.7 ± 3.6 scores in ESS were found in the CPAP-treated 
patients with MVA during the median treatment period of 9 years in study III. 
5.7.2 CPAP-treated patients after the initiation of CPAP   
and control patients 
MVAs were registered in 17 of the 1030 controls, and the MVA incidence per 1000 
person years was 2.6 (95 % CI 1.6–4.1). None of them had multiple accidents. The 
risk for having an MVA did not differ from CPAP-treated patients when all CPAP-
treated patients (RR 1.5, 95 % CI 0.9–2.7, p=0.2) or only those with CPAP use of ≥4 
h/day were compared to controls (Figure 20). The results did not change when all 
CPAP-treated patients (RR 1.8, 95 % CI 1.0–3.5, p=0.06) or those with CPAP use 
of ≥4 h/day (RR 1.8, 95 % CI 1.0–3.5, p=0.07) were compared to controls who had 
not used MAD after CPAP (N=965, incidence of MVAs 2.1, 95 % CI 1.2–3.6).  
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Figure 20.  Incidence of motor vehicle accidents (MVAs) per 1000 person years 9 years before and 
after CPAP in 1) all CPAP-treated patients, in those with 1a) CPAP use of ≥4 h/day or 
1b) <4 h/day, and in 2) controls 6.5 years before and after the discontinuation of CPAP. 
Modified with permission from original publication III. 
 
Figure 21.  Incidence of motor vehicle accidents (MVAs) per 1000 person years 9 years after CPAP 
treatment according to the level of CPAP use. Modified with permission from original 
publication III. 
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Compared to the rest of the cohort, the CPAP-treated patients and controls with 
MVA (N=53) were more frequently men, younger and had a higher prevalence of 
smokers. No differences were observed in terms of baseline ESS or GHQ-12 score 
or other comorbidities (Table 22). Male gender was associated with a 5.5-fold (95 
% CI 1.7–17.6, p=0.004) and current smoking with a 2.4-fold (1.4–4.1, p=0.002) 
increased risk for MVAs in an unadjusted Cox regression model, whereas a 1-year 
elevation in age reduced the risk by 4 % (HR 0.96, 95 % CI 0.9–1.0, p=0.001).  
An AHI of ≥15 /h was not associated with an increased risk of MVAs compared 
to <15 /h when all patients (HR 1.4, 95 % CI 0.7–2.8, p=0.3) or only controls (HR 
2.5, 95 % CI 0.6–11.0, p=0.2) were analyzed. However, HR tended to increase with 
increasing AHI among controls, since HRs were 3.0 (95 % CI 0.6–14.2) and 2.1 (95 
% CI 0.4–10.2) for those with an AHI of ≥30 /h or ≥15 but <30 /h, respectively, 
when compared to a lower AHI of <15 /h (p ≥0.05). 
Among patients with MVA, the only baseline difference was higher BMI in 
CPAP-treated patients than controls (median 34 vs. 31 kg/m2, p=0.03). Interestingly, 
a BMI of ≥30 kg/m2 was associated with an increased risk for MVAs only among 
the CPAP-treated patients (HR 2.45, 95 % CI 1.0–5.9, p=0.045) but not among 
controls. The association remained significant after the Cox regression model was 
adjusted for age, gender, smoking and an AHI of ≥15 /h (HR 2.43, 95 % CI 1.0–5.9, 
p=0.049). The prevalence of CVD and the number of professional drivers were low 
and did not differ between the groups. No differences were observed in sleep study 
data (Table 22) or accident conditions, including the hour of the accident (Table 
23).  
Time to the first MVA was almost three times longer among CPAP-treated 
patients than among controls (median 43 vs. 15 months, p=0.02). A further analysis 
revealed that the MVA incidence did not, however, significantly differ between the 
groups when the length of observation was reduced in both groups to 2 (MVAs N=11 
vs. N=12, p=0.8, respectively), 3.5 (MVAs N=21 vs. N=12, p=0.1, respectively), or 
5 (MVAs N=26 vs. N=14, p=0.06, respectively) years. 
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Table 22.  Comparison of the baseline characteristics between the CPAP-treated patients and 
controls with a motor vehicle accident (MVA), and between the patients with and without 
an MVA. Modified with permission from original publication III. 
 
 
 
CPAP vs. Controls MVA vs. without MVA 
MVA 
CPAP  
(N=36)     
MVA 
Controls 
(N=17) 
P MVA    
Total 
(N=53) 
Without 
MVA 
(N=2007) 
P 
Patient characteristics       
   Male gender, % 91.7 100.0 0.2 94.3 75.3 <0.001 
   Age, years (mean, SD) 51.5 ± 10.1 49.6 ± 12.3 0.6 50.9 ± 10.8 56.1 ± 10.4 <0.001 
   BMI, kg/m2 (median, IQR) 34.2 (6.7) ‡ 31.3 (7.5) 0.03 33.2 (7.6) 32.0 (8.1) ‡ 0.3 
OSA & questionnaires       
   AHI, events/h (median,  
   IQR) 
28.0 (28.5) 25.0 (38.0) 0.9 27.0 (28.5) 28.0 (30.0) 0.4 
   ODI4/5, /h (median, IQR) 14.6 (25.4) 21.1 (26.8) 0.8 15.1 (24.1) – – 
   SpO2, % (median, IQR) 
       Mean 
       Minimum 
       T90 
 
93.5 (2.8) 
82.0 (10.3) 
5.5 (15.2) 
 
93.3 (3.1) 
78.0 (11.0) 
8.5 (31.4) 
 
0.7 
0.4 
0.6 
 
93.4 (3.0) 
81.3 (11.0) 
6.2 (24.4) 
 
– 
– 
– 
 
– 
– 
– 
   ESS  
       Mean score (SD) 
       ≥16 scores, % 
 
8.8 ± 3.9 
5.6 
 
6.4 ± 4.8 
6.3 
 
0.06 
0.9 
 
8.1 ± 4.3 
5.8 
 
8.8 ± 4.7 
10.1 
 
0.2 
0.3 
   GHQ-12 (median, IQR) 1.0 (6.0) 1.0 (4.0) 0.4 1.0 (6.0) 2.0 (6.0) 0.2 
Comorbidity & lifestyle       
   IFG/ T2D, % 41.7 29.4 0.4 37.7 37.8 1.0 
   Hypertension/CVD*, % 61.1 70.6 0.5 64.2 73.6 0.1 
   Psychiatric disorder†, % 22.2 17.6 0.7 20.8 16.9 0.5 
   Current smoking, % 41.7 47.1 0.7 43.4 24.9 0.002 
 
Data are presented as % or mean ± standard deviation (SD) or median and interquartile range 
(IQR). AHI, apnea-hypopnea index; BMI, body mass index; CPAP, continuous positive airway 
pressure; ESS, Epworth Sleepiness Scale (N=1967); GHQ-12, General Health Questionnaire 
(N=1859); IFG, impaired fasting glucose; ODI4/5, oxygen desaturation index of ≥4 or ≥5 % (N=50); 
OSA, obstructive sleep apnea; SpO2, level of blood oxygen saturation [mean (N=49), minimum 
(N=49), T90 (N=38)]; T2D, type 2 diabetes; T90, percentage of time spent under SpO2 of 90 %. 
 
* Blood pressure greater than 140/90 mmHg and/ or use of antihypertensive medication or coronary 
artery disease, myocardial infarction, angina pectoris, stroke, intracranial atherosclerosis or 
peripheral artery disease. 
† Depression, anxiety or psychotic disorder. 
‡ BMI of the CPAP-treated patients with MVA compared to that among those without MVA, p=0.04. 
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Table 23.  Comparison of the characteristics of motor vehicle accidents between the CPAP-treated 
patients and controls. Reprinted with permission from original publication III. 
 MVA CPAP    
(N=36) 
MVA controls            
(N=17) 
P                    
Time to the accident, months* (median, IQR) 42.5 (48.5) 15.0 (41.5) 0.02 
Time of day, hour, %    
    8:00 p.m.–7:59 a.m. 22.2 29.4 0.6§ 
    8:00 a.m.–7:59 p.m. 77.8 70.6  
Autumn/ winter, % 50.0 47.1 0.8 
Weather/ road surface condition worsen†, % 44.4 29.4 0.3 
Speed limit ≥60 km/h, % 41.7 47.1 0.7 
Outside urban area, % 44.4 41.2 0.8 
Junction or traffic lights, % 41.7 58.8 0.2 
Alcohol/ drug/ medicine use, % 11.1 17.6 0.5 
DL CDE, % 62.9 66.7 0.8 
Vehicle type‡, %    
    Car, moped or motorcycle 83.3 82.4 0.9§ 
    Heavy vehicle 16.7 17.6  
Injured, % 38.9 41.2 0.9 
 
Data are presented as % or median and interquartile range (IQR). CPAP, continuous positive airway 
pressure; DL, driver’s license (data missing for 1 CPAP-treated and 5 control patients); MVA, motor 
vehicle accident. 
 
* Time from study baseline to the occurrence of motor vehicle accident. 
† The presence of fog, rain or snow or road surface bare and wet, snowy or icy. 
‡ Car including passenger car, van, truck ≤3500 kg; heavy vehicle including truck >3500 kg, bus. 
§ P value for the trend. 
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5.8 Patients with a normal apnea-hypopnea index 
treated with CPAP (studies I–III) 
Of the 1023 CPAP-treated patients in study II, 47 patients with an AHI of <5 /h 
fulfilled the study’s inclusion criteria, and were thus, included in the statistical 
analyses. Later during the data collection of the studies I and III, among 3 of these 
patients the previously observed normal AHI was discovered to be measured during 
CPAP treatment. Thus, the corrected number of patients with an AHI of <5 /h was 
44 out of the 1023 patients (4 %). On this account, the difference in IFG/ T2D 
prevalence became significant when patients with an AHI of <5 /h and the rest of the 
cohort were compared. 
Like the rest of the cohort, patients with an AHI of <5 /h were highly adherent 
to CPAP, since they did not differ in terms of short- or long-term use of CPAP or the 
mean CPAP usage slope. Differences in the mean BMI, ESS or GHQ-12 slopes were 
also not observed between the groups. However, they were more often women and 
had a higher prevalence of psychiatric disorders, while the prevalence of IFG/ T2D 
and hypertension were lower compared to the rest of the cohort. The prevalence of 
CVDs was low and did not differ (Table 24). 
Of all the CPAP-treated patients and controls with an AHI of <5 /h (N=86), a 
composite CVD event was observed in 11 of the patients (12.8 %). Of these patients, 
7 had been treated with CPAP and 4 were controls. In the adjusted Cox regression 
model, the risk of a composite CVD event (HR 0.97, 95 % CI 0.4–2.7, p=1.0), CVD 
death (HR 0.60, 95 % CI 0.08–4.4, p=0.6) or all-cause mortality (HR 0.68, 95 % CI 
0.2–2.2, p=0.5) did not differ between the controls with an AHI of <5 /h (N=42) and 
the rest of the controls with a higher AHI. The incidence of MVAs among all the 
patients with an AHI of <5 /h was low (≤3.5 % of the patients). 
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Table 24.  Comparison of the characteristics between the CPAP-treated patients with an apnea-
hypopnea index (AHI) of <5 /h and the rest of the cohort. 
 AHI <5 /h              
(N=44) 
The rest of the 
cohort (N=979) 
P 
Patient characteristics (N, % or mean, SD)    
    Female gender 18 (40.9) 230 (23.5) 0.008 
    Age, years 53.5 ± 9.1 55.7 ± 9.8 0.1 
    BMI, kg/m2 31.9 ± 5.3 33.6 ± 6.4 0.09 
Questionnaires (mean, SD)    
    ESS score 9.5 ± 5.1 9.4 ± 4.7 0.9 
    GHQ-12 score 3.1 ± 3.1 3.3 ± 3.6 0.7 
Comorbidity and lifestyle (N, %)    
    Impaired fasting glucose/ type 2 diabetes 10 (22.7) 402 (41.1) 0.02 
    Hypertension*  27 (61.4) 756 (77.2) 0.02 
    Asthma  7 (15.9) 93 (9.5) 0.2 
    Chronic obstructive pulmonary disease 3 (6.8) 43 (4.4) 0.4 
    Psychiatric disorder†  16 (36.4) 145 (14.8) <0.001 
    Current smoking  8 (18.2) 216 (22.1) 0.5 
Follow-up characteristics (mean, SD)    
    Short-term use, h/day‡  5.3 ± 1.8 5.2 ± 2.80 0.8 
    Long-term use, h/day §  6.2 ± 1.8 6.0 ± 1.8 0.5 
    Usage slope, (h/day)/year||  0.2 ± 0.2 0.2 ± 0.2 0.8 
    BMI slope, (kg/m2)/year||  0.1 ± 0.3 0.1 ± 0.4 0.2 
    ESS slope, score/year||  -0.5 ± 0.7 -0.6 ± 0.7 0.3 
    GHQ-12 slope, score/year||  0.0 ± 0.6 -0.2 ± 0.6 0.1 
Data are presented as N (%) or mean ± standard deviation (SD). BMI, body mass index; CPAP, 
continuous positive airway pressure; ESS, Epworth Sleepiness Scale (data available for 977 
patients); GHQ-12, General Health Questionnaire (data available for 908 patients). 
 
* Blood pressure greater than 140/90 mmHg and/ or use of antihypertensive medication. 
† Depression, anxiety or psychotic disorder. 
‡ Mean CPAP usage from the commencement of CPAP either until the first follow-up visit or 
alternatively until the 6-month follow-up visit (including missed days of use) (N=1017). 
§ Mean CPAP usage over a mean treatment period of 7 years (including missed days of use). 
|| Annual change in CPAP adherence, BMI, ESS (N=948) or GHQ-12 score (N=948) over a mean 
treatment period of 7 years. 
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6 DISCUSSION 
The main finding of this thesis was that CPAP adherence had a major impact on 
CVD outcome, since only those who had used CPAP for >6 h/day had a reduced risk 
of CVD death, a composite of cardiac events and all-cause mortality compared to 
controls independent of confounding factors. No association was found between 
AHI and the risk of CVD events or MVAs, implying that different OSA phenotypes 
may be related to different outcomes, and the effectiveness of CPAP may also differ 
between these phenotypes. Thus, the question may not only be whether CPAP is 
beneficial in reducing CVD risk, other comorbidities or MVAs in OSAS, but also 
which populations are likely to benefit the most from CPAP and at what level of 
compliance this may be achieved. Furthermore, patients with an AHI of <15 /h were 
shown to adhere to CPAP similar to those who had a higher AHI, suggesting that the 
evaluation of the need for treatment should not be merely based on AHI. Finally, this 
thesis further emphasized the importance of lifestyle interventions, since 10 % of the 
patients gained significantly weight during CPAP treatment. 
This thesis is based on real-world, retrospective observational studies, since all 
patients who had sufficient data on the assessment of OSAS and follow-up were 
included without further selection. Its results may be extrapolated to the clinic-based 
population but with caution to the general population. The methods used and the 
statistical aspects, in addition to the results obtained, are discussed in detail next. 
6.1 Methodology 
6.1.1 Subject selection and characteristics of the included 
patients 
All the CPAP-treated subjects included in the study had initiated CPAP treatment 
for OSAS at the Department of Pulmonary Diseases at the Turku University Hospital 
during 2002–2006. The only inclusion criteria were long-term use of CPAP (≥5 
years) in addition to adequate data on sleep studies and follow-up (≥4 follow-up 
visits). Study II further excluded from the analyses those who had engaged in 
bariatric surgery during treatment to more reliably investigate the associations 
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between CPAP and weight changes. Studies I and III selected controls from the same 
group as the CPAP-treated patients in order to minimize the selection bias. All 
included controls had adequate data on sleep studies, and they had discontinued 
CPAP treatment within 5 years (median 4 months) despite their doctor’s advice.  
CPAP-treated patients and their controls were matched according to age, gender 
and AHI, but however, the CPAP-treated patients did have a higher BMI in addition 
to a higher prevalence of IFG/ T2D and hypertension at baseline, while CVD, COPD 
and smoking were more common among controls. 
6.1.2 Diagnosis of OSAS 
All the 2060 included patients had OSA-related symptoms (e.g. daytime sleepiness, 
witnessed apnea) and were referred to an ambulatory or an in-hospital 
cardiorespiratory polygraphy to verify their OSAS. CPAP treatment was generally 
recommended for patients who had an AHI of ≥15 /h. Among those with a lower 
AHI, the need for treatment was assessed individually based on the patients’ 
symptoms and clinical findings strongly suggestive for OSAS. The initiation of 
CPAP in the region was centralized in the Department of Pulmonary Diseases, which 
likely reduced the selection bias of the patients. 
6.1.3 Study design, data collection and statistical aspects 
Careful manual examination of the electronic medical records enabled gathering of 
data on basic patient characteristics, sleep studies, self-administered questionnaires, 
comorbidities and other CVD risk factors both at baseline and follow-up visits. The 
data on adherence and treatment pressure were accurate and objective, since they 
were measured by an inbuilt-counter clock of the CPAP device. Mean long-term 
adherence to CPAP reported the mean CPAP usage over the entire treatment period 
(including missed days of use). Finland’s national registries on all-cause death and 
the incidence of police-reported MVAs enabled the gathering of objective data on 
these outcomes. 
The prevalence of patients engaging in bariatric surgery during study follow-up 
did not differ between the CPAP-treated patients and controls. Only a minority of 
controls had been treated with MAD after CPAP, and there were no reassurances 
regarding whether they had been compliant or continued the treatment. The 
exclusion of these controls did not change the results on the associations between 
CPAP and CVD or MVA incidence in the Cox regression or Poisson regression 
models, and thus, they were included in the final analyses. Furthermore, the follow-
up durations of controls were modified in those Cox regression models, which 
included death as an endpoint or as a composite of an endpoint, since none of the 
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CPAP-treated patients could have died during the first 5 years due to the inclusion 
criteria of long-term CPAP treatment for the study. Time to death was used in the 
analyses of CPAP-treated patients with death as an endpoint. It was assumed that 
they had continued CPAP until death, since a follow-up visit cannot occur 
afterwards. Among those CPAP-treated patients who did not have death as an 
endpoint, follow-up ended with the last CPAP follow-up visit. 
Individual slope values of both BMI and CPAP adherence were determined for 
each CPAP-treated patient based on the linear mixed model. The Bayesian 
Hierarchical model and the Monte Carlo simulation were used to account for model 
uncertainty and to minimize the effect of within-patient variation. Patients with a 
significant constant change were identified at the posterior probability level of 
>90 %. A multivariate logistic regression was further used to identify clinical 
variables that could potentially explicate differences between the patients.  
6.2 Beyond the apnea-hypopnea index 
CPAP treatment has been generally recommended for patients with an AHI of ≥15 
/h and for milder OSA in the presence of OSA-related symptoms or comorbidities 
(Chowdhuri et al. 2016, Gay et al. 2006, Loube et al. 1999). This thesis found that 
approximately one quarter of the CPAP-treated patients had an AHI of <15 /h. 
Patients with an AHI of <5 /h were also highly adherent to CPAP similar to those 
who had a higher AHI. They were more frequently women and had a higher 
prevalence of psychiatric disorders, while IFG/ T2D and hypertension were more 
common among the rest of the cohort. The ESS scores decreased similarly in both 
groups during treatment. Furthermore, no differences were observed in the risk of a 
composite CVD event when untreated patients with an AHI of <15 /h, or <5 /h were 
compared to those with a higher AHI, although among the latter the statistical power 
may not have been sufficient to detect a significant difference due to a small sample 
size. Those with an AHI of ≥15 /h did have an independent higher risk of all-cause 
mortality, while the risk for MVAs did not differ. 
The results of this thesis imply that the use of AHI alone is not a good predictor 
in the assessment of adherence to CPAP or the risk for CVD events, weight changes 
or MVAs. However, it should be acknowledged that AHI was determined by 
cardiorespiratory polygraphy, which has been shown to underestimate the AHI by 
approximately 20 to 30 % compared to PSG since an EEG is not included (Escourrou 
et al. 2015, Hedner et al. 2011). All studied patients were examined with the same 
approach, which should minimize the bias related to the AHI assessment. Night-to-
night variability may also lead to false negative results in a sleep study (Skiba et al. 
2015), and especially females with an AHI of <5 /h may have had prolonged episodes 
of partial upper airway obstruction, which could partly explain the good CPAP 
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adherence in this patient group (Anttalainen et al. 2016b). Furthermore, an OSAS 
diagnosis was not usually repeated during follow-up; thus, an OSAS resolution or 
progression in some patients over time cannot be excluded. 
More recent studies have focused on identifying different OSA phenotypes based 
on the complex pathophysiology, diverse symptoms, OSA-related comorbidities and 
polysomnographic findings instead of classifying patients merely according to AHI 
(Zinchuk & Yaggi 2020). Hypothesis-driven (traditional regression analyses) and 
hypothesis-generating (cluster analyses, such as K-means analyses) methods have 
been used to identify different OSA phenotypes (Zinchuk & Yaggi 2020). The 
PALM scale was developed to assess at which extent anatomical (defined as Pcrit) 
and non-anatomical (including arousal threshold, loop gain and muscle 
responsiveness) factors affect OSA development. PALM scale 1 consists of patients 
with severe (Pcrit > +2 cmH2O), PALM scale 2 of those with moderate (Pcrit between 
-2 and +2 cmH2O) and PALM scale 3 of those with minor (Pcrit < -2 cmH2O) 
anatomical impairment. Patients in PALM scale 2 are further categorized into two 
subgroups based on whether they have impairments in non-anatomical factors 
(PALM scale 2b), or not (PALM scale 2a). Approximately 70 % of OSA patients are 
likely to have an impairment in ≥1 of the non-anatomical factors (Eckert et al. 2013). 
The Icelandic Sleep Apnoea Cohort study of 822 patients with an AHI of ≥15 /h 
identified three symptom-based OSA clusters, of which EDS (primarily sleepiness, 
mean ESS 16) was the most common (42 %), followed by disturbed sleep (primarily 
insomnia symptoms, mean ESS 10; 33 %) and minimally symptomatic patients (less 
sleepiness or disturbed sleep, mean ESS 8; 25 %). The highest prevalence of 
hypertension and CVD was found among minimally symptomatic patients and the 
lowest among those with EDS, which could be partly explained by a delayed OSA 
diagnosis in the former group (Ye et al. 2014). Another study of 757 patients with 
an AHI of ≥15 /h suggested that these three symptom-based clusters may be 
accompanied by two additional clusters: EDS (mean ESS 12–16) with (22 %) or 
without (20 %) upper airway symptoms, disturbed sleep (mean ESS 8; 19 %), 
minimal symptoms (mean ESS 5; 20 %) and upper airway symptoms dominant OSA 
(mean ESS 8; 19 %). The highest prevalence of hypertension and CVD was observed 
among disturbed sleep (Keenan et al. 2018), possibly partly due to insomnia-related 
short sleep duration (Anttalainen et al. 2019). Those with upper airway symptoms 
dominant OSA were more likely younger, less obese and males. AHI and ODI were 
>40 /h in all groups. Thus, patients with the same AHI may have different symptoms, 
emphasizing the need for other tools to recognize heterogeneity (Keenan et al. 2018). 
The European Sleep Apnea Database study of patients with an AHI of ≥5 /h also 
showed that patients with insomnia-like symptoms (mean ESS 6) had the highest 
CVD prevalence, which was independently associated with a lower nadir SpO2. 
Those with EDS (mean ESS 15) had the lowest CVD prevalence, even though they 
Minna Myllylä 
 122
had a higher AHI (Anttalainen et al. 2019, Saaresranta et al. 2016). Conversely, the 
Sleep Heart Health Study of 1207 patients with an AHI of ≥15 /h identified four 
clusters, of which only the EDS group (mean ESS 14) had an adjusted 2-fold 
increased risk of incident CVD compared to subjects without OSA, while those with 
disturbed sleep (mean ESS 7) had a reduced risk of stroke compared to other clusters 
(Mazzotti et al. 2019). This thesis did not find an association between the baseline 
ESS score and the CVD risk, but the mean ESS was <10. However, ESS alone may 
be insufficient to identify the EDS phenotype (Mazzotti et al. 2019). 
Four polysomnographic-based, partly overlapping phenotypes were identified in 
a study of 1184 patients with an AHI of 5– 30 /h. These included rapid eye movement 
(REM) predominant OSA (45 %), non-rapid eye movement (NREM) predominant 
OSA (19 %), supine predominant OSA (62 %) and intermittent OSA, which was 
characterized by scattered respiratory events throughout the night (12 %) (Joosten et 
al. 2012). Particularly REM-predominant OSA has been associated with an increased 
CVD risk due to more frequent obstructive events, longer apneas and greater 
desaturations compared to NREM sleep. Sympathetic tone increases during REM 
sleep, while both respiratory drive and muscle tone decrease, which predispose the 
upper airway to collapse (Findley et al. 1985, Varga & Mokhlesi 2019). REM-
predominant OSA has usually been defined as a ratio of REM AHI/ NREM AHI of 
>2 with a REM sleep duration of ≥30 minutes. The definition’s reliability may be 
improved by additional criteria, including a total AHI of ≥5 /h and a NREM AHI of 
≤15 /h. Based on these criteria, its prevalence has been 10–20 %, being more 
common among women than men (Varga & Mokhlesi 2019).  
The Wisconsin Sleep Cohort Study reported that REM-predominant OSA was 
independently associated with prevalent and incident hypertension (Mokhlesi et al. 
2014), and a smaller study of 837 males similarly showed that the risk was over 2-
fold higher among those with an AHI of ≥30 /h of REM sleep (Appleton et al. 2016). 
Neither of the studies observed significant associations between hypertension and 
non-REM AHI (Appleton et al. 2016, Mokhlesi et al. 2014). However, a study of 
1247 veterans identified seven polysomnographic-based clusters, of which the 
cluster of REM and hypoxia was not associated with the risk of incident CVD events 
or hypertension. Interestingly, the clusters of PLMS, hypopnea and hypoxia 
(primarily hypopneas with desaturations) and combined severe (combined apneas, 
hypopneas and desaturations) all had approximately a 2-fold increased risk of CVD 
events when compared to a cluster of mild polysomnographic findings. AHI was in 
the range of 10–84 /h in these three groups. Conventionally measured, an AHI of 
<15 /h did not differ in terms of CVD risk from a higher AHI (Zinchuk et al. 2018).  
Based on the clinical and polysomnographic patient characteristics published in 
previous studies, a recent review identified six potential OSA phenotypes, which 
Table 25 summarizes (Zinchuk & Yaggi 2020). Overall, it has been suggested that 
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OSA’s severity should be based on several components instead of AHI alone. One 
grading system suggested that patients with an AHI of ≥15 /h may be categorized 
according to the level of symptoms (ESS ≥9 or less, dozing episodes, hypersomnia, 
insomnia, vigilance test) and the presence of comorbidities. Those with severe 
symptoms in addition to recurrent or poorly controlled comorbidities are defined as 
having the most severe form of OSA (Randerath et al. 2018).   
Furthermore, this thesis showed that male gender, younger age and current 
smoking were associated with an increased risk of MVAs, consistent with previous 
studies (Karimi et al. 2015, Sacks et al. 1994, Tregear et al. 2009). Smoking has been 
suggested to increase the MVA risk due to smoking-related diseases, distractibility, 
and smokers’ susceptibility to risky behavior (Sacks et al. 1994). Among patients 
with MVA, the only baseline characteristic that differed between the CPAP-treated 
patients and controls was baseline BMI, which was higher among the former. 
Interestingly, a BMI of ≥30 kg/m2 increased the likelihood of an MVA only among 
CPAP-treated patients. Most of the CPAP-treated patients with MVA tended to gain 
more weight during treatment. Previous studies have also found an association 
between a higher BMI and an increased MVA risk (Tregear et al. 2009). Adipocytes 
have been shown to secrete cytokines, which may increase daytime sleepiness and 
predispose to MVAs (Vgontzas et al. 2006). However, no association was found 
between the baseline ESS of ≥16 scores and the MVA incidence, although it has 
been previously identified as a risk factor for MVAs (Tregear et al. 2009). ESS also 
tended to decrease after CPAP in most patients regardless of having an MVA or not. 
Overall, a recent review of OSA phenotypes suggested that those who are younger, 
obese and male with symptoms of sleepiness, fatigue and involuntary sleep may be 
at the highest risk for drowsy driving and MVAs (Zinchuk & Yaggi 2020).  
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Table 25.  Potential phenotypes of obstructive sleep apnea (OSA) based on cluster analyses of 
clinical and polysomnographic patient characteristics. Modified from the American 
College of Chest Physicians (Zinchuk & Yaggi 2020) with permission from Elsevier.   
 
 
 
 
Potential phenotypes of OSA 
A 
“Classic” 
B 
“Oldest, 
comorbid” 
C 
“Female, 
insomnia” 
D 
“Youngest, 
upper 
airway 
symptoms” 
E 
“Severe, 
hypoxemic” 
F 
“Severe, 
non-
hypoxemic” 
Age Younger Oldest Middle-
aged 
Youngest Younger Older 
Gender Male Male Female Male Male Male 
BMI Obese Obese Overweight/ 
obese 
Not obese Severely 
obese 
Obese 
Symptoms Sleepy, 
fatigue, 
involuntary 
sleep 
Need for 
naps, 
snoring 
Difficulty to 
fall asleep, 
early 
awakening, 
sleep not 
refreshing 
Snoring, 
sudden 
awakening, 
less sleepy 
(low ESS), 
+/- insomnia  
Sleepy Less sleepy 
Comorbidities Low Highest Medium Lowest – – 
Sleep studies 
  AHI 
  T90 % 
  Apnea length 
  SpO2 nadir 
 
High 
Medium 
– 
– 
 
High 
High 
– 
– 
 
Medium 
Medium 
– 
– 
 
High 
Low 
– 
– 
 
High 
High 
Medium 
Low 
 
High 
Low 
Low 
High 
Consequences Drowsy 
driving,  
↑ CVD risk?  
Inadequate 
adherence 
to CPAP, 
no incident 
CVD risk 
(but high 
prevalent 
risk)  
Inadequate 
adherence 
to CPAP, 
↓ incident 
stroke risk? 
Inadequate 
adherence 
to CPAP, 
CVD risk 
unknown 
↑ incident 
CVD risk 
Inadequate 
adherence 
to CPAP, 
cognitive 
dysfunction? 
Effectiveness 
of CPAP 
Highest Least Medium Medium – – 
AHI, apnea-hypopnea index; BMI, body mass index; CPAP, continuous positive airway pressure; 
CVD, cardiovascular disease; SpO2, blood oxygen saturation level; T90, percentage of time spent 
under SpO2 of 90 %. 
DISCUSSION 
 125 
6.3 The significance of the level of CPAP 
adherence 
This thesis found that approximately one half of the patients commencing CPAP 
continued the treatment for ≥5 years, and furthermore, long-term commitment to 
CPAP could be predicted shortly after the initiation of treatment, since the mean 
short-term usage was already on the recommended level. These findings are in 
agreement with previous studies (Sawyer et al. 2011, Weaver et al. 1997, Weaver & 
Grunstein 2008). Long-term adherence to CPAP was increased by a mean of 11 
min/day per year over a mean follow-up of 7 years at the cohort level, which is 
similar to a previous, smaller study that reported a mean increase of 8 min/day per 
year in adherence over a follow-up of ≥5 years (Sucena et al. 2006). This thesis 
further showed that approximately a quarter of the patients had either a significant 
increase or decrease in adherence, while the majority showed no significant change. 
No single factor has been consistently associated with CPAP adherence (Weaver 
& Grunstein 2008). This thesis found that psychiatric disorders, a higher baseline 
BMI and increases in weight or the GHQ-12 score during treatment were associated 
with a significant increase in adherence. A weak association was observed between 
AHI and adherence, consistent with previous studies (Sawyer et al. 2011). Those 
with a higher baseline ESS score were less likely to achieve a significant increase in 
adherence, potentially since they may have committed to CPAP in a steady manner. 
Even though only a minority reported EDS, ESS was reduced in most of the patients, 
and a weak negative correlation was found between the mean slopes of CPAP usage 
and ESS. The GHQ-12 slope was also slightly descending, suggesting that 
psychological distress tended to reduce during treatment. Symptoms of psychiatric 
disorders may interact with OSA-related symptoms, and this patient group should 
not be overlooked when considering CPAP treatment. Overall, clinically significant 
improvements in sleepiness and other symptoms may be achieved by CPAP despite 
having a low baseline ESS score. The assessment of need for CPAP or response to 
the treatment should not be merely based on the ESS (Patil et al. 2019).  
Inadequate adherence has been a notable problem in RCTs and could explain the 
modest results on the associations between CPAP and the risk of CVDs. The 
exclusion of patients with EDS or the most severe OSA may also affect the results 
(McEvoy et al. 2016, Sánchez-de-la-Torre et al. 2020), since the effect of CPAP on 
BP has been reported to be greater in these patients than in those who are non-sleepy 
or have a milder OSA (Javaheri et al. 2017, Peker & Balcan 2018). A randomization 
of these patients to no treatment is ethically unacceptable, and it may only be 
hypothesized whether CPAP could have improved the CVD outcome in these OSA 
subgroups (Peker & Balcan 2018). CPAP may also be less effective in secondary 
than in primary prevention of CVDs potentially due to altered vascular structures 
related to established CVDs (Javaheri et al. 2017, Randerath et al. 2018). This thesis 
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demonstrated that CPAP use of >6 h/day was associated with a reduced risk of a 
composite CVD event in patients with or without established CVDs, while CPAP 
use of >4 h/day but ≤6 h/day was linked to a reduced risk only in the primary 
prevention of CVDs. Post-hoc analyses and meta-analyses of RCTs have suggested 
that CPAP use of ≥4 h/day may improve CVD outcome, particularly stroke and other 
cerebrovascular events (Javaheri et al. 2020b, McEvoy et al. 2016, Peker et al. 2016).  
This thesis further emphasized the importance of the level of CPAP adherence 
in CVD outcome, since only those who had used CPAP for >6 h/day had an 
independent reduced risk of CVD death, a composite of cardiac events and all-cause 
mortality compared to controls. A reduction in the risk of stroke was observed only 
among those who had used CPAP for >4 but ≤6 h/day. CPAP use of >4 h/day was, 
however, associated with a reduced stroke risk when the model was adjusted only 
for AF, while those with lower CPAP usage were not. Overall, the results of this 
thesis imply that CPAP use of >4–6 h/day is likely needed to achieve a potential 
improvement in CVD risk, although the impact may vary between specific outcomes. 
No association was observed between CPAP and the risk of cancer mortality 
regardless of the level of CPAP use. 
OSA phenotypes may also affect the effectiveness of CPAP (Randerath et al. 
2018, Zinchuk & Yaggi 2020). Poor CPAP adherence may result in the use of the 
device only during the early hours of the night, thus predisposing to unbeneficial 
effects of REM-related OSA on CVD outcomes. CPAP use of 3 to 4 h/day from the 
beginning of the sleep period has been estimated to leave 60–75 % of REM-related 
obstructive events untreated, since REM sleep is mainly concentrated in the early 
hours of the morning (Varga & Mokhlesi 2019). CPAP should preferably be used 
for the entire night to treat REM OSA, which is unlikely to be achieved in a notable 
proportion of patients, implying the need for alternative treatment strategies (Varga 
& Mokhlesi 2019). This thesis observed the beneficial effect of CPAP on most CVD 
outcomes only among those with CPAP use of >6 h/day, possibly at least partly since 
this level of compliance was sufficient to cover also REM sleep.  
Furthermore, some studies have shown an increased CVD risk particularly in 
patients with insomnia symptoms (Keenan et al. 2018, Saaresranta et al. 2016), 
while others have suggested that those with EDS could be at the greatest risk 
(Mazzotti et al. 2019). Insomnia symptoms have generally been associated with 
lower, and those with EDS with higher, CPAP adherence (Pien et al. 2018, 
Saaresranta et al. 2016). Long-term compliance with CPAP has also been reported 
to be challenging for CAD patients with non-sleepy OSA (Luyster et al. 2017). 
CPAP has been shown to help maintain sleep, but not the difficulties in falling 
asleep, suggesting a need for additional treatment options for those with insomnia 
symptoms (Pien et al. 2018). Moreover, a study of 706 patients from the Icelandic 
Sleep Apnea Cohort showed a reduction in diastolic BP in minimally symptomatic 
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and sleepy patients after a 2-year treatment with CPAP but not in those with 
disturbed sleep. The CVD incidence did not differ after adjustment for 
confounding factors (Pien et al. 2018). A study of veterans further reported that 
CPAP use of >4 h/day was associated with a reduced CVD risk among the clusters 
of hypopnea and hypoxia and PLMS, an interesting finding, since the latter has not 
been traditionally included in the consideration of CPAP treatment in an AHI of 
<15 /h. Only 29 % of the patients in the cluster of arousal and poor sleep had used 
CPAP >4 h/day, and they also tended to benefit the least from CPAP in terms of 
CVD outcomes. Thus, the CVD risk may remain increased regardless of treatment 
for some patient groups (Zinchuk et al. 2018). 
Studies have also shown a risk reduction by CPAP in terms of MVAs, although 
the effect of the level of adherence on the MVA risk has not been thoroughly 
established (Karimi et al. 2015, Tregear et al. 2010). No RCTs have been particularly 
designed to examine the impact of CPAP on MVAs due to ethical reasons (Tregear 
et al. 2010). The results of this thesis on the risk of MVAs differed from most 
previous studies, since no association between CPAP and the MVA incidence was 
observed regardless of the level of CPAP adherence. The MVA incidence before 
CPAP was, however, already at a lower level in comparison to a similar study from 
Sweden (Karimi et al. 2015). It has also been suggested that cognitive impairment 
and daytime sleepiness may not be fully normalized by CPAP despite good 
adherence (Antic et al. 2011). However, current data on the association between 
long-term CPAP treatment and cognitive changes are scarce, and the possible effect 
of the residual cognitive impairment on the results of the present study remains as a 
speculation. Overall, the risk of MVAs is likely to be multifactorial.  
Conversely, adherence to CPAP has also been linked to a modest increase or 
no significant changes in weight (Drager et al. 2015). Baseline BMI has been 
shown to predict the BMI outcome, while no other predictors have been 
consistently identified (Drager et al. 2015). This thesis showed that the mean 
change in BMI was 0.06 kg/m2 per year for the entire cohort over a 7-year follow-
up, which was similar to that observed among a middle-aged Finnish population 
(mean change in BMI 0.06–0.11 kg/m2 per year) (Silventoinen et al. 2013). 
However, the baseline BMI was clinically significantly higher among the former 
than the latter (men: 33 vs. 26, women: 35 vs. 25 kg/m2, respectively). 
Heterogeneity was observed at the individual level, since 10 % of the patients 
significantly gained weight with a mean rate of 0.6 kg/m2 per year. Male gender, 
younger age, current smoking, a higher BMI or GHQ-12 score at baseline and an 
increasing GHQ-12 score during treatment, were associated with a significant 
increase in BMI. The results of this thesis further emphasize that lifestyle 
interventions should be offered for all OSAS patients, and particularly for those 
who are younger and severely obese already at the initiation of CPAP. 
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6.4 Strengths and limitations 
The retrospective study design is the most significant limitation of this thesis. There 
may be underlying patient characteristics, such as different OSA phenotypes and 
personal types, causing bias in the results, since patients compliant with CPAP may 
differ from those who discontinue the treatment. The latter may adhere poorly to 
other medical therapies, while the former may have a healthier overall lifestyle, a 
phenomenon known as the “healthy adherer” effect. These potential, underlying 
biases are extremely difficult to control in retrospective studies except by matching 
cases and controls, which was conducted in this thesis by matching the CPAP-treated 
patients and controls for age, gender and AHI. The patients were recruited from the 
same clinic based on the same principles to minimize the selection bias.  
The search for controls was extended by several years to find the best matching 
case-control pairs. The treatment protocol did not essentially change during these 
years. However, the AASM hypopnea criteria did change in 2007, and thus, the same 
AHI value of those controls diagnosed with OSAS in 2007 or later is likely to differ 
from that of the CPAP-treated patients, since their diagnosis was based on the 
Chicago criteria (Iber et al. 2007, The Report of an American Academy of Sleep 
Medicine Task Force 1999). This may have reduced the accuracy of pairwise 
matching of the patients according to AHI, since the 2007 hypopnea criteria were 
generally stricter than the Chicago criteria (Ruehland et al. 2009). Sleep recordings 
were also scored by pulmonologists or clinical neurophysiologists, which may have 
affected the AHI of the patients, although the scoring principles were the same. 
Furthermore, data on nocturnal SpO2 levels were not available for all studied 
patients, and variably reported ODI values (ODI of ≥4, ≥5 or ≥10 %) complicated 
comparisons between patients. Thus, data on SpO2 and ODI were utilized only for 
those who had an MVA and were not used in the analyses of CVDs. Follow-ups 
were not modified in terms of non-fatal outcomes, since both cases and controls 
could have had an event from the beginning of observation period. Other well-known 
risk factors were included in adjusted analyses on the associations between CPAP 
and the risk of CVDs or mortality. Data on alcohol consumption, medications, 
physical activity and family history of CVD were unavailable due to the 
retrospective nature of the studies.  
As a further limitation, data on patients’ waist circumference or the amount of 
adipose tissue were unavailable, and thus, it is not clear how much of the gained 
weight was fat and how much fluid in those with a significant increase in BMI during 
CPAP treatment. Long-term weight changes of the CPAP-treated patients could not 
be compared to a control group, since no data on weight changes were available for 
controls after they had discontinued CPAP. Instead, the development of BMI during 
CPAP treatment was compared to that among middle-aged Finns from the general 
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population (Silventoinen et al. 2013). No data on changes in BMI or ESS score were 
available for controls in studies II–III for the same reason. 
The statistical power or sample size estimation were not conducted prior to the 
study. This could at least partly explain why a significant difference in the MVA 
incidence was not observed after CPAP, since MVAs are likely to occur rarely, 
especially in a sparsely populated country such as Finland. The MVA incidence of 
the patients was already low 9 years before CPAP. Furthermore, data on actual 
annual driving exposure in the cohort was unavailable, although differences in 
driving habits were likely reduced by matching the cases and controls for age and 
gender. Potential differences should not affect before and after comparisons.  
Overall, the sample size of the studies, even though unpowered, was large and 
the proportion of females significant. Those with concomitant diseases or an AHI of 
<5 /h with clinical presentation strongly suggestive for OSAS were included in the 
study to better represent real-world patients. Most of the treated patients showed 
good adherence to CPAP in both the short and long term. However, despite good 
compliance, the sleep duration of the patients may have been insufficient. The data 
on both CVD events and MVAs were objective. The latter was based on a national 
registry in which small, near-miss accidents or close shaves on the road are not 
reported. Only MVAs involving the study subject as the actual driver were included. 
Data on accident conditions, a possible confounding factor for MVAs, were 
provided, which previous studies have not assessed.   
CPAP-treated patients had multiple follow-up visits during treatment with 
objectively measured data on CPAP usage and weight, which enabled the evaluation 
of individual trends of BMI and adherence over time. This differs from the traditional 
statistical methods, in which the outcome measures are compared between before 
and after treatment or determined for the whole cohort at one cross-sectional time 
point. These methods do not acknowledge the model uncertainty, while the approach 
of individual development enables the classification of patients into high- or low-
risk at a specific probability level. The number of patients in this thesis with a 
significant increase in adherence was likely restricted due to a ceiling effect, since 
most of the patients had already adhered adequately to CPAP from the initiation of 
treatment. The evaluation of individual trends of patient characteristics provides a 
step towards a more personalized medicine.  
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7 SUMMARY/CONCLUSIONS 
OSA has a range of adverse consequences to patients’ health and is a heavy burden 
on health care systems. Its prevalence is increasing, particularly due to a growing 
rate of obesity and to an aging population. CPAP has been the primary treatment for 
OSA, particularly in patients with moderate to severe disease, for forty years. 
Identifying those who benefit the most from CPAP in addition to those who are likely 
to require additional support to achieve adequate treatment response remains a 
challenge. However, advances in the knowledge of OSA pathogenesis provide an 
opportunity towards more personalized medicine, since new targeted therapies could 
be developed. The main purpose of this thesis was to investigate long-term adherence 
to CPAP treatment, the risk of CVD events and MVAs and the associations between 
CPAP and weight maintenance. Another aim was to further evaluate whether the 
level of CPAP adherence would affect the results.  
 
The main conclusions are the following:  
 
1) Approximately one half of the patients with OSAS commencing CPAP had 
continued the treatment for ≥5 years. Among these patients, CPAP 
adherence was extremely good both in the short and long term. Adherence 
increased slightly at the cohort level by a mean of 11 min/day per year of 
follow-up. Most of the patients had no significant change in adherence at the 
individual level, implying that long-term CPAP adherence can be predicted 
shortly after initiation, which is in agreement with previous studies. 
2) A significant increase in adherence was associated with the presence of 
psychiatric disorders, a higher baseline BMI and increases in weight or the 
GHQ-12 score during treatment. A weak association was found between 
AHI and CPAP adherence. Mean long-term adherence to CPAP was 6 h/day 
in the cohort, even though only 37 % of the patients had reported EDS (ESS 
≥11). These findings emphasize that the assessment of treatment response 
should not be merely based on the ESS score and that symptoms of 
psychiatric disorders may interact with OSA-related symptoms, and this 
patient group should not be overlooked when considering CPAP treatment.  
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3) In comparison to controls matched for age, gender and AHI, CPAP treatment 
was associated with an independent, reduced risk of CVD events and all-
cause mortality over a median follow-up of 9 years. However, this was only 
observed among those with CPAP use of >4–6 h/day depending on the 
specific outcome. As an exception, no association was found between CPAP 
and the risk of nonfatal cardiac events regardless of the level of CPAP 
adherence. The results further imply that CPAP use of >4–6 h/day is likely 
needed to achieve potential improvements in CVD risk. This finding is 
consistent with several recent meta-analyses and post-hoc analyses of RCTs. 
4) The CPAP-treated patients at the cohort level slightly gained weight at a 
comparable rate to that observed in the general middle-aged Finnish 
population, although their baseline BMI was clinically significantly higher. 
Heterogeneity was observed at the individual level, since 10 % of the 
patients significantly gained weight. The most concerning observation was 
that these patients were already more severely obese despite being younger 
than the rest of the cohort. The results underline the urge for lifestyle 
interventions for all OSAS patients and particularly for the younger and 
severely obese who appear to be at the highest risk for weight gain. 
5) The incidence of police-reported MVAs did not change after CPAP when 
compared between 9 years before and after treatment or between the CPAP-
treated patients and controls. The level of CPAP adherence did not affect the 
results. Among patients who had an MVA, no differences were observed in 
sleep study data or accident conditions. Baseline BMI was the only 
characteristic that differed between the CPAP-treated patients and controls 
who had an MVA and tended to further increase during CPAP treatment. 
Male gender, younger age and smoking were associated with an increased 
risk for MVAs, which is consistent with previous studies. A BMI of ≥30 
kg/m2 increased the likelihood of an MVA only among CPAP-treated 
patients. No association was found between the baseline ESS score and the 
risk for MVAs. The MVA risk is likely to be multifactorial, and even longer 
observation periods may be needed to detect a significant difference. 
6) No association could be verified between AHI and the risk of weight 
changes, CVD events or MVAs. This emphasizes that OSAS is a 
heterogeneous disease, and the use of AHI alone is not sufficient in the 
assessment of OSAS severity or in the identification of high-risk patients for 
adverse outcomes. New tools for these purposes are needed. 
7) Daytime sleepiness and psychological distress tended to reduce during 
CPAP treatment in the majority of the CPAP-treated patients, which is 
consistent with earlier studies. 
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8 FUTURE ASPECTS 
Mounting evidence has shown that symptoms related to OSA are heterogeneous and 
do not associate with AHI, and furthermore, all symptom-based phenotypes are not 
presented with increased ESS score (Zinchuk & Yaggi 2020). The identification of 
OSA phenotypes that are most likely to benefit from CPAP would be useful, 
particularly for those asymptomatic or minimally symptomatic patients who are 
unwilling to initiate or continue CPAP unless other benefits of treatment can be 
predicted (Randerath et al. 2018). New pathophysiological mechanisms, genetic risk 
factors and potential treatment alternatives for OSA could also be revealed, and lead 
to a more personalized OSA treatment (Zinchuk & Yaggi 2020). 
Patients with moderate to severe anatomical impairment are likely to differ from 
those who have only minor impairment in anatomical factors in terms of treatment 
alternatives (Eckert et al. 2013). The former probably benefit the most from 
interventions that aim to protect the patency of the upper airway, such as CPAP, 
MAD, surgical approaches, positional therapy and weight loss. As the role of non-
anatomical factors, particularly a high loop gain or a low respiratory arousal 
threshold, becomes dominant, patients may be less likely to respond to anatomical 
interventions. These patients are more likely to benefit from interventions targeted 
towards one or more non-anatomical factors or a combination of these approaches.  
Accordingly, patients with impaired nocturnal dilator muscle function may 
benefit from interventions that aim to improve the muscle function such as upper 
airway muscle training, hypoglossal nerve stimulation or a medication that increases 
the muscle activity of genioglossus during sleep (e.g. desipramine). Patients with a 
low respiratory arousal threshold may benefit from the use of hypnotics that increase 
the arousal threshold but do not predispose to muscle relaxation, while those with a 
high loop gain may benefit from supplemental oxygen, stabilization of CO2, and the 
use of acetazolamide, which has been shown to reduce loop gain approximately by 
40 %. Patients who have both moderate anatomical and non-anatomical impairments 
(PALM scale 2b) may particularly benefit from a targeted combination therapy such 
as MAD treatment in addition to supplemental oxygen (Eckert et al. 2013). At 
present, these potential treatment options are, however, only suggestive, and further 
studies are needed to verify their effectiveness in different OSA-related outcomes.  
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Optimal treatment and the effect of CPAP in patients with different clinical and 
polysomnographic phenotypes may also vary. For example, patients with insomnia-
like symptoms may benefit from a combination of cognitive behavioral therapy and 
CPAP in order to improve symptoms and CPAP adherence (Anttalainen et al. 2019). 
The timing of CPAP use in relation to sleep onset and adequate adherence to CPAP 
may be particularly important for patients with REM-predominant OSA in order to 
cover REM sleep. Preliminary data has suggested that MAD may not be as effective 
in the treatment of OSA during REM sleep when compared to NREM sleep or CPAP. 
Furthermore, patients with REM predominant OSA may also benefit from 
interventions that aim to improve the upper airway muscle function, since REM sleep 
is characterized by muscle atonia (Varga & Mokhlesi 2019). The potential role of 
medications that suppress REM sleep such as serotonin/ norepinephrine reuptake 
inhibitors and tricyclic antidepressants have yet not been explored in the treatment 
of REM OSA in human subjects (Varga & Mokhlesi 2019). 
Most of the studies investigating OSA phenotypes have mainly included middle-
aged or older male subjects with moderate to severe OSA. Thus, studies on patients 
of different ages, including more women, are needed both from clinic- and 
population-based cohorts, since those who have visited clinics may differ 
particularly in terms of symptoms from subjects of the general population. Even 
though specific phenotypes have already been identified, it is not clear whether the 
same phenotypes are present in mild OSA, or how clinical phenotypes interact with 
pathophysiological-, polysomnographic-, biomarker- (e.g. inflammatory markers, 
markers of sympathetic activation) or genetic-based phenotypes. Multidomain 
analyses are needed to combine different patient characteristics, although these are 
likely to provide a broad spectrum of data that may be difficult to interpret (Zinchuk 
& Yaggi 2020).  
Overall, the identification of OSA phenotypes is likely to expand our perception 
of OSA, its consequences on health, and treatment options towards a more 
personalized medicine. Future OSA treatment is likely to be based on the assessment 
of phenotypes similar to the current treatment of asthma and COPD. A better 
understanding of phenotypes could also enable exact identification of those patients 
who are at the highest risk for a CVD, MVA or other unbeneficial OSA-related 
outcomes. CPAP has been constantly shown to be efficacious in OSA’s treatment. 
However, inadequate adherence to CPAP has been a notable problem, and the 
effectiveness of second-line treatments in these patients has varied. Thus, in addition 
to studies investigating the effectiveness of adequate CPAP use and methods to 
achieve it, there is also a need for new treatments for OSA (Eckert et al. 2013, 
Keenan et al. 2018, Randerath et al. 2018, Zinchuk & Yaggi 2020).
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APPENDICES 
Appendix 1.  Epworth Sleepiness Scale (Johns 1991) 
 
 
Sitting and reading 
Would never doze or sleep (0 points) 
Slight chance of dozing or sleeping (1 point) 
Moderate chance of dozing or sleeping (2 points) 
High chance of dozing or sleeping (3 points) 
 
Watching television 
Would never doze or sleep (0 points) 
Slight chance of dozing or sleeping (1 point) 
Moderate chance of dozing or sleeping (2 points) 
High chance of dozing or sleeping (3 points) 
 
Sitting inactive in a public place 
Would never doze or sleep (0 points) 
Slight chance of dozing or sleeping (1 point) 
Moderate chance of dozing or sleeping (2 points) 
High chance of dozing or sleeping (3 points) 
 
Being a passenger in a car for an hour 
Would never doze or sleep (0 points) 
Slight chance of dozing or sleeping (1 point) 
Moderate chance of dozing or sleeping (2 points) 
High chance of dozing or sleeping (3 points) 
 
 
Lying down in the afternoon 
Would never doze or sleep (0 points) 
Slight chance of dozing or sleeping (1 point) 
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Moderate chance of dozing or sleeping (2 points) 
High chance of dozing or sleeping (3 points) 
 
Sitting and talking to someone 
Would never doze or sleep (0 points) 
Slight chance of dozing or sleeping (1 point) 
Moderate chance of dozing or sleeping (2 points) 
High chance of dozing or sleeping (3 points) 
 
Sitting quietly after lunch (no alcohol) 
Would never doze or sleep (0 points) 
Slight chance of dozing or sleeping (1 point) 
Moderate chance of dozing or sleeping (2 points) 
High chance of dozing or sleeping (3 points) 
 
Stopping for a few minutes in traffic while driving 
Would never doze or sleep (0 points) 
Slight chance of dozing or sleeping (1 point) 
Moderate chance of dozing or sleeping (2 points) 
High chance of dozing or sleeping (3 points) 
 
 
 
Appendix 2.  General Health Questionnaire (Goldberg et al. 1997) 
 
 
How have you been feeling, in general, over the past few weeks? 
 
Have you been able to concentrate on what you were doing? 
More than usual (0 points) 
Same as usual (0 points) 
Less than usual (1 point) 
Much less than usual (1 point) 
 
Have you lost much sleep over worry? 
Not at all (0 points) 
No more than usual (0 points) 
Rather more than usual (1 point) 
Much more than usual (1 point) 
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Have you felt that you were playing a useful part in things? 
More than usual (0 points) 
Same as usual (0 points) 
Less than usual (1 point) 
Much less than usual (1 point) 
 
Have you felt capable of making decisions about things? 
More than usual (0 points) 
Same as usual (0 points) 
Less than usual (1 point) 
Much less than usual (1 point) 
 
Have you felt constantly under strain? 
Not at all (0 points) 
No more than usual (0 points) 
Rather more than usual (1 point) 
Much more than usual (1 point) 
 
Have you felt you could not overcome your difficulties? 
Not at all (0 points) 
No more than usual (0 points) 
Rather more than usual (1 point) 
Much more than usual (1 point) 
 
Have you been able to enjoy your normal day-to-day activities? 
More than usual (0 points) 
Same as usual (0 points) 
Less than usual (1 point) 
Much less than usual (1 point) 
 
Have you been able to face up to your problems? 
More than usual (0 points) 
Same as usual (0 points) 
Less than usual (1 point) 
Much less than usual (1 point) 
 
 
Have you been feeling unhappy and depressed? 
Not at all (0 points) 
No more than usual (0 points) 
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Rather more than usual (1 point) 
Much more than usual (1 point) 
 
Have you been losing confidence in yourself? 
Not at all (0 points) 
No more than usual (0 points) 
Rather more than usual (1 point) 
Much more than usual (1 point) 
 
Have you been thinking of yourself as a worthless person? 
Not at all (0 points) 
No more than usual (0 points) 
Rather more than usual (1 point) 
Much more than usual (1 point) 
 
Have you been reasonably happy, all things considered?  
More than usual (0 points) 
Same as usual (0 points) 
Less than usual (1 point) 
Much less than usual (1 point) 
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